<SEC-DOCUMENT>0001193125-12-467649.txt : 20121113
<SEC-HEADER>0001193125-12-467649.hdr.sgml : 20121112
<ACCEPTANCE-DATETIME>20121113170137
ACCESSION NUMBER:		0001193125-12-467649
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20121107
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121113
DATE AS OF CHANGE:		20121113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		121199605

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d438628d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): November&nbsp;13, 2012 (November 7, 2012) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue, 35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York, 10019 </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
489-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01. Regulation FD Disclosure. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;7, 2012, Delcath Systems, Inc. (the &#147;Company&#148;) hosted a conference call to discuss the Company&#146;s financial
results for the 2012 third fiscal quarter ended September&nbsp;30, 2012 and recent operational progress. A copy of the transcript of the conference call is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this
Item&nbsp;7.01 by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information disclosed under this Item&nbsp;7.01, including Exhibit 99.1 hereto, is being
furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended, except as expressly set forth in such filing. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following exhibit is filed herewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. Conference Call Transcript</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November 13, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President,</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. Conference Call Transcript</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d438628dex991.htm
<DESCRIPTION>DELCATH SYSTEMS, INC. CONFERENCE CALL TRANSCRIPT
<TEXT>
<HTML><HEAD>
<TITLE>Delcath Systems, Inc. Conference Call Transcript</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g438628g39q32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CORPORATE PARTICIPANTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Doug Sherk</B><I> EVC Group, Incorporated - IR </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Eamonn Hobbs</B>
<I>Delcath Systems, Incorporated - CEO, President </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Graham Miao</B> <I>Delcath Systems, Incorporated - EVP, CFO </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFERENCE CALL PARTICIPANTS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Chris Lewis</B><I> Roth Capital Partners - Analyst </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Jason Mills</B> <I>Canaccord Genuity - Analyst </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Greg Wade</B> <I>Wedbush
Securities - Analyst </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B>Jason Butler</B><I> JMP Securities - Analyst </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PRESENTATION </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Good day, ladies and gentlemen,
and welcome to the Third Quarter 2012 Delcath Systems, Inc. Earnings Conference Call. My name is Erica and I&#146;ll be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to your host for today&#146;s
call, Mr.&nbsp;Doug Sherk. Please proceed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Doug Sherk. Thank you, Erica, and good afternoon, everyone. Thank you for joining us today for
this conference call and webcast to provide an update on Delcath&#146;s third quarter 2012 results and recent corporate progress. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of
the conference call will be made approximately&#151;will be available approximately two hours after the conclusion of today&#146;s call, and it will be available for seven days. The operator will provide replay details at the conclusion of
today&#146;s call. A live webcast of this call is available at www.Delcath.com, and the call will also be archived on the website. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before we
begin, I&#146;d like to remind you that some of the statements made during this conference call will contain forward-looking statements within the meaning of the Safe Harbor provision of the US Private Securities Litigation Reform Act of 1995. These
statements are subject to certain risks and uncertainties, and actual results could differ materially from those projected in any forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Factors that could cause actual results to differ are discussed from time to time in the Company&#146;s filings with the SEC, including our annual report on Form 10-K, and our reports on Form 10-Q and
8-K. These documents are available on the Investor Relations section of our website, and we encourage you to review the material. The Company has no obligation to publicly update or revise these forward-looking statements to reflect the events or
circumstances after the date they are made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participating on today&#146;s call are Eamonn Hobbs, President and Chief Executive Officer, and
Graham Miao, Executive Vice President and Chief Financial Officer. Following their opening remarks, we will open the call to questions from analysts and institutional investors. To maximize the time allowed for Q&amp;A, please ask two questions, and
if you have additional questions, please re-queue to ask those additional questions. In advance, we thank you for your cooperation with this procedure. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">And now, I&#146;d like to turn the call over to Mr.&nbsp;Hobbs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thanks, Doug, and good afternoon, everyone. Since our call with you in early August, the team at
Delcath has achieved several significant milestones. Most important of these was FDA acceptance of our new drug application for our proprietary chemosaturation system with Melphalan Hydrochloride for injection for substantive review. As we announced
recently, the FDA has designated a goal date of June&nbsp;15, 2013. Acceptance of our NDA is the culmination of many months of work and we hope represents the first step towards U.S. commercialization. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also during the quarter, we continued to implement our launch in Europe, completing applications for
interim reimbursement in key markets and signing our exclusive distribution agreements in Italy and Spain. Recently, we also received regulatory approval for our Generation Two CHEMOSAT delivery system in Australia, and have satisfied all the
requirements to affix the CE mark to the hepatic CHEMOSAT delivery system device for intrahepatic arterial delivery and extracorporeal filtration of Doxorubicin in October 2012, which helps establish a pathway for regulatory approval in large key
Asian markets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These developments help lay the foundation for realizing the full potential of our system in the U.S. and other markets around
the world. After reviewing these achievements with you briefly, I will turn the call over to Graham for a review of our financial results. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I&#146;ll begin with the most important development for Delcath in many years, the FDA&#146;s acceptance of our NDA. This is a tremendously important
development, not only for Delcath but for the patients in the U.S. who have a critical need for our treatment. We look forward to working closely with the agency throughout the review process with the goal of securing approval of our application.
Our most important objective is to be able to provide patients in the U.S. with unresectable metastatic melanoma in the liver a new option for treating their disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The NDA was accepted with our generation two hemofiltration cartridge included as a technical change in the chemistry, manufacturing and control module of the NDA. Assuming our NDA is approved, this
potentially represents the rapid availability of Gen Two for U.S. patients we&#146;ve always hoped for, and will help enhance our launch of the system in the United States. Our NDA has been assigned a Prescription Drug User Fee Act or PDUFA goal
date of June&nbsp;15, 2013. FDA also advised us that we should expect an Oncology Drug Advisory Committee, or ODAC, panel to be convened as part of the review process. No date has been set and we will announce the date once it has been determined.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we work with the FDA on review of our application, we continue to move forward with our expanded access program in the United States.
As you know, the FDA accepted our amendments to our investigational new drug or IND application, and our EAP to include the Generation Two filter. These amendments permit physicians at select U.S. cancer centers to use the Generation Two system in
expanded access and compassionate use cases after they obtain institutional review board, or IRB, approval. We expect to enroll six centers under the EAP, all of which were phase three trial sites, one of which has already obtained IRB approval, and
the others are in various stages of their IRB approval process. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also working with each site to finalize the clinical trial agreements
necessary to begin treatments under the program and we continue to expect patient treatments under the EAP program to begin this fall. This program will play a valuable role in providing access to patients in urgent need of our treatment while our
NDA is under review. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we said on our last call, the IND amendments also laid the groundwork for the use of the Generation Two system in the
clinical trials we have planned as part of our clinical development program, and it is our intention to use Gen Two in all upcoming prospective clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Turning now to Europe, we are continuing to execute on our rollout plan. As we stated previously, revenues for this year are expected to be minimal and weighted towards our fourth quarter with sales
driven primarily by the centers we have activated so far and by third party distributors. Drivers continue to be the current status of reimbursement, which is critical to our commercialization efforts, and expanding our clinical experience. We
continue to address both elements in parallel. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On the reimbursement front, a concentrated effort is underway in three EU markets we believe
offer the quickest path to establishing reimbursement, namely Italy, German, and the U.K. In Italy, we learned this week that the CHEMOSAT procedure can be reimbursed under an existing diagnosis related group code, or DRG. This is highly significant
news in that we believe it provides us with our first national reimbursement mechanism for CHEMOSAT procedures in Europe, and these procedures are now eligible to be reimbursed in Italy. We believe the reimbursement under this code will be between
EUR11,000 and EUR16,000, depending on the region in Italy, and while not ideal we believe this provides a viable pathway to reimbursed procedures in Italy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To potentially increase the level of reimbursement, we will continue to seek additional supplemental new technology payments and potentially pursue a new national DRG specific to CHEMOSAT. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In Germany, we have submitted two extraordinary insurance effort applications to date, and we and the sponsoring institution are awaiting response. These
are case by case applications for reimbursement. Additionally, 12 centers agreed to sponsor a new diagnostic and therapeutic methods application, or NUB, as it&#146;s known in Germany. The German Radiology Society has also agreed to sponsor that
application. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">An NUB is a specific reimbursement payment for a new technology treatment paid to the sponsoring hospitals. If approved, this
NUB application will be sufficient to provide referral coverage across Germany. We are hopeful that all of the reimbursement activity in Germany will lead to a positive response in the first quarter of next year and enable all German patients to be
covered for CHEMOSAT procedures. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the U.K., our lead centers are seeking to gain PCT, or primary care trust funding, which we hope will
be granted in Q1 of 2013. This would allow us to perform CHEMOSAT procedures in three to four key centers in the U.K. with referrals being made nationwide. The U.K. is currently reorganizing its healthcare system and our partner centers are
preparing to apply for reimbursement from a new national body in April. This will provide us with the opportunity to seek interim reimbursement for CHEMOSAT on a nationwide basis and it is worth pointing out that we are supported by key members of
this new national body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuit of reimbursement in other key European markets is continuing, but the timeframe for success in these markets
is a work in progress. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">While we pursue reimbursement, we are seeking to build clinical experience by sponsoring investigator initiated
trials, or IITs, with leading EU key opinion leaders that have approached us to support new clinical research. Currently, we hope to initiate one IIT of CHEMOSAT with Melphalan in primary liver cancer or HCC at a major institution in Germany in the
first quarter of next year, and additional IITs are on the drawing board for centers in Spain, the Netherlands, and France for 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition to building our clinical case, these small trials help drive clinical experience at key centers, which we hope will facilitate wider usage once reimbursement mechanisms are working and become available. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to IITs, we also expect to activate our EU patient registry by the end of this year. This registry will serve as a standardized safety and
efficacy database for up to 15 centers in all seven EU markets. Three of our initial launch and training centers are currently applying for ethical approvals and we expect that the first patient will be enrolled in the registry by the end of
December. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Going forward, this registry will serve as a viable source of case studies and clinical outcomes and will further drive clinical
adoption. As we have communicated in the past, our EU commercialization strategy includes a mix of both direct sale channels by our own field force, and indirect sales channels through third party distributors. During the third quarter, we entered
into our first European third party distributor agreement with reputable companies in Italy and Spain, and we have already received the first distributor order for Italy. Of course, our ramp up in sales will continue to be dependent on the efforts
to gain clinical adoption and regional reimbursement. The existing DRG code for Italy I mentioned earlier will be of particular benefit in the near term, while we pursue additional supplemental new technology payments and-or a new, higher
reimbursing CHEMOSAT specific DRG in that country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Turning to Symposia, at the Annual Meeting of the Cardiovascular and Interventional
Radiology Society for Europe, or CIRSE, held in Lisbon, Portugal in mid-September, physicians from Italy and Germany shared their experience with, and benefits of, the Generation Two CHEMOSAT in treating patients with cancers in the liver.
Specifically, they discussed CHEMOSAT&#146;s ability to directly treat the liver by addressing both visible tumors and micro metastases with higher dosing designed to improve tumor killing efficiency, thereby potentially allowing additional time to
treat disease outside the liver that is not imminently life threatening. Later that month at the Annual Congress of the European Society for Medical Oncology, or ESMO, in Vienna, Austria, leading clinicians presented findings from their experiences
in the use of CHEMOSAT and the potential role it may play in the management of European patients with cancers in the liver. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both the symposia
were well attended by clinicians throughout Europe and there is strong interest in offering patients the benefit of CHEMOSAT treatment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Turning to other developments, we are pleased with the regulatory approvals we&#146;ve received in the recent weeks. In late October, we received
approval in Australia for our Generation Two CHEMOSAT delivery system device for intrahepatic arterial delivery with extracorporeal filtration with Melphalan. This approval is another significant milestone for Delcath since it represents our first
approval of the Generation Two system in the Pacific Rim and enhances our opportunity to address a market of potentially $50 million to $70 million. We are currently evaluating multiple exclusive distributor candidates to help develop the Australian
market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To support clinical adoption and eventually training of CHEMOSAT with Melphalan throughout the Pacific Rim, we plan to initiate an
IIT in primary liver cancer, or HCC, at Kobe University Hospital in Japan that we hope will eventually serve as our main training location for Asia. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As we announced recently, we have satisfied all of the requirements to affix the CE mark to the hepatic CHEMOSAT delivery system device for intrahepatic arterial delivery and extracorporeal filtration of
Doxorubicin. This helps establish a pathway for regulatory approval in large, key Asian markets. Doxorubicin is an established chemotherapeutic agent commonly used in Asia to treat hepatocellular carcinoma, or HCC, which is the most common primary
malignant tumor and is substantially more prevalent in Asia than western economies. Unlike Melphalan, the drug we used to launch CHEMOSAT in Europe and as part of our NDA in the U.S., Doxorubicin is approved and readily available in many Asian
markets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the CE mark for delivery system device for intrahepatic arterial delivery and extracorporeal filtration of Doxorubicin in hand,
we can now submit the product testing specifications to the Chinese State FDA for their evaluation by the end of 2012. In China, establishment of product testing standards would enable Delcath to import the CHEMOSAT system into China and use it in
human patients for clinical trials. At the same time, we believe the CE mark for the hepatic CHEMOSAT delivery system device for intrahepatic arterial delivery and extracorporeal filtration of Doxorubicin should help us advance partnership
discussions in China. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Meanwhile, the CE mark for the CHEMOSAT delivery system device for use with Doxorubicin, has put us in a
position to submit a product registration for CHEMOSAT to the Korean FDA. We intend to submit this application by year-end. As with China, this submission activity should advance partnership discussions for the Korean market. With that, I&#146;d
like to turn the call over to Graham Miao for review of our financial results and then we&#146;ll take a few questions. Graham? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Graham Miao </B><B><I>- Delcath Systems,
Incorporated - EVP, CFO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you, Eamonn. Good afternoon, everyone. Let me begin by providing an update on the Company&#146;s
financial condition. Our cash and cash equivalents as of September&nbsp;30, 2012 was $28.3 million. We are pleased to report that we have been able to maintain a solid balance sheet in the third quarter. Our cash position as of September&nbsp;30 is
only $1 million less than where we stood as of June&nbsp;30, 2012. The factors that lead to this development are as follows. First, our use of cash during the third quarter was $14.6 million, which was slightly higher than the second quarter. The
use was primarily driven by NDA submission related costs, and ongoing EU commercialization efforts. Second, offsetting the cash spend in the third quarter were cash resources from the realizing of $4.4 million in September from 2007 warrant
exercises. A modest amount from accounts receivable collections and approximately $9 million raised from our at-the-market, or ATM facility. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, we had $21 million available through the ATM. We believe that our cash position and access to capital provide us adequate funds
for our operating needs through our PDUFA date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continue our efforts to reduce operating costs and are committed to reducing average
monthly cash spend in the fourth quarter to between $3 million and $4 million as a result of expected decrease in NDA related spend in the fourth quarter. In addition, we remain debt free, although we have a $20 million working capital credit
facility with SVB. This facility provides us with additional financing options to access capital to support our commercialization plans, if needed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Turning to the income statement, during the third quarter we recorded sales of $97,000 from the sale of CHEMOSAT kits in Europe, of which $39,000 was recognized in revenue and $58,000 was deferred revenue
associated with initial order from a distributor in Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we communicated in the past, our EU commercialization strategy employs a mix
of both direct sales channels by our own sales force and indirect sales channels through third party distributors. In the near term, we expect the revenue ramp to be slow and steady. But as Eamonn reviewed earlier, significant revenue growth is
expected to occur once procedure reimbursement mechanisms are available and the clinical experience in Europe continues to grow. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the
third quarter ending September&nbsp;30, 2012, our operating loss was $12.2 million, which included approximately $1 million in non-cash stock based compensation expense, as compared with an operating loss of $12.2 million, including approximately
$0.9 million in non-cash stock based compensation expense, in the year ago period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general, and administrative, or SG&amp;A
expenses, were $7 million for the third quarter of 2012, compared to $5.7 million for the same period in 2011, due to our ongoing commercialization efforts in Europe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses were $5.3 million for the third quarter of 2012, compared to the $6.4 million for the same period in 2011. The lower R&amp;D expenses reflect the anticipated lower
consulting expenses associated with the preparation of the NDA submitted in mid-August 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, I would like to let our audience know
that we will be presenting at the Lazard Healthcare Conference in New York on November&nbsp;13 this year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With that, we are ready to take
questions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTION AND ANSWER </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Operator Instructions) And our first question comes from the line of Matt Dolan with Roth Capital Partners. Please proceed. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Chris Lewis </B><B><I>- Roth Capital Partners - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hey, guys. This is
[Chris Lewis] on the line for Matt. Good afternoon. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Hey, Chris. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Graham Miao </B><B><I>- Delcath Systems, Incorporated - EVP, CFO</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Hey, Chris. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Chris Lewis </B><B><I>- Roth Capital Partners - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Just first off, could you provide some more commentary around the pace of procedures you&#146;re seeing in Europe and just maybe describe some of the general adoption patterns that you&#146;re seeing
there with the training centers and the doctors there? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Well, the path we&#146;re following is we&#146;re focusing on really leading cancer centers in our target markets. And we currently have six centers that are actively doing cases. The program is we
provide them with training and with some product to gain some clinical experience, and then we provide them with the support they need to recruit patients under either research funding or private pay funding while we work on reimbursement. So in
Italy and in Germany we&#146;ve had commercial orders [to date]. Two centers have actually gotten to the point where they had cases that they categorized as commercial and purchased product. Clearly, we&#146;re waiting for reimbursement to be
established. And as I mentioned, just this week we learned from our reimbursement experts that an existing DRG was deemed to be appropriate by the Italian government reimbursement authority for use immediately as an interim reimbursement method. And
although that doesn&#146;t pay as high as we ultimately would like to seek for reimbursement, it covers the majority of the cost of the procedure. And that we would expect is going to translate into removing a major barrier to commercial adoption,
and allow for commercial adoption to accelerate in Italy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Same as the&#151;happening in Germany and the same thing is happening in the U.K.
as far as very tangibly pursuing interim reimbursement. So once those click in, which we believe will be in the first quarter of next year or sooner, that will be very important. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Now, what we&#146;ve seen from the cases that have been done is we&#146;ve seen the product perform extremely well. We&#146;ve seen Gen Two provide tremendous benefits in a number of ways. Patient
tolerance for the procedures is much better. The days in the ICU are dramatically reduced, if not eliminated, and we&#146;ve seen a wide variety of tumor types being treated. So not just melanoma, we&#146;ve seen breast cancer, gastric cancer,
primary liver cancer, gall bladder cancer, and I believe tomorrow there&#146;s a neuroendocrine case being done. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">So it&#146;s slow and steady
and we anticipate adding additional centers prior to the end of the year. And reimbursement is really the catalyst that we are working towards and we&#146;re making great progress on. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Chris Lewis </B><B><I>- Roth Capital Partners - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay, great. Thanks for
the detail there. And then, just turning to the Asian market, how does the CE mark with Doxorubicin change the types of discussions you&#146;re having there with potential partners? And should we be expecting some type of partnership announcement
here in the next six to 12 months or three to six months or maybe a better timetable there would be great. Thanks. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Well, certainly that&#146;s a very high priority for us and has been for a very long time. And to
go back in history a little bit, we got very far down the road with a potential partner in China with our Melphalan system, and only to find out with our partner that although Melphalan was routinely used in China, it had actually never been
approved as a drug for injection. So that put us in a bit of a tailspin in that we had to regroup. And our plan to regroup was to get our Doxorubicin delivery system </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
approved with a CE mark, and that is a very important milestone for us because now we can actually approach clinical use in China on the back of the CE mark for the device, as Doxorubicin is
approved with very broad labeling in China and we believe our device can be approved in the Chinese system to deliver Doxorubicin in a rather straightforward way. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">So we&#146;re just now back on track at being able to have substantive negotiations with regard to Chinese partnerships and we are working very hard on those. I would also add that although not directly
related, the FDA accepting our NDA is&#151;was very important to numerous potential Chinese partners. So now that the FDA has done that, we have that asset in our camp, if you will, and we&#146;re leveraging that as well. So although we can&#146;t
put any timing on a potential Chinese strategic partnership, we&#146;re working very diligently on it and we are certainly seeing a significant amount of interest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Chris Lewis </B><B><I>- Roth Capital Partners - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay, thank you.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your next question comes from the line of Jason Mills with Canaccord Genuity.
Please proceed. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you. Hi, Eamonn. Hi,
Graham. Thanks for taking the questions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Hey, Jason. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">How are you? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Good, thanks. How are you doing? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity -
Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very good. Thank you. Let&#146;s stick with Asia for a second. Do you have any sort of projections as to when you might
see out of Asia revenue, any timing for initial commercial development there? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Eamonn Hobbs - Delcath Systems, Incorporated
- CEO, President </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Well, definitely we wouldn&#146;t expect revenue in Asia until we have a partner in real terms. So the pathway to
revenue in China, for instance, is find a partner and pursue state FDA approval of our device system for use with the already approved Doxorubicin. And that we expect would entail some clinical trials. Not very lengthy trials, but even a small trial
is not without its timeline. So I think we&#146;re a ways away from material revenue in China. The first step is getting a partner signed up. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Now in Japan, we have some opportunities for short term revenue that center around working with leading key opinion leaders and their institutions to
pursue clinical use of both Doxorubicin and Melphalan investigator initiated trials. So on the Doxorubicin side, we think we could get some revenue sometime in the next year, maybe 1.5 years. And the regulatory approval there for a Melphalan system
would be&#151;again, be dependent on local trials. So our partner there is going to be important as well. We did mention in this call that we have a relationship with Kobe University that we&#146;ve developed over the last few years and are looking
to expand that. So we do have a base of operations there in order to provide local data to potential partners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Okay. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On the Korean side, it&#146;s a Doxorubicin story very similar to China. And the other Pacific Rim, although not Asian&#151;the other Pacific Rim market that is much more near term would be Australia and
New Zealand, both of which have very per capita large markets in melanoma, our sweet spot. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity -
Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Perfect. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">So we&#146;re at the stage where we&#146;re very actively involved in choosing our distributor
for those markets and gaining the TGA, the local regulatory approval for our Gen Two system was a pivotal milestone there. So I would expect that we would have revenues in Australia and New Zealand sometime in 2013. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay. That&#146;s helpful
color, Eamonn. Thanks. The next question, staying offshore in Europe, I think you mentioned you have six centers actively utilizing CHEMOSAT. How many centers are you negotiating contracts with now and sort of what do you expect by the end of the
year the number of centers utilizing CHEMOSAT could be? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Well, I would expect another half dozen centers or so would be active before the end of the year. And we have many more than that signed up, but they&#146;re waiting for reimbursement to be established,
so&#151;which again, we think Italy we&#146;re now at a point where we have interim reimbursement established and we expect first quarter interim reimbursement in the U.K. and Germany. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay, that&#146;s helpful.
Slip in one more and then I&#146;ll get back in queue. As part of the expanded access protocol, how many patients do you expect you&#146;ll enroll in that ultimately or maybe over the next 12 months? And will you book revenue as part of that or will
that be part of the operating expense line? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Well, it&#146;s very hard to say how many patients will go through the EAP program. So it is really impossible for us to estimate. I think it&#146;s between&#151;since it&#146;s between now and June,
it&#151;let&#146;s say we think it would be more than five and less than 30 as a wild guess. I don&#146;t think it will be 1,000 patients for sure. I think it will be a relatively small number. But at this point in time, we are not planning to
charge for the systems, although we are revisiting that very actively at the moment. So&#151;and the driving force in our desire to consider charging under the EAP program, which you&#146;re allowed to do up to the cost of the system, is not only to
defer the cost of the system and our&#151;its financial impact, but also to really initiate substantive conversations on a real basis with reimbursement channels in the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Now, we can say that while we&#146;ve been preparing the EAP, which is a formal clinical program, there
have been compassionate use cases being conducted in the United States. We can&#146;t say how many. We can&#146;t say much about them at all other than they are a way for patients to access the therapy at certain centers. And we have been providing
kits free of charge to those compassionate use cases. And we have been made aware by the hospitals conducting those compassionate use cases that they have been successful in obtaining reimbursement from private payers for those cases, which is a
very good sign. And we&#146;d like to&#151;when we run the EAP program, we have a lot more insight into the ability and the negotiations on reimbursement than we do with compassionate use. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">So
that&#146;s an attractive prospect. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Right. Just as a clarification for one of my previous questions, Eamonn, you said six are currently using it, but many more signed up. I think last quarter exiting the quarter you had 13. What&#146;s that
number at right now? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Well, no, I was referring to&#151;I thought we&#146;d have an additional half dozen or six&#151;. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity -
Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;Utilizing&#151;. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;By the end of the year. And currently we have six centers up and running. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I
thought we&#146;d have close to a dozen. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jason Mills </B><B><I>- Canaccord Genuity - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Thank you. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your next question comes from
the line of Greg Wade with Wedbush. Please proceed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Good afternoon, Eamonn. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hey, Greg, how are you? </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I&#146;m good, sir. How are
you doing? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Good,
thank you. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Good. Hey, so let&#146;s
just turn back to the expanded access program. Is it your plan to potentially begin charging on this program? And&#151;. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;Well, I just mentioned that actually. And we haven&#146;t made a decision yet. But I can
tell you that we are very seriously considering that because of the ability for us to get into a substantive conversation on reimbursement far earlier than waiting until after FDA approval. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">And our
compassionate use cases are getting paid for, getting reimbursed. I shouldn&#146;t say our compassionate use. The compassionate use cases are being done under various institutions&#146; protocols and IRBs, so we really don&#146;t have any insight
into those other than we&#146;ve been told by those institutions that they&#146;ve been successful in gaining reimbursement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities -
Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right, okay. And just remind us with respect to what you could potentially charge per device in this setting. It&#146;s
up to a fully burdened cost&#151;. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#151;Correct&#151;. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities -
Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;Per device, right, so pretty much whatever you want. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">That&#146;s right. Well, we would&#151;considering all the investment we&#146;ve made in this technology and how few we&#146;ve actually made, practically speaking, we would be able to burden the cost
quite significantly. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Okay, that&#146;s helpful. Thanks. So it would be sort of can I say a near commercial cost then? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes, I would think so. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay. And then, if I just
might follow up. With respect to the reimbursement that&#146;s in place in Italy under this DRG, would the entire amount of that payment be available to&#151;for the system or is that to cover all of the procedure related expenses for the patient?
And I just have one follow-up. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems, Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">That is intended to cover all of the procedure related expenses. So we&#151;as we mentioned during the call, the range depending on the region is between EUR11,000 and EUR16,000. And just like in the U.S.
where reimbursements in New York City are far higher than those in Iowa, the same in Italy. So in the Milano area, Lombardy, we expect it to be on the higher end than the lower end. And that is a great step in the right direction in that at least
that much of the cost is now paid for. Now, the situation in Italy is that we have a distributor that we sell to at a discount. So if we have to discount in the interim while we&#146;re pursuing higher reimbursement or a dedicated DRG, we can
certainly do that and share that&#151;share those discounts with the distributor. So the net effect to us is not as significant at all as it would be if we were direct. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right. How much of
that&#151;how much of the percentage&#151;the real percentage do you think is left over for the product versus the cost of doing&#151;? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eamonn Hobbs </B><B><I>- Delcath Systems,
Incorporated - CEO, President</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;Well, the majority of the procedure cost to the hospital is going to be the CHEMOSAT
system. The drug is extremely inexpensive and the procedure costs are relatively small. Many of the procedure workup costs are reimbursed under other codes currently, so they&#146;re not burdened on the procedure itself. And we&#146;ve done
extensive work in laying out the business case for CHEMOSAT in various European countries. So these reimbursements are pretty material. They&#146;re going to allow us to get moving right now. We&#146;re&#151;we have applications in for interim new
technology supplemental payments, which go on top of the DRG to the hospital to help defray some of the additional cost of new technologies like ours. And then ultimately, that can either become permanent or it can become&#151;roll into a creation
of a dedicated new higher reimbursing DRG for CHEMOSAT. So frankly, we&#146;re pretty pleased with the EUR11,000 to EUR16,000 reimbursement because that will allow us to get moving. That&#146;s a major step in the right direction. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Greg Wade </B><B><I>- Wedbush Securities - Analyst</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">That&#146;s great, Eamonn.
Thanks. I&#146;ll jump back in the queue. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems, Incorporated - CEO, President </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Thanks, Greg. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Operator Instructions) And the
next question comes from the line of Jason Butler with JMP Securities. Please proceed. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Jason Butler</B> <B><I>- JMP
Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hi, thanks for taking the question. Eamonn, you kind of touched on it before, but maybe you could go into a
little more detail about what you&#146;re actually doing in anticipation of FDA approval in terms of reimbursement in the U.S. What are the steps that you can take here to minimize the time following product availability that you can get paid for
the product? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems, Incorporated - CEO, President </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sure, Jason. What we&#146;ve been doing over the last couple of years actually is working through getting a dedicated CPT code, a category one CPT code,
in the works and have lined up specialty societies to sponsor it. Now, the CAT-1 can&#146;t be applied for in earnest until we get FDA approval, so we&#146;re ready to go when we do get FDA approval. So that begs the question, what are we going to
do in the interim? So what we&#146;ll do in the interim while we&#146;re waiting for the CAT-1 code is to work with each institution to go under unspecified 99 codes, which will allow them to get paid. But each of these are theoretically a one-off
negotiation. So as I mentioned earlier, in the compassionate use cases we&#146;ve been paying as much attention as we possibly can to how the institutions conducting compassionate use with CHEMOSAT have been successful in getting paid under 99
codes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">So the good news is they have been&#151;these multiple institutions have been successful in getting paid and getting paid at a level
where they&#151;it wasn&#146;t prohibitive. Their administration allowed them to not only do it, but to do&#151;continue to do it multiple times. And these are from very large, prominent private payers, so they&#146;re laying the groundwork. So as
we move into post-FDA approval, we would have dossiers ready for new clinical sites to be able to present their arguments to the medical directors under a 99 code, while our CAT-1 code is in the queue, which normally takes approximately a year to
1.5 years. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Jason Butler</B> <B><I>- JMP Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Okay, great. Thank you
very much, Eamonn. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our next question is a follow-up question, which comes from the line of Greg Wade
with Wedbush. Please proceed. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Greg Wade</B> <B><I>- Wedbush Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Thanks. Graham, didn&#146;t want to leave you. Can you just tell us how many options and warrants were outstanding at the end of the quarter? </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Graham Miao</B> <B><I>- Delcath Systems, Incorporated - EVP, CFO </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I&#146;m sorry? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath
Systems, Incorporated - CEO, President </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">How many options and warrants were outstanding at the end of the quarter. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Graham Miao</B> <B><I>- Delcath Systems, Incorporated - EVP, CFO </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Yes. So we have at the end of the third quarter we have a total of 4.8&nbsp;million shares of options and 5.6&nbsp;million warrants. So if you want to calculate fully diluted numbers, then these two
numbers (inaudible&#151;accented). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Greg Wade</B> <B><I>- Wedbush Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Okay. And then, Eamonn, when do you think the expanded access program could be put in place? Is there an approval timeline? </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems, Incorporated - CEO, President </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The&#151;it&#146;s pretty imminent. We have six centers in various stages of getting their internal approvals. We&#146;ve been working with them for a
long time. One center is&#151;has gotten their IRB approval and they are lining up patients now. So we&#146;re hopeful that they&#146;ll be enrolling their first patients within the next month. The other five centers are very close to that same
position. So our goal is that we are enrolling patients before the end&#151;or before the end of the fall, which would be mid-December. So it looks pretty likely that&#146;s going to happen. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Greg Wade</B> <B><I>- Wedbush Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">And how will we find
out whether you&#146;re giving away the product or selling it? </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems, Incorporated - CEO, President </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Oh, we&#146;ll let you know. When we&#151;when the EAP kicks off we&#146;ll likely announce that and that will be one of the things that we discuss, what the&#151;whether we&#146;re giving the product
away or charging for it. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Greg Wade</B> <B><I>- Wedbush Securities - Analyst </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Okay. Thanks for taking my second questions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath
Systems, Incorporated - CEO, President </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">My pleasure. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no further questions. I will now turn the call back over to Management for any closing remarks. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B>Eamonn Hobbs</B> <B><I>- Delcath Systems, Incorporated - CEO, President </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Well, I&#146;d like to thank everyone for participating in today&#146;s call. We look forward to seeing you next week at the Lazard Conference, as well as
updating you on our progress on the next quarterly call. Have a great day. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOVEMBER 07, 2012 / 09:30PM GMT, DCTH - Q3 2012 Delcath Systems, Inc. Earnings Conference Call
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operator </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thank you for your
participation in today&#146;s conference. To access the replay for this call, you may dial 866-233-1854 or 617-614-4949 internationally, with the replay passcode of 87111973, again, 87111973. The replay will be available in approximately one
hour&#146;s time. This concludes the presentation. You may now disconnect and everyone have a great day. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="99%"></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DISCLAIMER</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Thomson
Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of
items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks,
which are more specifically identified in the companies&#146; most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove
inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY&#146;S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO
PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY
INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY&#146;S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY&#146;S SEC FILINGS BEFORE
MAKING ANY INVESTMENT OR OTHER DECISIONS.</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters.
All Rights Reserved.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THOMSON&nbsp;REUTERS&nbsp;STREETEVENTS&nbsp;&nbsp;|&nbsp;&nbsp;<U>www.streetevents.com</U>&nbsp;&nbsp;|&nbsp;&nbsp;<U>Contact&nbsp;Us</U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&copy; 2012 Thomson Reuters. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. &#145;Thomson Reuters&#146; and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="right">


<IMG SRC="g438628g69f51.jpg" ALT="LOGO">
</TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g438628g39q32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g438628g39q32.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!I0++`P$1``(1`0,1`?_$`0<``0`!!`,!`0$`````
M```````(!@<)"@0%"P,"`0$!``(#`0$!`0````````````<(!`4&`PD"`1``
M``8"`0$#`PX'"`H/!@(+`0(#!`4&``<($1(3"2$Q%-$BDE,5E197UZ@I:0H:
M07*R=-2W.5$R(Y-5%Y<8822U5G;6=SA8>'%2TC-#-+0E==4VEK8G&9%"-28W
MF(&AL6*"1&5&9[A9>3H1``$#`P("`P8.#0D'`08#"0$``@,1!`42!B$',4$3
M46$B%%0(<9'1,E)RDI/3%68G-QB!H;%"([/#A*2TU$6ELM)TE%5U%C878C-3
M<R0T-8*B0V0E5G;CY)7!X6.#HT1EA3C_V@`,`P$``A$#$0`_`-C[QB_$MW5X
M>0Z`#4-.UI;`VN.R`GQV&QLST6/P."E#&^Y/P=LE?[OTCX2+]]WO>]>P3L]G
MUW69>4O+K#[]\>^-9;B+Q7L=/9%@KVG:5U:F/Z-`I2G755ZY[<V\_P`KCC?B
M2"TF%Z)]?;-D=3LC#ITZ)(^GM'5K7H%*<5A)^\L<TOB>XU>\6R_E(R9?J[;0
M\KR'NHO@57OZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZV
MV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWE
MCFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD
M8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^
M!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[
M2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+
M9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(
M>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/
MO<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<
M:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM
M#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]
M\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:
M7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8
M^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/
MK;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?
M>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9
M?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J
M+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S
M_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:
MO>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*
M\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'
M$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7
MQ/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZN
MVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MM
MOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>
M6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*
M1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@
M4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`
MM*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]X
MME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'
MNHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[
MW/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]
MQJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0
M\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?
M(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8Y
MI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/
MJ[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3Z
MVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI
M]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7
M\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB
M^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W
M/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\3W&K
MWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KMM#RO
M(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(
M<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWECFE\
M3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD8^KM
MM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZV
MV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[2GWE
MCFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+9?RD
M8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^
M!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/O<_[
M2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<:O>+
M9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM#RO(
M>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]\AQ/
MO<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:7Q/<
M:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8^KMM
M#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/K;;]
M\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?>6.:
M7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9?RD8
M^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J+X%/
MK;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S_M*?
M>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:O>+9
M?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*\A[J
M+X%/K;;]\AQ/O<_[2GWECFE\3W&KWBV7\I&/J[;0\KR'NHO@4^MMOWR'$^]S
M_M*?>6.:7Q/<:O>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/\`M*?>6.:7Q/<:
MO>+9?RD8^KMM#RO(>ZB^!3ZVV_?(<3[W/^TI]Y8YI?$]QJ]XME_*1CZNVT/*
M\A[J+X%/K;;]\AQ/O<_[2IH^'GXY/*#EOS"T]Q[V!K71L%4=A.;:C,2M2B;R
MVL+0L!1;-:&@QRTO=Y:.(95]"I$4[QNH`I&,`=#=!#C]^\EMM[5VG=YZQN+U
M]U;AA:U[HRTZI&,-0V-IZ'&E".-%W_*[SBMW;WWU8;8R5ICH[*Z=('.C9,'C
M1#)(-)=,]OKF`&K3P)ZUM/Y657*6IE]J!\_#'\;>OY.JLM)YMG[W_-ORZI-Y
MX7[A]"\^[;+4VRTBI*F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3"+*IX)?[3OC%^?[)_5#?<C'G)]&^2]K#^/B4T
M^;U]+V']O/\`JLZ]$+*"KZE+4R^U`^?AC^-O7\G566D\VS][_FWY=4F\\+]P
M^A>?=MEJ;9:14E3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A%E4\$O\`:=\8OS_9/ZH;[D8\Y/HWR7M8?Q\2FGS>
MOI>P_MY_U6=>B%E!5]2EJ9?:@?/PQ_&WK^3JK+2>;9^]_P`V_+JDWGA?N'T+
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MU`^?AC^-O7\G566D\VS][_FWY=4F\\+]P^A>?=MEJ;9:14E3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%E4\$O]
MIWQB_/\`9/ZH;[D8\Y/HWR7M8?Q\2FGS>OI>P_MY_P!5G7HA905?4I:F7VH'
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MY.JLM)YMG[W_`#;\NJ3>>%^X?0O/NVRU-LM(J2IA$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBRJ>"7^T[XQ?G^R?
MU0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC^-O7\G56
M6D\VS][_`)M^75)O/"_</H7GW;9:FV6D5)4PB81=LS@)Z10!S'P<R_;"8Q`<
ML8I^[;B<G0#D!9NW42$Y.OE#KU#\.8\EW:0NT32QL?W'.:#Z1*S(,=?W,?:V
M\,KXZTJUI(KZ("Y)JI:B%,<]8L92$*8YSF@I4I2$*`F,8QA:`!2E*'41'R`&
M?@9"P)H)X:G_`&V^JO4X?*@$FVG`'^P[U%U*C-XBW;O%F;I%H\[ST1VJV63:
MN^Y,!5O17!R%1<=T8>ANP)NR/GS(;+&Y[HVN:9&TJ`145Z*CI%>JJPWP31QM
MF>QPB?722#0TX&AZ#0]/<1NR>.RN#M&;MT1HB9R[,V;+."M6Q/(=PY,B0X-V
MY!\YS]"A^[A\L49`D<UI<:"I`J>X*])[P2.":8.=$QS@QNIU`30#I)[@[Z^2
M**SE9)NV15<.%U"I(-VZ1UEUU3CT(DBBD4RBJAQ\Q2@(CGZ<YK&E[R`P"I)X
M`#ND]2_,<<DSQ'$TND)H`!4DGH`"[J:JUHK0-QL=:L->!V'5J,["2<.#H!#M
M=6XR+5L"_K?+ZWKY,Q;:_L;VOB<\,VGIT/:^GHZ2:?96;>XC*XT-.1MIX`[H
M[1CF5]#4!5=<RC9*2%8(Z.?R`MT^]<`P9.7@H)>4.]7!LDJ*2?4!]<;H&>TL
M\,-.V>QE30:B!4]P5Z5C06MS=5\6C?)I%3I!-!W33H7"SU7@N8O'R#5!LZ=,
M'S5J]*)V3ERT<(-WA"@43':+JID2<D`#`(B03`'4/W<\V30R.<R-[7/;T@$$
MCT0.(^RO:2VN(8V2RL>V)XJTD$!P[QZ_L+MHJH6V>9KR,'5;--1[43`Y?Q$!
M+2;)N)/WX+NV+1=!(2!YP,8.F8\^1Q]K((;J>&*9W0U[VM)]`$@E9EIA<O?P
MNN+*UN)H&]+F1N<T>B0"!]E4\("43%,`E,4QBF*8!`Q3%$2F*8H]!*8I@Z"`
M^4!S,!!%1T+7%I:=+A0A=["U6T64'`URLV&PE:!U=F@H23F"M0`.UU<FCFKD
M$/6^7UW3R9B7-_8V5/')X8=71K>UE?0U$5^PL^RQ&5R0<<=;3SAGKNS8Y]/1
MT@T^RNE616;+*MW"*K=P@H9)=NNF=%=!4@]#I+(J%*HDH4?.4P`(9E-<U[0]
MA!814$<01WCUK"DCDB>8Y6EL@-""*$$=((7U<,WC0&YG;-VU*[0*Y:&<MEFY
M738_4".6QEB$!PW.(>0Y.I1_=S\LDCD)$;FN+30T(-#W#3H/>*_4L$T(:Z9C
MFA[=3:@BH/01W0>ZOXFT=K(.'2+5RJU:=UZ6Y2;K*-VO?&["/I*Y"&2;]\<.
MA.V(=H?('4<_IDC:\1N<`]U:`D5-.F@Z33KHOXV&9\;IF-<8F4U$`T;7@*GJ
MJ>CNKYHHK.%4T&Z*KA=8Y4D4$$SK++*G$"D3223*9110YAZ`4H"(CYL_KG-8
MTO>0&`5)/``=TE?EC'RO$<8+I'&@`XDD]``[J[L:G:P`1&KV0``!$1&!E@``
M#SB(^B>0`S%^,+#_`(\/NV^JL_XGRPXFVGI[1WJ+I.Z5[T4.Z4[\%.Y%#NS]
M\"W:['<BET[P%>V/3L].O7R=,RM3=.JHTTK7JIW:]Q8'9OU]G0ZZTIUUZ*>F
MN\^"5L_O6LOO!+?H>8OQAC_^/#[MOJK8?$V6\FG]P[U%PG$+,M'#9H[AY9J[
M>"!6;5S&O6[EV83@F`-6ZR!%G`BH(%#L`;UWD\^>K+FVD8Z2.2-T;>DAP('H
MD&@^RL>2PO89&PRQ2-E?ZT%I!=QIP!''BN"LBLV65;N456[A$YDED%TSHKHJ
MD'LG3524*51-0A@Z"4P`(#GJUS7M#V$%A%01Q!'>*QY(WQ/,<@+9&FA!%"".
MD$+EDB953T+NXN24]TN\"-[M@[/[HBD(@J##LHCZ:*0AZ[NNUV?PYYFXMVZM
M3V#1Z[PAX->C5QX5ZJKW;9W;^STQ2'M:Z/!/A4Z=/=IUT78?!*V?WK67W@EO
MT//'XPQ__'A]VWU5D_$V6\FG]P[U%QCU^P)NDF*D#-D>N$SK(,CQ,@1VNBEU
M[U5!L9N"ZR2?0>T8I1*7IY1S]B\M#&91+$8@:$ZFT![A-:`KR.-R#91`Z"43
M.!(;H=4@=)`I6@7)^"5L_O6LOO!+?H>?CXPQ_P#QX?=M]5>OQ-EO)I_<.]1<
M%.&F5GJL:E#RJLB@43+QZ4:]4?H%+V.T99F1`7*12]X7J)B@`=H/W0SU-S;-
MB$SI(Q">AVH:3Z!K0K';8WKYS;,BD-PT<6AIU#T12O6%R%ZU9&J1UW5=GVR"
M8"91=Q#22"*90\HF455:E3(4`_"(@&?AE]92.#&31.>>H/:3Z0*]9,5DXF&2
M6WF;&.DEC@!]FBZ3J'3KU#ITZ]>ODZ?N]?-TS*6!0UIUJI'-.M[.))/NZG9V
MD$H4#IS;FOR[>'.0W3LG))JLR,C$-V@Z"!^@]<PF9''27!M([B!UT/O!(PO]
MR#J^TMG)A,Q%:"_EM;AMD142&-X8:]%'$:3Z:IS,Q:Q=C%1$O.O"1T'%2<U(
MJE$R;"(CW<F]4*7H!C$:,45W!BE$0ZB!>@=<\;BYM[6,S74C(H1]\]P:/3)`
M63:65Y?S"WL8I)IST-8TN<?0`!*2L/+P+P\?.Q,G"2"90.=C,1[N,>D(/4`.
M9J^107*01#R")>F+>YM[N/MK61DL)^^8X.'I@D+^W=C>V$QM[Z*2&<?>O:6N
M](@%<XM4M1RE.2L6,Y#E*<ARP4J8IR&`#%.4P-!`Q3%'J`AY!#/(Y"P!H9X:
MC_;;ZJ]QB,JX!S;:<M(J/`=ZBX[NOS[!'TA_!3;%OVR)]^\B9!JAWB@]$T^^
M7;II]XH/D*7KU$?-G[CO+29VB*6-SZ=`<TGT@5YS8W(6[.TG@E9'6E7-<!4]
M`J0N3\$K9_>M9?>"6_0\_'QAC_\`CP^[;ZJ]?B;+>33^X=ZBZ1=%9LJHW<HK
M-ETA[*J#A)1!9(>G7HHDJ4BA!Z?N@&937->T/80YAZ"#4'[(6!)%)$\QRM+9
M!T@BA'V%W1:I:CE*<E8L9R'*4Y#E@I4Q3D,`&*8I@:"!BF*/4!#R"&8IR%@#
M0SPU'^VWU5G#$95P#FVTY:17UCO47">PLS&@D:2AY6.*N<4T#/XUZR*NH``(
MIHBY02!4X`(=0+U$.N>L5S;3DB&2-Y'3I<#3T:'@O&>PO;4`W,,D8<:#4TBI
M[U0N=\$K9_>M9?>"6_0\\OC#'_\`'A]VWU5[_$V6\FG]P[U%QU*]8$7#=HM`
MS:3MV"IFC16)D$W+HJ!>TL+9N=N"S@$2^4XD`>R'E'IG[;>6CF&1LL9C;2I#
MFT%>BIK05ZJKR=C<@R5L+X)1,^NEI:ZIITT%*FG6N1\$K9_>M9?>"6_0\_'Q
MAC_^/#[MOJKU^)LMY-/[AWJ+C#7Y\'98\8&;!^=$7)&(Q,@#TS8INR9P5IZ/
MZ09N4P=!.!>R`_AS]^.6AC[;M8NRK35J;2O<K6E>\O+XMR`F\7,$O;ENK3I=
MJIW:4K3OKD_!*V?WK67W@EOT//Q\88__`(\/NV^JO7XFRWDT_N'>HNN6BI1N
MDX7<1DB@@S<@R=K+L722+1X(`8&;I51(I&[L2F`>[.)3]!\V>S;B![@QCV%S
MFU`#@21W1QXCOC@L9]G=QL=))&]K&.TN):0&N]B3U'O+@>?R!Y1'R``>41$?
M,`!^$1SU6,NX3KMA5<+M$H"<5=-2I&=-4XB14<MBKE[:!G"!&PJH%7('4@G`
M`.'E#KF.;RS:P2.EB$;JT.IM#3IH:T-.ON+-;C<B^1T+()3*RFH!KJBO$5%*
MBO5W5R/@E:_[UK+[P2WZ)GX^,,?_`,>'W;?57K\3Y;R:?W#O474%9/3MEWA&
M;L[-JHFDZ>$;+F:ME51[*23ER5,44%%3>0I3F`3#YLR#+$'B(N:)'"H%14@=
M)`Z33O+#%O.Z)T[6.,+"`YU#0$]`)Z!5?ANV<O%TFK1NN[<KF`B#9JBHX<+'
M$!$"(H(E.JJ<0#S%`1S^O>R-I?(0U@Z230#T2>"_$44L\@BA:72N-``*DGO`
M+L&D!//R**,8.:?)HJG;JJ,XI^Z(DX3Z=X@J=!NH5-9/J':(/0P=?*&>,EW:
M1$"66-I(J*N:*CN\3T=]9,..R%P"Z"&5[0:&C2:$=(-!T]Y<KX)VO^]:R^3R
MC_S#+>8//_\`NF?CXPQ__'A]VWU5[?$^6\FG]P[U%P(N'EYQZ2-A(F4FI%0#
M&)'Q$>\DWQRD$`,8K1DBNX,4HCT$0+T#/6>YM[6+M[J1D<(^^>X-;Z9("Q[2
MQO+^86UC%)-<'H:QI<XT[P!*2L/+P3PT=.1,I"R!"@<["7CW<8](0PB!3F:O
MD4%RD$0\@B7H.+>YM[N/MK61DL1^^8X.'I@D)=V-Y83&WOHI(9QTM>TM</L$
M`KKL]EBIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"+*IX)?[3OC%^?[)_5#?<C'G)]&^2]K#^/B4T^;U]+V']O/\`
MJLZ]$+*"KZE+4R^U`^?AC^-O7\G566D\VS][_FWY=4F\\+]P^A>?=MEJ;9:1
M4E3")A%)34O+'D5J*$C*'K;:L]4JB$Z=^$''M()9J#R7=-@DG`*2$2\<]MT"
M9>T';Z!T\@!G%[@V#L_<-R_*YJPBN,AV6G6XO!HP'2/!<!PKW%)6T^:O,':M
ME'@MOY.:UQ7:EW9M;&1J?34?"8XU-!U]2G7SYY;\C]<<CMAZWI&V+!7J.G7Z
MH@G76C2"59D1L%)BEYE,%7D0Y>"5^L^5,?JJ(@)Q[/0.G2+>5'+_`&;F=G6>
M9R=A%-DS-*3(2\&L<SPS@'`>"&BG#JXJ;>>G-?F%MW?]_MW#9.>#"]A".R#8
MRVDMM&9!4L+O"+G$\>LTIP5,7#1>X=V<'^%;74NO;)?CUE7=:LVE7VZ3@8E*
M4N22<<9T"SA'L`\.Q6`G3KU[LW7I^'-QVZ-N[9YG;DDS]W#:"<6089"1K+8?
M"I0'HU"OHA:_+[)W;O7DSM"/:]C<7SK<Y$R=F*Z-=R-.KCPU:74]J5VO&OCG
MO;2FMN9LUM76%KH41-<5[W$1C^>:H-VS^1(9%Z9BB9)RL)E@:('4Z"`!V2CY
M<\-Y[QVMN;-;;ML#?07=Q'G8'N:PDEK>(U&H'"I`^RLCEWR]WMLS;6[[O<^.
MN;*UFVS=,8Z1M`Y_@NTCCTZ6D^@"K9TJ?/Q+XD4;<U'8Q:6^N1=KN$57[U)1
MC*5D-<ZVHZQ(Q^-21D$7+1A.S\N<!.[[L3@B<`#RIDS=Y.T&_P#F!=;;R;GG
M:F'@A=)`USFMN+B<:F]J6D%S(V=#:TU>B5SN'OO]*N5=GN_#,C&^,_<W#(KE
M[&O?:VML0Q_8!P<ULDLA!+Z5T4'`@%=7H+F/M"W;$KVKN1-ED-X::VE/1U,N
M-8V$9*=6C"V=XE%-;+5Y5RE[I5^9@WSM-<AVZI"]D@@``?L'+[;LY<X/'8>;
M.;/A9C-QV,3IH9+?P`[LP7&.5@\&1CV@M(<#TCJJ#B[$YO[ER^?@VSO^=^9V
MEDYVP3PW/X4L[9P8)H7N\.*2)Q#VECAT$4K0B27$Y+^I[MCGFV7,,O&:6BJP
MU<F=%`YY2HI;08ME57!"@4IG+BJ20G-T#L][Y@Z9QF_7?ZAX':KV_@YLD^0B
MGWLOBSB*=X2MIZ"D?E?&>4NY=[1D=M;XAD0(/2^`7L;34>R="XF@'KBH(;<X
MZ2<3R\F>/M33[Y&T[*BXVA.4BB9!Q4K^[9RM6DTC!ZT[-I7YA,YS@/9`$#^7
MR#DJ;?WC#<<O8]VWYHZ"R<Z<'I$L`+96GOF1A`'?"@S=7+ZXM>;,NQL6*QW.
M08VV('@F&Y<U\#^^T12,+CT<#W%,OQ`K53;5JCBP:"2%'6E3V%NC6T"$=_OC
MBCZRFJA14Y!OV1$!=2;""4<%$.G452_AR..4MADK#/9WQHUS5Q:6=P_5U37+
M)9RT]YKGAI]!3!SUR>'R>U]L^)C3MRUOLA:1:>DV]G);VS7COO;&7_\`J"N=
MOQSSICYQ"S</):8><5F<1"'U*TX_&KK^%CJXWB&0"WL=;C4%IMU/^FE5%V#I
M!<#&'H/0>T4-'M1G*Z:U-ES$CC;OMTC_`!HW_:->Z0O/&.1Q#!'2FC0YM!]@
MKIM\R\ZK>[;DN4LDC^6;(8S9-QG9NC;$&-X211@R&2M>T[1KN-:]P0MM+V/Y
MD<E-#U"0H+[6&S[4I6*'OEZ6/:P1++9VCXQYJZ,ZVDS:*0<HXKJ9^^(N3M'6
M(0PAT#RR58QS<N=EY7(17;;[!P"6>Q;J+^SB+?`A,A)UM$G00>`)4.Y22VYN
M<Q<)BI[%^.W+<F&WR3M+8^UF:_\`"3B(,;V<ABXN#AQ<T+M=^<R=J538=CUA
MQZLS_1^FM73\E3:95M=BC`'?HUAZM%+V.S2C9()*?F9MXT4<*'<*G+V3@`@)
MNT<WAM3EQ@K_``\.<W=`S)[COHFS32W%9-)D:'".-I\&-C`0T!H'1TTH![[[
MYP;GQ.X+C;6PKA^&VEC9W000VOX(N$+BPRRO;X<LDI:7N+W'II2M2>TN\\/+
M3B3=MU75A&&WWQUM51A[->8V-9Q;[96M[NL:-C5;8A'H-FKVP0$L4W9=]@#B
MB00'_?#9X8NU_P``<P+;;6->_P#PIF()7QPN<7-M[B$:G"(N)+8Y&?>UIJ/>
M"R\S?-YJ<J[S>&8CC_QS@+F!DUPQC6.N[6Y)8PS!H:UTL<@-'TKHX<22I7[/
MI=2Y%:.X^\>4FK>/WQ7.)^N]NZ-EUE4T_AH4L2Z97;59SJ=GLN7\=!)/&1>U
MV3+D$WK034[?!83)9#9^Z,ONYSG/VK-G[BTO6`'\#X8=#=<.IKGEC_\`9-.-
M123]QX?%<P=E8'8(8V/>MOM:TOL=(2/^H\!S;BRXT\)S(A)&*T+@3P`=J@YI
M!%RTX:<[&;I%=HY;O./S9VT<)G07;N6^Q7R2[=R@H!3I+H+$$IR&`#%,`@/E
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MI.S6WA3*;-CX*(Y/2C.$6WI'PS>+92`E3N\*2D/K@PAP*S9VIW&=^*Q>R!@Z
M"7H!"I@&QY?.8,?N6#"OEDV0QSQ9.>7.;QA?VS87/XF(.TZ34CKZ25J>:S)3
ME]GW.XF01<QI(VG(MC#&OX3L%LZ=K*-;,Z/5K%`>%*`!H4CN5=L\2YCR%VBT
MTDVW6KJM&>0+35*S38V3@C1XP\8=R,:_7@W:KE'W3,OVA,H;H?M!U\G3..V)
M8<EI=HV,FYG8T9TQ'MNTF<U^K6ZFIH>*'3IZAP4@\S\KYQ<&_,E%LQN7.V!.
M.P,-N'QZ=#*Z7=FZHUZNL\:J%,5:N3T]S'XN,>4BUU+<(78FO5*ZRO,.SA)1
MI796[-E._:MF<?']XR>2+-7H<Q3")TS``^3IDESV&R+7EUG)=C"V^+Y+.X$C
MH7E[3(V$\"2YW$-(X=PA0U;97F5?<W-M6_,MUW\:PW]H8FW$8C>V)]RWB`&L
M\$N:[C0\05'+EF(CR@Y!B(B(CN"_"(CY1'_YB?9V.P/\CXC^[H/Q;5'/-7CS
M)SO]ZW7XYZE3N*\6S7'&;PYKQ2)MU7;968/<SZ!FF9&ZKF-=GMK9L==!-X@Y
M:F,9!<Y?7IF#H;S=<X/;N+Q^9WKO#%Y2)LUA/+9M>PU`<.Q)H:$'I`/`J4]X
M9S*[=Y=[`S6%F=!E+>'(NCD;0EKO&6BH#@1T$](5YM2\ON2MAX>\K-C3.W+$
M_N]`L&G6E.L*K2`*[@6UBL9F<XBU22ATV:A9%KZP_>IJ"`?O1*/ESG-P<O=E
MV?,/`X>VQ\+,9=Q79FC!?1YCC!82==1I/$4([]5U^U^;7,3(<I=S;BN\I._,
MV,U@V"4MCK&)9RV0`:*'6W@:@T'10\51/!O>FX-X\S*%-[1N\M=IVOZSVQ%U
MYY((1J+ABW7JDJ^!HW)&L&*9P4D#`<.V4P]H>G7IY,V?-#:VW=L<N;JVP=K'
M;6LU[:ND#2XAQ$K&U.IQ^]X<*+3<E=\[MWMS:LKO<MY+>7D%A>,B<X-!:#;R
MNH-+6_?&O&O%<@;MXP(F$`9<B.G:$"_^7T/YNOK?-6OW,_'Q9YO-/78CW]WP
MB]OCKSLJT#,[3^BCX%<7@[8]O37*CD7/W1U8G&[AT+N`DHL[8I(6HM[B/@Y'
M,FQXUJU12)-,Y%@BB5$J/E53`O9$?/Z<S[/;UML/#VF-;"-L?&UGI`<3%V#^
MT<3J)/@%KB22>@UJL;DQD=VWO,[<%]F'7#MY_$60#R6TF\9C[)K1H#1^$:]K
M6ANGUP`HO[0]A^+(]MM::%9;ZE#+RC`B\=>:(9&I.VPKI@\1L:LW7VD>A$&0
M[0.%#J)B1/J)3`8`'/YE<1R#BQ\TA=BF`,=1T$]90:<#&&2%Q?7UH`-30$$+
MVPVX/.CFS$,+(\U('2CP;FV<('"O$2F2(,$9'KB2*"I!!XKE/V_'*(\4*02,
M:BM=;H33@[<KD&2FL8[<*M([;=%YV?\`FT*RTV4<.\#R-TW("`]"%$`_$3]Y
M7'(]CAXT[,F(5IJ\9=:=MQ(^^[0VW1]\6]\K^SLY>VGG)R-_Z)N!$Q(U:39L
MOC;5`=][V3;SI^]#N'!H516>_P#BBZ9N9+CM)C?K_KA"4(M98:)BH*\:ALE1
M%P'NG'-65?8OXV,AGD4)R(*'2;G1*)3&Z=!`<.RQ/([<F-..P3[2TS)CI&]S
MGP7<<M/!<3(YKG/#J%P!<#Q`6SR6=\Y3:&8&6W+'>WVW1+66-C([BRE@KX30
MV)KHF1N94`EK"T<>"Q;[4G:5:-CW6R:YK#JET>=L,A+5JI/'+=VO78U\KZ06
M)[]H1-L9!FL<Y42D`"IH]D@?O<G/`VN3L<-;6>8G;<Y2*%K))0"!(YHIKH:F
MI%":])J>M5@W7?8;);CO,AMZV=9X::=[XH'$.,37&NBH`%&UHT`<&T"R6\<T
M-PO^(D<RX52L4QW@EL2U.=\LX1]7HW;LA6NZ;%H(5QS.F3<J55%F"@J$9J$,
M+H3=D1-WH#"N\G;=BY@ODYE1R.VP;2(6)>V1UHV2I[?M`RH[4FE"\$:*=6DJ
MR'+QFZY^5$<7)V2)F\Q?3')-C=&R^?%1HMNR,A#NP#=6H1D$R5I7P@K,[KW1
MNAYIZT::YCZYODQLDDS"3&F]DW:#0A+'5!:N#%MD2[FW$:W<6J`F(T0(1-)5
M7NU3=LYA`B?9Z/;.VMM1[A@W'RYO+6/#&-[+RWA>7QRU'X)P8'$12,=Q)(%1
MP`XNKR.\=X[QDVE=;4YM8^]EW"V:*2PN[B/LY8=+OP[#(Y@=-$]E`!J-'\23
M1H%^^`G+7D=L;D50-;W;:]@L%'&L6U$:Z[:P23,4JY1Y1:$3[UG$MGG2/58H
MF)_"]1%,.UU#KUY7FQL#9V'VA=YG&6$4.4[>(]H"\FLD[`_@7$>$'&O#KX47
M;<BN:W,'<._;';N9R<\^%\7F'9$1AM(K:0QBH8'>"6M(X]0K7BH3WGEGR,VZ
M#6B;)VM/VVHJ7*$?GA)!I!(MC/(B9`T<X%2/B6;GMM1.(EZ'Z#U\H#DEXS8&
MSMOZLKAK"*WR`MWMUM+R:/;X0\)Q''T%#F9YK<PMUZ<'N')S76*-RQQC<V,`
MN8[P3X+&GA4]:R3\R;UX@L/R*V`QT@IOO^;!`*V-=&F5&1E:UVE*O#J2ON>_
M0@GJ2W_.YU^]Z*F[*W:+Y.G0(9Y<XKE)<[/M)=S#%?'9[3M.VE:V3A*_3J:7
M@CP--.'10JQ/-S.<^;/?]_!LSX[.VVF+LNP@D?%Q@C+]#FQN!_":Z\31U0HZ
M\RS763XKZ+GN2L<RC.4KJZ6MLW%['Q<3L&6TZ2-5.R?WR-C$FQT5$YH42M3.
M$R*"4PCT`YELZ[EP,;#OK*VFRWN?L9MK$31SG0,N]7%L#G$U\"I=I-*]X-7!
M\VSE[CEO@[[F''''S*=?2@:FL9=/L--6NN&-#2"):",O`=I)/27E2NY/V;Q`
MHRXT1KQJ0VXMK4-*ZJ4`]+JL?-0OPB/72A,%!ZZAWROI@%*CWA.\Z%\G0`ZY
MPFR++E-/C[N3>AQXS7QG=#\-*6/[/M/`X![>'30TXJ3N9&2Y[6N4L8N7+<F[
M;WQ/9'_IX!)'VO8C7X79NX]%17AW%C:Y`V_F3+R6LH3E8IL5!JG8AF*4QOM?
M807>."O(IA,O8ST6+CU'/=IJ()J]1,4O:+Y`$<F;:6.Y<V\-[<[#%F9.QT3.
M@D+Z"CG,#JN=3[XCHKQ5>-]Y?F]=76.LN9YOVQ=L7V[;F(15-6-D<SP&$T\$
M'IIP627EQ:O$AC^0%[::$;;G5U2E\'O@PI5*?&RL"8QZS$'F/07Z\(\67Z31
MG`*=I0W95[10Z``!D,\O[#DU+M.UDW4<:,\>T[7M9G-?_O'Z-30\`>!IIPZ*
M*P_-3*><+;[ZOHMC-RQVP#%V)AMP^/\`W,9?I=V;B?PFNM2:.J.BBQN[;W=S
M?H^R-?VG<]EV+4]FU"'G'FO'UM@(>(F(R%LX+0TXZC&IX5%NX:2?HAT#G434
MZ&3$"B40R9=O[8Y8Y3#7=CMN&SGPMQ(P7#8I'/8Y\5'L#CK)!;4.`!'2*U5=
MMV[TYT83<5AD]WW%_:[BM(I'6KIHFQO9'-JCD+6F,`A^ES22#T&G0IA4WE[R
M4DN"^Z=J/MMV%QL&L[NU[5X&T':0(/8V`F(U!:3C$421!6)T'BIQ,83I&.`^
M8P9'>1Y>[,AYHXW!18^$8B?&3ROCJ^CI&.HUQ.O54#N$#O*7L-S9YAW/)3+[
MIGRD[L];9>VACFTQZFQO82YH&C30GCQ!/<*I#@GNG<6Z>5DQ;+W<9FZ7J+XY
M[4A:S)N&\<210%JV0?0S!FC'L6;=4Y)AX)TP,F83*'Z#U#H&;'FGMK;FVMB1
MV&+MX[;%OS%J^1H+M)J=+W$N<2/`;0T/`!:?DAO+=N\N9D^5S=W+=YJ/`7D<
M+R&ZAI:71M:&M`)[1Q(J#4FB_"=V\80P$#T'D2)S`4.G\WT/VA.(!Y.GP:\X
MCG].,\WD??8BG](=\(OT<UYV1=1K,[2O#_I1\"J-XSVFX;KF>5/&;;4@]>W;
MD!`S]GCU)U-%J^0Y!ZR4<3;'TAHBBW0:2DF6/7;."ID)U%L4G3-CO6PQVV;;
M!;UV^QK<9B98XW:*EIL+FC'4))):W4US:D^N)6DY<Y7+[RN]S<N-UR/?F<Y#
M+*SM?!<,G:%TK`6@`-<_2]CZ`>M#:*/7#76##8G(:IM;>EZ+2==A*[2V8H[+
MV$F%2UL@:=E6[T#@`%*\?M4&9BFZ=17$,Z_F/G)<1M">3'G5D[S3;6P'2Z6X
M.AI;Z#2YX]JH_P"4&V;?.[_MH\J-.%Q^N\NR[@&P6H,KPX'J<6MC(/LU._C+
MMW<^VF?B+;?U?\(3[?N+?7D[2&M=:)2<\T%2UV%O%146Q70=(.#1553]'`@I
MG`$TA$`ZAUR*][;>VW@'[.V]F^Q&WK<W#)C(2UA_!1ESG.!!&J4ZJU'$J<N6
MVZ]W;I&_]U;=[<[JNA9R6XB:'R-K<2AK&MHX.T0U9T'P6\%0#S87B\1[-Y(/
MDN0;1BP9NGSYVO089-!JQ9H*.7CI=0:WT30;MDS'.8?(!2B.;>/$>;[-(V*(
MXETKW!K0)W5+B:`#\)TDD`=]:*;<'G700OGG&<;!&QSG.-J`&M:"7$GL>``!
M)/<78\(;QKZI\5>1+C<,3[O:QNVX-6T._@!A*O&0MWC)=BM:V@$(81?5I\*3
MY,2`!R"D)B>O*4!\.9N,RU_OO#MV[)V6;ML==3P=QSX7,<(C_LR-JPUX&M#P
M)63R8S&$QG+'/.W9%VVWKS*6=M=<:%D<[9FF9O\`MPN#9&TXU;5OA`*V^DM(
MV#CWXC6DM>3#@LFR0V1"3-.M#7LFC[C2I=G(.:Y9XU=,1151?LO6J@03%3<$
M4)U'L]1W.YMS6F[N3F3R]N-$ILGLFB/KH9F%HDC<.D%KNBO2T@]:YS9>R[[8
M7G!8C!73A);B_CD@F;ZR>WDJZ*9A'`A[>FE0'!S:G356-1Y4<@])6/9]5U5M
M"=I=>>;/O,\ZBXUK"+H+2[F8<-%WQCR44^7!51LQ2((`<"]"!Y.O41ZAVQ-I
M;FLK*_SMC%<WC;&%@<XO!#`P$-\%P%*N)Z*\5Q;.:&_-F97(8K;.1FM,>_)3
M2.8T,(+W.TEWA-<:EK6CIZE.+G;R[Y)ZLW1#5;7VVK#6*^]T]K"P.HQDT@5D
M%IFP5\SB9?F.^B':X*R"_KC@!P(`_O0`/)D8<K.7NS,[MN6^R]A#/=MR%S&'
M$O!#(Y*,;X+@*-'`<*]VJFCG?S8YA[6W9!C<#E)[>Q?BK25S&MC(+Y(6N>[P
MF$U<22>-.Y14UQX2W+*<1HYOPLEHMGO`-BVY[OYK"/J[&[?DH!0&_P``QKSB
M<%)R>JI,Q4%0C-0AA=";L]3=Z4<W=YVY!S`>_F3'([;'B<0L"]LCK1LG'M^T
M#*CM2:4+P1HI7AI*UW+\;MN>54;.3\L3=Z>/3.R;8W1,OGQG3XMV1D(=V`;J
M+A&0>TK2OA!66W5NG=#O3]FTYS%UU?)?9B,W!S.G-EW6#0A+'5`:.#%MD0\F
MG$:W<VJ!EX[H0B:2JO=JF[9S"!$^STNV=M;:CW#!N+EU>6L>%,3V7EM"\OCE
MJ/P3PP.(BD8[B20*C@!Q=7C]Y[QWA+M*ZVGS;Q][+N)LT3["[N(^SEATFD[#
M(Y@=-$]E`!J-'^$2:-`Q\Y+BKZF$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(LJG@E_M.^,7Y_LG]4-]R,><GT;Y+V
ML/X^)33YO7TO8?V\_P"JSKT0LH*OJ4M3+[4#Y^&/XV]?R=59:3S;/WO^;?EU
M2;SPOW#Z%Y]VV6IMEI%25,(F$7.C/_B<;_TBP_Y6CGG/_N'^T=]PK(M/^ZC]
MN/NJ<_B8`)>8VQP$!`?<77GD$.@_]@X#(MY*&O+JSI_Q;C\?(IM\X\$<VL@#
M_P`*U_5854N[+#8J]P<X,J0$_.P(NW.]RN3PLO)1/I14;@S%('`Q[EOZ0"(J
M&[/;Z]GM#TZ=1ZX6VK.SO.9^Z!=Q12Z6V--;&NI6$UIJ!I7KITT6TWCD<CC>
M2VS'V$\T!><G70]S-5+EM*Z2*TXTKT5-.DK[<,K1:K!1>;2$[9;'.MVW$N\K
MHH3,Y*RJ#=47+5,5TD7[MPDDKW9A+VP`#=D1#KT$<_/,>QL+/*[9=:PPQ/=G
MX`2QC6DBAX5:`2.\OWRARN5R6!WDR_N)YV-VM=$![W.`-6"H!)%:<*]-*]TK
M^4J#'EKQ-HVEZ9(1?\_G'2SVZ3K%'E)-G%/-EZVNRY).12JCB16;-'EBK\L0
MH&:"H!C($`0\J@=&3NO\`;_NMR9%DG^%,Q!$V69K2X6UQ"-+3*&@D1R,^^IZ
M[T$PUD.:O*VSV?B)(_\`'.`N9WPV[WM8Z[M;DB1XA+BUKI8I!ZRM=%"*DT77
MZ%X;[/INPZ[M+D;7'VCM-:NGHZY6^R[!%"#<2Q:T\2E6E9JL0NL,G8)F<?-$
MT"$;I&+V#&$#"?L$-[;JYC8/)8B;!;.F;E-QWT3H8HX*O#.T!:9)7@:8V,!+
MB7$<0.%*D8VQ>4&Y,-GX-S\P('X;:6-G9//+<_@R_LG!XAA8[PY9)7`,`8#T
MDUK1IK6D;*/N>+\47:9FJC1&\ZT93S1FJ`"JSBG&R6",2U<=D3%[]"+11(IT
M$0[8#T\F:S)X4;;GV/@M0<ZUO3&2.@N%LXO([Q<21WEO\)N1V[[;F/N8-+&7
M=BV1H/2UAO(]`/?#=(-.%1P5S:K88:0T#2.<3M\T&]Z)T;;^.BB"JG;D'FW"
MN&U/U!8!*/4RBT?0[BX=G./K@,T((>0HB&DO[2YBW9<\L(VN^*LIE(LA6G@B
MUH9;N/O!T\+6`?[9[JZ#%Y"RN-B6?.:1[?CK"X:?%=-7F]J(+&2G66VMPZ1Q
M/&L3:='".=]+7AXA<"/AF:3"HJ;)WJ6U+1)R%EPKQKY7@G%HU59%RG[I$CS*
MF2$R:@"H`=2CYL[+%&\',+=?Q;H^,!96/9!_K.T["30'`$'3JI7B.'6H]S8Q
M[^5&R/CCM!BG9')]L8Z:^R-U#VFBH<-6FNFH(K2H*JRQ<0N5&L;\\L7$)?8%
MVU)8'Q9K6NP]37--<DE7GW9<1B5E-#R<:5O,,$3@BZ]);D1,<@F#H`B4NOM.
M86Q,WBFV?,(6EKN"%FBXM[J$C3(W@XQZVNJQQXMTN)`/V3M;_E/S.VWG79#E
M0^^O-JW#^TM+JSGJ'Q.XL$IB<VCV-HU^MK6U!IPX"X_(/<DMJ':7">\[3=05
MJY.:E:+2O(!>NK1+J04A%;`E\&JS9W\/TC'=U:5)9V"O9-T345`1]8<HCIMH
M[<@W#@]RXO!-E@V3?N#;`2!X;K[,]I)$U_A"$RAM.'$#N@KH=^;PN=I[FV?F
MMS.@N>8V,:7Y,Q%A?V?;`PPS/9X!N&P%X=QX%P)J"%93>_#;:%PV#8-H<<ZX
M^WEIK:$[(W&GV;7W<3CB*)97BLJZK5JB4%@DJ],P;UVHW4(X2(7LD*(F`_;(
M7IMK<Q\'CL1#@]XS-Q>X[&)L,T<]6!W9@-$D3R-,C'@!P+2>D\*4)XO?')_<
MN8ST^Y>7\#\SM+)3NG@FMJ2%@E<7F&9C?#BDB)+'![1T`UK4#L[Q!AQ,XEW?
M2ESD8K^?SD3:JC+VFCQ<FSE7FM-;TE8TE&HVMQ'+.6;.PSTL8>RU!0QRHG$1
M_P!['KX8NZ_Q_O\`MMRXYDG^%,/!*R*9S2T7-Q,-+C$'`$QQL^^I34.^LK-6
M3>5?*N\V=EY(O\<YZY@?-;L>U[K2UMB7L$Q:7-;+)(3X%:Z.)H0NDY96:P4B
M5X27"K23F$LE:XGZ6G(*5:F$CAC)1[R:<-7"8^8Y04)T.0>I5"")3`)1$,R=
M@V-IDX-S8Z^8V6SFS]XQ[3T.:X,!'J'I!XCBL'FCD[_!W.S,OC9'0Y"WVMCI
M(WM-"US72D$?9'0:@]!!"E?L*5UUM3A7R@Y)T,K2$G-P)Z58[AH3,A2-ZMMJ
MHWUB$_+,2E'JG%W5M,HOT0$/7&$Q^HG,H4O!XB#,8+F5@]EY75+:X[QUUI.>
MF6UE@=V;'=UT)86'N"@Z`"91W!<X#<_)W<O,3!Z(;S+#'-OK9O1#>P73>UD;
MW&7`D$H!Z]1KJU`8RN*0=>3G'T`#KUW'KP.GGZ];/&^3IDV;\_R3EO[NN/Q3
ME6WE;QYD8(?_`.6M/Q[%)7;?+3?VGN7NVI&O[)M\A!U;<%S9DH<[8963I<A7
MVU@>(+5ES`.W*S!O&+L@%$@HID4;=0,D)3%`<XK;^P-I[BY>X^*[LK=EU/CH
M3V[(V-F;(8VD2"0`.+@[B:DAW0X$$J2=U<U=\[0YL92>QR%U)8V^5N&^+22R
M/MW1"9X,1B<XL#"WP1I`+1Q:00".3R!U!5$-A:)Y-Z82>K:0WW<JE(I-5W3B
M2<Z^V,C86'PHH4J[<*N'"8I.453M`5.8>B2R9!%--,1_&T]PW[L1E-D[D+1N
M;%6\K20`T7%N6'LIV@4'$$!]!UM)XN-,C?.TL8S/X3F1L\/.S<W<Q.#2XO-K
M=!X[:V>XDG@X.+*DU`<!X+`3(_E_H/GC;.2NV[%J>)W`OKR4L+5:KJUW81H:
M%.S3@XENN,?&?"R/]$2]/16`2]RGU/U'IY>H\;R]W7RJL-F8^TS\F.&89"1*
M)(-;ZZW$:G=DZITD=9X+O^;.Q^>.4YB92_VK'E3@))P83%<]G'I$;`=+.V;I
M&H.X:1QJH02=5WYQQWEHK97)J$NC$S&[5R=CWUPGR6B3>U^F62*?3:+)P28F
MG)48Y)_VRHB8@"=7UH"(CDG07^T]X[7RF%V3+;.#K:1CFQ,[)K9)HW-87#0P
M5=IH3QX#CU*%KC&;[Y?;VPFXN9$-VPLO(I&.GD$SW16\T;Y`TA[S1NK@VHXN
MX=)5Y^3/"WD!?=[7W8FGJ(_VYK3:UHD+Y2KQ1WL1+03V+M2WNJ5!\["02)%N
M6"SDZ2GI'=DZ$`P&$!'IS>R>96TL3M:TP^XKIF/S5A`V":&8/8]KHAHJT:?"
M#@*C34\:478\R.3>^L]O6]W!M*S?E-NY.X?<V]Q;N8^-S)G&2CG!U&%NK2=>
MD<*]"I#FP:/HE"XL\<%)F)FKMI'7EB4V5[AOT)2/@K9>IQ":-5Q?M3';K/H=
MNW$%P*(]GMD$>G7IFPY9B;*Y7.[R$<D>,R=Y&+;6TM<^*!A9VND\0UY/@^@5
MJ.=!M\)@]M<OC-%-F</8S&[[-P>V.:YE$O8ZVU!=&!X5.Z%^-&`(\!^;H@`]
M`M&@^H]/('6V&Z=1_LY_=TD?ZK;9'7V%_P#B@OYLH'_0K>1ZO&,7^L.7Z\,1
M-97EQ6TVX',X4H6TR(`F/0XKGI,F5'L&ZAV3=X(=!ZAT''.XM;L"8OIH%W:U
M]#MFU7\\VMKW<T8&QU[0V=W2G37Q:6E/LKN#<8O$T[1A"$WWT[1A#_S6-YNH
M]/\`^>?W,QO\;<DO^+BOZK_^"LT\M_.1KPAS=/Z9_P#F%6'"ZI;-U=R)Y%PF
MQF<[7=FPW&#;\W+>Z,D5Y8&DJ^C:]/,99:6:/7IE)%8KE)R"X+F4`Y@,(@;K
MFOYDY#"9S9^'N<.Z*;"29RT8S2VD9:UTD98&$-\$4+=.D"G"E%M.3^*W+MGF
M!N&RW"V>WW)#MJ_D?J?JE:]S(I6O+VN=5QU-?J#B:FM:JS_'+F1<H6T_`SD%
M=+CLS1.R&Q*KL:'M%FG)9Y!Q\EV4$;A7)19Z>6AY.OKF*NIZ,J0%D"G*)3'!
M,2]#O'ESCKFP^,MI6UM9;ILSVMN^*-C`]S>)AD:&Z'MD'@C4#1U#4"M>7V!S
M=RUIEW83?=W=Y'9.0_`74<TTKW1M>:":)Y<7QOB-'>`1J:"*$Z2.\/Q%H=#Y
M3S.@MO7!U`TZYU6<D-$;/+(,F%<G7\XS%UK"4L$DLS=,U81VX(=B_!(4NKTH
M`50I#E$<4<P<KE=BQ[KV];-ER-M.QM];:7.D8UAI<MC:""'@4>RM?`Z02"LM
MW*C"83F=-LC=5XZ#$WEK([&WFIK8I'R-U6<DCRUS>R<08Y-.G\)P:X-XFOM2
M<>O$OTS>HN+HC'8-/BH^3;`YFEK>Q<:;&)1<D%S(R2KR7<5EU7C-"F4.`(^D
M"CU`I`/T`-3N#=W);<F+?/E'6EQ</8:,$3A=ZR.#6@-$HDKP''37I-%O]J[!
M\XO9^:CML&V]M+2.05>9FFQT`\7O)>8'1TXG@7:>@5X*+G-.:UU8.3^W9?5A
MHE6H.Y]OW;R`332@)*>1B8]"URD(1$`1]S)"RINE4S$]8KVA4*(E,`YW7+6V
MS%IL?'V^=[09!L1X2<9&L+W&)KZ\=38]((/$4H>(47\Y;S;]_P`RLK=;9[(X
MITXHZ(`1/D#&"9\8'#0^8/<".!!U#@0KF4OBW*[6TKK_`&EQ8?3MGVU7G4]$
M;KH;&T1["Z0,B1_WM8LE-CDQAWZE<D8?IWG8675[_P`A1,)5"DTF2WS;X'<M
MW@]]-B@P$S8WV<[HG.AD;II+',XZVB1K^BH:-/32H)Z?#<L[K<^SK#<W+"2:
MXW3`Z5F0MFS,;/$[7^!E@8`QQB='TD%[@\4%:.#9(/D^0-'XA;Z@N;3V5+!S
M,-`1_'VJ[0E&4QLO^<Y&836]UZP5PZ>V5E!QD6!S/#N#@0$P$I0`IC@?C(G;
M3RG,+%77+-L?C,<DCK^6V:66WBQ81HDH!&Y[G4T!HK7B>(%)$F;OG"<I\W9<
MY7R^)RQ1-QD-X]LEWXV)`>TAU.,S8V,U=H7$#3P:*%U8[^&:`FYA4```1'X.
M[(\@!U'_`+!SV=ASK-.7EW7_`(UO^/C4=^;>">;%B!_P+K]5F4*&/_:UE_A.
MV_NP3)+E_P#'N_Y)_DJ&[?\`\LS_`)X_E+)ISIY$[UU1S2V`2A;5O-<CZVYI
M+V*KS:PR9JLDH>FUYZY07K*S@\*Z9/G"IS.$CHB17O#"/E'KD*<KMG[6S_+:
MT.5L+6:69LP=(8V]J?PT@!$@&L%H`TD.J*"BLCSLY@[UVKSBOQA,G>P6]N^W
M<R(2O[$5MX7$&$GLRUQ)+@6D.)-0:JW?+&F5W=.K*WS:U7'&9,[*X"I\@J<U
M=.WZ6OMI(ID*$JT(Z5<.&-8M1E0.B7J5%,ZR(E`#+F*7;["R5YMK.3\L\Z_5
M)"WM;"8@-,]K[$T`#I(J4/60'5X-!.DYFX;'[RV[:<X]L1Z(KB00Y.!KG.%M
M>"GAM!)+89Z@M%0&DM'2_2V6?+O2O,^^7^B3VB(S:3JB?S':F9=[4+R-=A_=
MMM7>LF7W.^$T3_;8`JEWBG<^O\GKAZ>3@>7VY.6^*Q5U:[J?8MROQG=&DL/:
M/T&3P?"[-W#@:"O#N*4.:^S^<&<S5C>[&CR3L)\363:P7'9,[00C7X/:LX]%
M33CW5CQV[I/E;KY2BV?D-![`;0Z]MCX"O2=VM:5F(22<K)R3B/CP-/S+AH9P
MVCQ4/V2D(?N@ZB(@&2]M[<NPLLVZL=H2VCK@6[I)&PQ=GX(\$.=X#`:%U!TD
M54!;IV;S2P3[+)[_`(;YMF;D11/N)A+1[O#+6_A'EM0VIX`&GH+(3S/T3SGN
M/)#85BTY%;<<:[?A60@%:QL`T'"&,VJL*UD_0XOX5QOHW2416!3^`)VU`,;R
M]>HQ'RWW3RNQVS;.SW%)CQF&=IV@D@UOXRO+:N[)U?!(IQ-!0=5%/7.'9/.S
M+<PK^_VA%E#@).R[(Q7/9Q\((FOTL[9M/##J^"*FIZZG&9OW3W);6QZW,<B(
M6[,5ITK^,K,C=;*E973E**%!V_9,G'NW,N&R#4\F102")""941`!$1R:]I[B
MV5F1-;;/EMG-B+72-AC,8!?4-<1H8"3I(KQ/!5NWYM+F/MXV]YS`AO&.F#F0
MON)1*2&4+FM/:/(#2\&G`5=PZU?G7X#_`.FKR'-T'H'(W50"/3R=?<AMY.N<
MIEOIHQ`Z_B>Z_EE=[M\'ZNF>/5\?6GXLKL/#$;/WG(BTM(DJYY5UH7;K:+*V
M4[IR:27BH]&/!NMVT^Y7%X<G8/VB]DW0>H=.N>7.]\,>T()+B@@;E;0NKQ&D
M/<75'6*5J.L+U\VF.>;?=W%:AQNG82]#*&AUF,!M#PH=1%#44/&H7T3XQ>)L
M4I.L)OL#`4OE_G6-U`P`'X?ASY^N?D[VY)?\7%?U7_\`!7H[EQYR.HEL6;I7
MRS_\PHGIN]H<<-[1\Q96,E![5UC=8FR2K"3>I.Y()A!=K.+(23YNZ>)NCS#1
MUT7-WJ@J$7-VA$1'.^='@]Y;5?;V3F2X*]MGQL<UM&Z""P%K2!301X(H*%HH
MHI9+N;EWOF.ZR;)(-S8Z\9*]KW`N[0%LE'N!=76#X1J:AQJLCG)6+J.A-6[T
MV307+4"\Z['5U-9^BJ)BO$Z:D8:-V3L=$I2")VQ'5QF21*A/(`I$`/P9#FRY
M\ANO.XO"Y9KJ[6AE%S4<'7C7NM[<]^D+#*#W2K#\QH,5L;;&:W%@W-`WI/";
M2A%66#V,N[H4Z@9Y&6[F^Q:K;<#J]L"UZ*YOU[5:$TXV%*4S5+>K)5V1&(FC
MR!;3/+J!'R8/(_T-;T%%81-WR?4@&#KY>@[KFK>8FPW1MB[SIC&(9<W1E,C=
M;-/9,'A-HZHU$=1XT*YOD589W)[+WE8[9$SL[):6(A$3M$FH3RDZ7ZFZ3I#J
M^$.%1UT5-J<6O$P=IJ-%J[O9RB[34:K-UMI`JBX1<$%%5NLDI>!35163.)3%
M,`E,41`?)F8W?/)2-PD;-B@YIJ"+:A!'$$'L>!'2%KW<L_./F:87P9IS'@M(
M-X""#P((-Q0@@T(/`A4_2(YY$\!>5,7(-CM7T5R"TQ&/VQ^R)FKUB6<:NFQS
M)F.F)T5T3%'LB("(>01#,O)S17'-?!3PD.BDQ-XYI[K3V9!^R"%B86VGM.1F
MYK:Y:6W$6:L&N!ZG-$X(-.'`A2J\/>_5G?$WI+6.PY$C3;/&JWH7/25E<%!1
MU:-;%*H2VZJ>+'$%%SPI%2O8X.HF302Z%#L(J`?A.;F)O=JVV3S>(878#-6Y
MAO8QT17'_NKH#JU^LDZBXU)JX4DSD)G\?OB[PVV\[(&;IV]=MGQ\I%736@_W
M]DXGI+.$D76UK2``UCM6)#9O_P!1-C?X<W+_`,0R>6`PG_AK/^BP_BVJJNY/
M\S7W]-E_&.4U/$N`2\B*X`@(#_,-I<>@AT\@U@V1KR5X[0FI_:MY^-4Q><@"
M-]6M?[%L/Q#5U-,XM2VU=*Z^VGQ7?3MGVQ7G$[$;KH;"T1["Z5^43D.\K-CI
MT<F:'D%*W)0_3M]A9=7O_(43"50I,C);YM\#N6[P>^V108"8,?9SNB<Z&1NG
M\)',XZVB1K^BH:*=/2TG%PW+.ZW/LZPW-RPDGN-T0.E9D+9LS&SQ/UUAE@8`
MQQB?'TD%[@_@*T<&R.D$^0%(X@[Y@N;3Z6"&F8BO1_'RJ[0E&,QLL-F(S":Q
MI>M%7=/;(Q@XR**879W!P)W8"4H`4QP/QD3MIY3F%BKKEFR/QF.21U_+;-++
M;Q8L(T24`C<]SZ:`T5KQ/$"DB3MWSA.4^:LN<KY/%)8HFXR&\>)+OQL2`]I#
MJ<Z9L;(]7:%Q`T\&]+@<0.6'514PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A%E4\$O]IWQB_/]D_JAON1CSD^C?)>
MUA_'Q*:?-Z^E[#^WG_59UZ(64%7U*6IS]IZ0!8W#/JX;(=DV]/\`C!SD[74N
MJ_WG834Z].GE\WGRT?FW$CXWH"?^VZ/_`.>J4^=^W5\0\0.%YT^C;+4^]!+_
M`"A&_P`<M^C9:+6?8N^UZJI1V0]DW[?J)Z"7^4(W^.6_1L:S[%WVO53LA[)O
MV_43T$O\H1O\<M^C8UGV+OM>JG9#V3?M^HOZ#(H"`A(QP"`@(""ZW4!#R@(?
MVOYPQK/L7?:]5.R`XA[?M^HOLY3</5C.7LTV>.#@4#N';YVY7.!"@0@'671.
MH8"$``#J/D`.F?A@;$W1''I8.H``>D%Z2F2=YEGEUR'K))/IE?U0CA9!!JK-
M-U6K7O/16RKYXHW;=Z/:5]&0.B*2'>F#J;L`':'RC@!K7F1L='NZ2`*FG14]
M)IWT<97QMA?+6)E=()-!7IH.JO6B!'#4JY6LVW;%=(F;N2MWSQ`KEN;]\@X*
MDB0%T#?A(;J4?W,/#9"#)'J+345`-#W1W#WTC,L0<(I=(>VCJ$BH/4>Z.\OF
MDV.@JDNA*LD%T#E5171=.4ED52#U(HDJF@51-0@^4#%$!`<_3CK:6/82PBA!
M`(([X7YC#HGB2.0->#4$$@@CHZEV\Q,6*Q>C_"&YO9\&@=&H3=@F)8&P=.ST
M;A("X!'UH=/6]/)F-;6EG9U\3MV1:NG0QC:^CII59M[D,ED0T9"[DG#>C6][
MZ>AJK1=6DFX;IN$D)IL@D[3!)TDB^=I)NDBF`Y4G*::)2+I@<.H%.`@`^7/=
MP:\ASXZN::@D`T/='<^PL1ADC:YD<NECQ1P!(!'</=0$URMCLRS38&:BI7!V
M@/78-3KD*)"+G;`CW)EB$'H!Q+V@#R=<$-+Q(8_P@%*T%:=RO33O(#((C`)?
MP)-2VII7HK3HK3K0Z:ZJ"#529;*-6PJ&;-E'KL[=N980,L9N@9$4D3+&`!.)
M0`3#Y^N`&M>9&QT>ZE305-.BIZ33J1QD=&V%TM8FUH*F@KTT'57K7<1,]:(!
M!9K`WB2@VKCM"X;0UDFXMNN)PZ'%9!B9!)43!Y^T`]<Q[BRL;MXDN[:.60=!
M>QCB/0+@2%FVF3RMA&8K&\EAB=TADCV@^B!2JZ([3O#G54DV"BBIS****.7!
MU%%#B)CJ*',W$QSG,/41$1$1S*#M(#6L(:.C@/56O<PO<7/>"XGB37U%W,-,
M6.N^D!7KF]@`=AT=!"6"8B0<AT[/1P$>+<%P[/D]=U\F8US:6=Y3QRW9+IZ-
M;&.IZ&JM%G660R6.#AC[N6`.Z>S>]E?1TTJNH5;'75577E62ZZYS*K+K.G*J
MRRIQZG45540,HHH<?*)C"(CF2TZ&AC&$,`H````.\%A/#I7F220.>34DDDDG
M["_:Z:[GN0<S+9R#=$C=OZ0]=K^CMT^O=MT.]1/W*"?4>R0O0H=?(&?E@;'7
M1'IJ:F@`J>Z:=)[Z_4ADET]K+JTM#14DT`Z`.X!W%_4R.$D%VJ4TW2:NA3,Z
M:IOGB;9R9$>TB9P@1$$EQ2-Y2B8![(^;I@AKGB1T=9&UH:"HKTT/2*]=$:96
M1NA;+2)]-0!-#3HJ.NG4OFDV.@JFNA*LD%T3E4261=.4EDE"#VB*)*IH%.FH
M0P=0,`@(#YL_3CK:6N82TBA!`(/HK\L:Z-XDCD#7M-002"".L&B*MSN%5%W$
MJR776.9199=TY5654./4ZBJJB!E%#F$>HB(B(CAIT-#6,(:!0```#T`CVND>
M9))`YY-22223W3P7W*9Z1L5D2?3(R(N5T1F22?%:$=%'J5R5L5,$2N"B'D.!
M>T'[N?@LC+^U,7X0BE:"M.Y7IIWEZ"2=L0@;,1"':M-32O=IT5[Z['W9LG]^
MLA_WBFO]UGCXI9^3Q^X8LGXQR7E4GNW+@O59"2[L9&Q!("B!@1%_*2#P4@/V
M1."0N4U>[`XE#KTZ=>@=<]8HXH:]C$&5Z=+6BOHT6//+<75/&9C)IZ-3G&E>
MFE5V47/VJ#:+1\)>I.&8.!,*[&)LLY&LUA/^_%5JR.@@H)_P]2CU_#GA/8V-
MU()KFVCDE'0YT;'$>@2"5EVN4RUC";>RO)HH'=+62/:T^B!0'[*Z`60&,8QI
M*/,8YC'.8SA<QC',(F,8QA;B)C&,/41'RB.9@<0*!KJ?8]5:YT>HZG/!<?1]
M1?=,CA)!=HE--TFKD4S.6J;YX1LY,D/:2,X0(B"2XI&\I1,`]D?-GX(:YXD=
M'61M:&@J*]-#TBO6OVTRLC="V6D3Z:@":&G14==.I&I7+%8'#&;;LG!0,4KA
MF^>-5RE.'9.4JR"*:A2G*/00`?*&)&LE;HECU,[A`(](I"9;=_:02Z)!U@D'
MCWPNT]V;)_?J_P#^\4U_NL\/%+/R>/W#%E_&&2\JD]VY<+OY(7"SP;)U=N43
M-W+L961%TX;F*4AD'#CL=\L@8A0`2&,)1``#IT#/3LH=`C[$=FTU`TMH#W0.
M@'OKP,]T973&=W;.;0NU.J12E">DB@Z%P/02?RA&_P`<M^C9[:S[%WVO56/V
M0]DW[?J+DN0=/2()O)Q%XFU2!!J1W(/7)&R````@W*LD<J"(`4/6EZ%\GFS\
M,:R,DQQZ2XU-`!4]TTZ3WRO:1\TP:)9M08*-J2=([@[@]!=RI8;8K%>X*M\E
M58,2`F,*I9IT\0*8!T!/W,,<67=@'_N]CIF,+&P;/XTVUB%U6NOLV:_=4K]M
M9CLKEG6GB#KR8V-*=GVC]%/:^M^TJ=]!)_*$;_'+?HV9FMWL7?:]5:WLA[-O
MV_47.CE9"'=D?P]B+$OTP$J;Z+E)"/>)E-^^*1TS317(`]/*`&#KGE-'%<QF
M*XB$D1Z6N:UP](U"R+6:YLI1/9SF*<=#F.<TCT"*%?66>S$^Z]/GK2I./NP"
M8/9F9DY5V"8#U!,'+\KA8"`/X.UTS\V\%O:1]E:0MBB[C&M:/2;0+]WEU>Y"
M3MK^X?--3USW.<?3=4KB-B.&2Q7#*:;,W!`,!'#1\\;+D`Y1(<"K((D4*!RB
M(#T'R@/3/1X;*W1+'J8>H@$>D5X1&2!XD@ET2#K!(/'OA?#T(`'M!(QX&Z]K
MM`NN!@-UZ]KKZ/UZ]?PY^]1I32ZGV/57GV?&NMM?L^HOLY3</5CN7LTV>.5.
MSWCAV]=N7"G9*!2]M99$ZI^R4``.HCT`.F?A@;$T,BCTL'4``/2"])3)/(99
MI=<AZ2223U=)[R_:8.T6SAFC.HHLW?9%TT2D'J;5T)!`2"Y;D2*BN)!`.G;*
M/3IG\<UCGB1T=9&]!(%1Z!Z1]A?UCYHXG0LEI"[I:"0#3HJ.@KL2R]B*4I2W
M-\4I2@4I2V&9*4I2@`%*4H"`%*4`Z``>0`SQ-I:$U-NROM&K*%_D0`!=24'^
MVY<9V[EGY")O[.=\FDH"J:;V8DW9$U0`2@JF1P50I%``1#M``#T'/2.&"$ET
M4+6DBAHUHX=SAU+QFN+NX:&SSN>T&H#G.-#W>*Y7NS9/[]7_`/WBFO\`=9Y^
M*6?D\?N&+V^,<EY5)[MRX3Q>2D@3"1L?N@"(F%('\K(O`2$X`!Q2!R14$Q.!
M0Z].G7H&>L444->QB#*].EK17T:+PGFN;H`7,YD`Z-3G&E>Y5?`I')&RC(DV
MW(S64(LLS*^>%:*K)AT365;`B"*BI`\QA*(A^`<_1#2\2&/\(!0&@J!W`>FB
M\P96Q&`2TA)J6U-"1T$CHJOZT!TP5](83B+%?LF)W[*0>M%NP?IVR=ZW234[
M!N@=0Z]!Z8D:R9NB6/4SN$`CTBO["Z:V?VEO+HDI2K20:>B%V?NS9/[]7_\`
MWBFO]UGAXI9^3Q^X8LKXPR7E4GNW+J7"*SM91R[F&KIPJ(&5<.7CIPNJ8``H
M&4661.HH(%``ZB(^0,R&4C:&1QEK!T```#[`6'+KF>99I`Z0]))))^R5^EB.
M7"3=!Q-MUT6A#)-$5WSQ9)HF80,9-LDHB8C=,Q@ZB4@``CG\:&L<7,CHYQJ2
M``2>_P!W[*_LCI96M9)+J8P4:"20!W!W%]F2LA&BH,=8BQXK`4%A82D@S%4"
M=H2`J+9-+O`()AZ=>O3J/3SY^98XIJ=M$'TZ-36FGH57[@EN+6OBTQCU=.ES
MA6G16BYWNS9/[]9#_O%-?[K/+Q2S\GC]PQ9'QCDO*I/=N76=EUW*[?W<0]'=
M*E7<M_3WG<.5R"(D7<(]UW:ZQ!,(@<P"8.H^7/?2S4']GX;10&@J!W`>H=Y8
MNJ;0Z+M?P;S5PJ:$CK(ZROPW26:+)N6DPU:.43=I%PU>.V[A(P@)1,DLBB11
M,PE,(=0$/(.?U^F1I9)&7,/2"`0?L%?F+M()!+#)ID'002"/0(7S,S[9C'/)
M1YSG,8QSG<+F.<QA$3&,8S<3&,81ZB(^41S^AQ`H&.`'H>JOR8]1+G/:7'T?
M47V<D<O5`6>S;=XL5,B157;YXY5!),.RFD"BZ)S@FF'D*7KT`/-GY8&Q#3''
MI;6M``!4]?!?N4RSNUSRZWT`J22:#H''J"^T<K(P[LC^'L01+](!*F^BY20C
MGB93=.T4CIF1%<@#T\H`;/S-'%<QF*XB$D1Z6N:UP](U"]+6:YLI1/9SF*8=
M#F.<TCT"*%?66>S$^[]/GK2I./NP"?ILS,2<H[[L/*"8.7Y7"P$`?P=KIGYM
MX+>TC[*TA;%%W&-:T>DV@7[O+J]R$O;7]P^::GKGN<X^FZI76>@E_E"-_CEO
MT;/?6?8N^UZJQ.R'LF_;]1/02_RA&_QRWZ-C6?8N^UZJ=D/9-^WZB>@E_E"-
M_CEOT;&L^Q=]KU4[(>R;]OU$]!+_`"A&_P`<M^C8UGV+OM>JG9#V3?M^HGH)
M?Y0C?XY;]&QK/L7?:]5.R'LF_;]1/02_RA&_QRWZ-C6?8N^UZJ=D/9-^WZB>
M@E_E"-_CEOT;&L^Q=]KU4[(>R;]OU$]!+_*$;_'+?HV-9]B[[7JIV0]DW[?J
M)Z"7^4(W^.6_1L:S[%WVO53LA[)OV_43T$O\H1O\<M^C8UGV+OM>JG9#V3?M
M^HGH)?Y0C?XY;]&QK/L7?:]5.R'LF_;]1/02_P`H1O\`'+?HV-9]B[[7JIV0
M]DW[?J)Z"7^4(W^.6_1L:S[%WVO53LA[)OV_43T$O\H1O\<M^C8UGV+OM>JG
M9#V3?M^HGH)?Y0C?XY;]&QK/L7?:]5.R'LF_;]1/02_RA&_QRWZ-C6?8N^UZ
MJ=D/9-^WZB>@E_E"-_CEOT;&L^Q=]KU4[(>R;]OU$]!+_*$;_'+?HV-9]B[[
M7JIV0]DW[?J)Z"7^4(W^.6_1L:S[%WVO53LA[)OV_43T$O\`*$;_`!RWZ-C6
M?8N^UZJ=D/9-^WZB>@E_E"-_CEOT;&L^Q=]KU4[(>R;]OU$]!+_*$;_'+?HV
M-9]B[[7JIV0]DW[?J)Z"7^4(W^.6_1L:S[%WVO53LA[)OV_43T$O\H1O\<M^
MC8UGV+OM>JG9#V3?M^HGH)?Y0C?XY;]&QK/L7?:]5.R'LF_;]1/02_RA&_QR
MWZ-C6?8N^UZJ=D/9-^WZB>@E_E"-_CEOT;&L^Q=]KU4[(>R;]OU$]!+_`"A&
M_P`<M^C8UGV+OM>JG9#V3?M^HGH)?Y0C?XY;]&QK/L7?:]5.R'LF_;]1/02_
MRA&_QRWZ-C6?8N^UZJ=D/9-^WZB>@E_E"-_CEOT;&L^Q=]KU4[(>R;]OU%E1
M\%!H5/Q-^,9P>,E>C_9/\&DJJ90W745]#UH&0(`].O7SAY,C+G&XGEQD@6D>
M#%^/B4S^;Y&&\W<0=33X<_=\EG[R]#;*#KZC+4R^U`^?AC^-O7\G566D\VS]
M[_FWY=4F\\+]P^A>?=MEJ;9:14E3")A%7^N=4[0W#.N*OJ775WV=96D8O-.J
M_0:O,VV:;P[5PU:.91>-@V;UXE'MW3Y%,ZQB`F518A1'J8`'!R&4QN)@%SE+
MB&VMRX-#I7M8TN()#:N(%2`33IH#W%M,3A,QGKDV>$M;B[NVL+RR&-\K@T$`
MN+6!QT@N`)I0$@=85[?ZB?-O_1!Y,?T([&_Q>S3?XWV;_:N._K$/\]=%_IKS
M"_L/+?U2X^#3^HGS;_T0>3']".QO\7L?XWV;_:N._K$/\]/]->87]AY;^J7'
MP:LCL?56S].SB%8VUKN[:QLCF,0FVT!?ZQ,U*97AW*[IJWE48V=9L7:D<NY8
MK)D6`@IF.B<H#U*(!N<?E,;EH#<XNXAN;<.+2Z)[7M#@`2VK214`@TZ:$=U<
M[EL'F<%="RS5K<6EXY@<&31OC>6DD!P:]K202T@&E"01U*\S3@[S1?M6KYCQ
M*Y(O&3UL@\9O&NEMA+MG;1TD1=LY;KI0!DUD%T5"G(<HB4Q1`0\F:=^]-GQN
M+'Y3'A[200;B($$<""-?2%T$?+C?\K&RQX7*NC<`01:7!!!%001'Q!'04=<'
M.:3)NL[=\1^2J#9`@J++*:1V/V$R!YS&[-=,/0/]C#=Z;/>X,;E<<7'_`.(A
M_GH_EQO^-I>_"98-'7XI<?!J-<K$RL#)/(6=BY*#F8Y46\A$3+!W%2K!</.@
M]CGZ+=XT6#_:J$*;^QG11317$8F@<U\+A4.:001W01P/V%R5S:W-G,ZWNXWQ
MSM-"UP((/<(/$'O*HJ'KN_[3LK6F:RI-LV';WS=X[95:E0$I9["[:QS<SM^X
M;0\.V>/UT&34AE%3%3$J9`$QN@9X7V0L<9;F[R4T5O:M(!?(YK&@DT`+G$#B
M>`X\2LG&8G*9J[%AB+>>ZO7`D1Q,=(\@`DD-8"XT`)/#@!55;=N/F^=:S]5J
MFQ-+;4HEGO3DC*DUVX4*S5V;M[Q1\TC$VM:BY:-:O9MP>1?H-P(W(H85EB$Z
M=HQ0'$L\_@\C!+=6%Y:SVT`K(Z.5CVL%":O+7$-%`3QIP!/4L_([5W+B+F&R
MRF/O;>[N32)DD,K'2&H;1C7-!>:D"C0>)`ZU<W^HES;#R?U0>3']".Q?\7LU
MW^-]F_VKCOZQ#_/6W_TUYA?V'EOZI<?!I_43YM_Z(/)C^A'8W^+V/\;[-_M7
M'?UB'^>G^FO,+^P\M_5+CX-=!:.'G+2CUV8M]TXQ[]J54KS%63G[+9-2WF%@
M86-;]!7?RLK(PC=BP9H@(=I14Y2%_".>]MNW:U[<,M+/)6,MU(ZC6,GB<YQ/
M4UH<23W@%C7FP=[X^U?>WV(R4-G$W4][[:=C&@=;G.8`!WR:+J:!Q;Y+[7KB
M-QU?Q\W3L:I.';Q@WL]'UG<+3`+O8]3N7[-*6A8AXQ4<LEA["I`/VDS>00`<
M];[<VW,7<&TR5_9V]T`"6231L<`>@Z7.!H>KAQ7AC-E[NS5H+_$8S(75D20)
M(K>:1A(Z0',86U'7Q5:_U$^;?^B#R8_H1V-_B]F'_C?9O]JX[^L0_P`];#_3
M7F%_8>6_JEQ\&@<$N;8^3^J#R8_H1V+_`(O8_P`;[-_M7'?UB'^>G^FO,+^P
M\M_5+CX-6*IFM-B['MR=`U]0[A>+TL,D"5,J5<EK!:%!ADEEI<$X*+:NI(XQ
M:+=0[CHG_`E(83=``<W5YDL?C[3QZ_GAALA3\(][6L\*@;X3B!Q)%./%<WC\
M-ELK?#&8RVGN,B:_@HXWOD\$$N\!H+N`!)X<`#57U_J)\V_]$'DQ_0CL;_%[
M-+_C?9O]JX[^L0_SUTG^FO,+^P\M_5+CX-4?=.*G*'7$0K/[`XX;VI4"W(91
MS-VC4M[A8AJF3]\HZDW\$BR:IE_"90Y0S*L]T;:R$H@L<A933D\&LGC<X^@`
MXD_8"PK_`&/O+%P&YR6*R-O;-%2^2WF8T#ON>P`>FK!`(&`!*("`AU`0'J`A
M^Z`AY!#-ZN6((-#P*_N$5^:#Q9Y-;5K;:Y:PX];JV)47CEXS:6BD:RN-HK[E
MW'+F;/VJ$O#1#QBJX9.2"FJ0IQ,F<!`P`.:.^W/MS&7!M,E?V=O=``EDDT;'
M`'B"6N<#0CB.'%=/C-E;OS5H+_$8O(75DXD"2*WFD82.!`<QA:2.OCP59_U$
M^;?^B#R8_H1V-_B]F)_C?9O]JX[^L0_SUG_Z:\PO[#RW]4N/@T_J)\V_]$'D
MQ_0CL;_%['^-]F_VKCOZQ#_/3_37F%_8>6_JEQ\&K61VA=XR^R)'3D5I[9TG
MMN'(X5EM8,*/8W=_C$V;1N_=J/ZBA''G6A&S)VDLH)T"@5)0IA\A@$=G)G,+
M%CVY:6[MFXM]-,QD8(C4T%'DZ34@C@>D+31;7W'/EGX*&PO'YIE=4`AD,S:"
MIK&&ZQ0<>+>CBKI_U$^;?^B#R8_H1V-_B]FL_P`;[-_M7'?UB'^>MS_IKS"_
ML/+?U2X^#7`DN$W,J'9JR$KQ-Y(L&*!1,NZ<:3V,5%(A0$QCJ&"NCV2E*'41
M'R`&?N/>6T97B./*8]SSU"XB_GKSEY=[]@89)<+E6L'23:3@#T28Z!1K>,WD
M<\=1\BT=1\@Q74:O6#]LLS?,G*0]E5L[:.2).&SA(WD,0Y2F*/G#.B8]DK!)
M&0Z-PJ"#4$=T$=*Y&6&6"0Q3-+)6D@@BA!'`@CO'@N-GZ7FKQ:TX\;]W/'24
MOJ#26V-I1,,^3C)>3U[K^TW"/BY)5N5VG'OWD#&/F[1Z=JH50$CF`_=F`W3H
M(#FHR.X,%AY&PY:\M;:5[:M$LK(R16E0'.!(KPJ.M=!B-J;GW!$^?!X^]O(&
M.TN=#!+*UII6A+&N`-.-#Q5%WF@7K6%F?TK9-,M.O[C%$:*2=5N<#)UJPQZ<
M@T1?L%'D/,-FC]LF]9.$UDC'3`%$CE,7J`@.9ME?V62MFWF.FBGM'5H^-P>T
MT-#1S20:$$'CP/!:[)8O)8:[=C\M;S6U\RFJ.5CHWBH#A5KP'"H((J.((/05
M2(B`!U'R`'E$1\P!F4L#IX!2$4XD\J$J8;8RG&W>Q-?EK@7$UW'5-W^"@5(8
M\)<+.,^$*,9[@#%"#GTOO.X]'_A.UV/+FA&ZMLF\^+QD;+Q_M.S[/MX]>NNG
M1IU:M6KAII6O"E5U)V-O(8_XV.*R/Q9V7:]KXM-V?9Z=7::]&G1I\+573IXU
MHH]@("'4/*`^4!#S"&;Y<MT<"KYZ\XP\DMN5[X6ZJT#N7955]/=1?PDHFMK=
M:X+W38@D9['^ZL)$O67IK0JY!42[?;)VR]0#J&:6_P!R[=Q4_BN3OK.WN=(=
MHDFC8ZAZ#I<X&AH:&G4NDQ>S=V9RU\>PV,O[JSU%NN&WED9J%"1J8QPJ*BHK
M7B%9%9%9NLLW<)*(.&ZJB"Z"I#)JHKHG,FLBJF8`,FJDH42F*(`("`@.;D$.
M`<T@M/05SKFN8XL>"'@T(/`A7WT[Q6Y*\A$G#G1^A]J[28-%3(.Y>G4N:E(!
MJN0>R=NYL)6Q()NX(;R"F=P!P'SAFCR^Z-N8$AN9OK:VD/0V21K7$=T-KJ([
MX"ZC`['W=N<%^`QUY=1#I='$]S`>X7AI:#WB0J\V/P'YL:C@W-GV-Q7WA6*V
MR3,L_GUZ%,R4-'(D*)CKR4C"(R;2-0(4HB)US)E``ZB.8./WUL[*S"VQ^3LY
M+@F@;VK0XGN`.()/H56SRW*_F#@[<W>3Q%_':M%2_L7EC0.MS@TM:/1(41@$
M#``E$!`?*`@/4!#^P(>0<ZM<$00:'@5_?W/[(@4`_")C"!2E`/PB8P]`#\(X
M7]`+C1O$J8M#\/3G/LV":V>C<3MZ3E>?)%783!J'*P[&00.'4CB/5GR17I[<
MX#U*HB!R&#R@.<C?;^V5C9S;7F4LF3CI;VK7$=XAI-#WC12!C.5/,7+VPN[#
M#W[[9W$.,+VAP[K26@.'?%0K+;;T%O'0DJWA=VZAV-JB2>=KT!"^5&:K:4EV
M"]HXQ3V1:(L)4I2CU$6RJH`'ES<8K/87.1F;#W=O<QCI[-[7T]L`21]D!<[G
M=J[DVS*(<_8W5G(>CM8GQZN^TN`U#OBH5L8R,D9J2CH:'8/)67EWS.+BHN/;
M*O)"2DI!PFT81[!H@11=V]>NEB)))$*8ZBA@*4!$0#-G))'#&Z:9P;$QI+G$
MT``%223P``XDGH"TD,,US,VWMVN?.]P:UK02YSB:``"I))X`#B5)X>"7-L/(
M/$'DQY/_`.B.Q?\`%[.;_P`;[-_M7'?UB'^>NR_TUYA?V'EOZI<?!K\*<%N:
MZ29U5.(?)<B:91.<XZ1V-T*4OG,/2O"/0,#>VSB:#*XZO](A_GK^.Y;<P6@N
M=A,M0?\`PEQ\&H]6NFW"AS*U=O53L]*L+<@*+P5OK\O69E%,1$H**1<VS8OB
M)F,`@!A3Z"(>?-_:WEI?0BXLI8YH#T.8YKV^FTD+E[_&Y'%SFVR4$MO<CI9(
MQS'"O15K@"/LA5)K73FV]S2<C"Z@UA?]I3$.P)*2T5KVHSMPD8R,4<$:)R#]
MG`L7SAHR.Z4*F"IRE(*A@+UZCF/D<OBL/&V;+7,%M$]U&F61L8)I6@+B`33C
M0=2RL1M_.;@E=!@[.ZO)F-U.;#$^4M;4"I#&N(%2!4\*D+K]AZRV/J*P#4]K
M4*XZUM)8]K*FKE[KDM5)PL6]%8&<B,5-M&3T&3H6Z@)J]CL'$AN@CT'/W89+
M'96#QK&3PW%MJ(UQO:]M1TC4TD5'6*KSRF%R^$N_$<Q:W%K>EH=V<L;XWT/0
M=+PTT/4:<5>MGP>YH2#1I(,.)?)!ZP?-F[UD]::7V$X:O&;I(B[9TV72@#)+
MMW""A3D.41*8H@(#T'-._>FT(WF-^4QX>TD$&XB!!'`@C7P(70Q\N=_2QMEB
MPN5=$X`@BTG(((J""(Z$$<05]%^#/-5LBHNOQ%Y+)(I%$ZBAM(['[)"AYS#V
M:Z(]`_V,_C=Z[.<=+<KCB3_\1#_/7]=RWY@,:7NPF6#1_P#"7'P:CC8*[8:E
M,/:[:X"<J]@C3@G(P-DB)""FF"A@ZE(]BI5LT?M3&+Y0`Z9>H>;.@M[FWNX1
M<6LC)8'=#F.#FGT""05REY8WF/G=:W\4D-RTT+7M+7`]P@@$'O%7QJ7$'E??
MJW$7&C<9]]7*I6!KZ=!6>KZGO$[`3+(5%$0=Q<O&PKEB^;"JD8O;2.8O:*(=
M?)FENMV;7L;A]I>Y&QBNHS1S'SQM<T]-"TN!!]$+HK+8>]LE:LOL?B<E/92"
MK'QVTSV.%:5:YK"TBH(X%5%_43YM_P"B#R8_H1V-_B]GA_C?9O\`:N._K$/\
M]97^FO,+^P\M_5+CX-/ZB7-O_1!Y,?T([%_Q>Q_C?9O]JX[^L1?ST_TUYA?V
M'EOZI<?!J,\Y!S59FI:N6.)DH&PP$D]AIR#F&3B-EX:7C7*C.1BY2/=II.F,
M@P=HG2615*51-0HE,`"`AG103PW,++BW>U\$C0YKFD%KFD5!!'`@CB".!"X^
MYMKBSN'VEVQ\5U$\M>QP+7-<TT<US30@@@@@BH(H5U>>J\4PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+*IX)?[3OC%
M^?[)_5#?<C'G)]&^2]K#^/B4T^;U]+V']O/^JSKT0LH*OJ4M3+[4#Y^&/XV]
M?R=59:3S;/WO^;?EU2;SPOW#Z%Y]VV6IMEI%25,(F$6P3]FV$?Z]^P?+Y^,M
MX`?[(?SB:J'H/_XAD$><-_DF#^\8_P`5,K0>:;](]S_=$WX^V6<7Q+?&2<^'
MMO.KZ:1X^H[5+8]8Q.Q!L*FRC4X6AI2R6BO^Y(1A:39.^!$*WWO?=^7M=]V>
MP'9ZFA;EURC;OW"RY<WYM3'<NBT]CVE=+&.U5[1E*ZZ4IU=/%6*YM\^7\K]Q
M0X%N,%X);1D^LSF*FJ25FG3V,E:=G6M1TTIP6/#[T"__`-#%M_3LI\E&=_\`
M5L9_:[OZL/AU%GUPI/[!;_7#^S+!UXD_.E;Q!MWPV[%M:$U6:"U;#ZY"N)VL
MUQ!R6&G[9/\`NM[J&@*YW(N!LXI=P"`@7N>UVQ[70)GY>[*&P\(_#"Y-UKN7
M2Z]'9TU,8W3IU/Z-%:UZ^C@J]<T^8YYG[H@W`ZT%F8[6.#0).UKHDD?JU:(Z
M5[2E-/"E:\>&^%N;D*IQ3X&O^0Z=5+>%-6:6HMA+5#S(P!9L5&-:B_133(1L
MN+#I[H=OM^C+?O.G3R]0I%B<"-S;W&!,O8BYO)6Z].K3Q>ZNFK:]%.D+Z0YS
M<QV=RY.YA#XP;2Q@=V9=HU5$;*:M+J>NKZT]"P75+[3W4UY5FC?.(5EB811<
MA9"2J.VHJQR;-N)^BB[6%F:55FT@J1/R@F9\W`P^3M!DUW?FW738BZQRL;YJ
M<`^`L!]%S9'D>CI/H*N=AYW]A),UN3PDD=N3Q='<B1P'>:Z&,'T"]OHK(OS/
MXG\<O%RX;QNZ]/MH:0V1)T5S<]`;8:QJ479%91BDX$VM[FJ)$WJT._DV*T2_
M8NS*>Y3\#+)`"B(@>/\`:&Z-P<J]VNP^5+VX]LPCN8"=3-)I^%CZM0:0]KFT
MUMX'@>$J[^V7M7G;L1N>PC8WY1]N9;.X`#7ES:_@)3TZ2X&-S75[)]7-X@AV
MLWX"*#AIXG.L&CM!5J[:T?=#5VU7(*:[9RWI$FBX;+IFZ&(L@L02F*/E`P"&
M6+YXN:_ES</806F6`@CK!E;0JI'FTQOBYM6T3P0]L-P"#P/""3J*R9?:'+\;
M57*KP]-HEC`FS:T<6'8)807@QY9@U-V1K6QA%B_*@Z%B$B,:"(K`DJ*7;[78
M-TZ#'/(2P^--M9[&:M'C`;%JI73VD4K*TJ*TK6E17NJ7/.ARAPF[]LYD,[3Q
M1SIM%=.KLYHGZ:T-*Z:5H:=-"OBP^T[OWT@P8_U,VR?ISYFR[S^?0YQ3]+<I
M-^\['\U10,).\Z].H=>GGS]R>;>QD;G_`!N>`)_[8=0_YZ\8?.^DEE;'\0M&
MHT_[P_LRV">=G*Q3A?Q;O_)%*CEV&I2%J<D%0/8!K)9+X5W"!JHF&;"(G!:^
M@A-]_P#\54[SN^QZWM=H((V3M<;PW-!MXS>+B82?A-.NFB-S_6ZFUKIIZX4K
M56=YC[T.P-G7.ZQ;^-&W,0[+7V>KM961^OTOIIUU]::TIPK5:MW*;[0>\Y+\
M=MPZ"4XJH4XFV:-,4LUH)N%2<-!!+)E3&1"(_FXBO=`4`+U[KTE'M?[8,LMM
MKD,S;N?M,X,F93:S-DT=@&ZJ=6KMG4]&A5.]W^=%)NK;-[MTX9L`O('1]IXT
M7:=77I\7;7T-0]%9F?L^'[-VG?V-J[=_\4&R(.>_TA3?T:'^2I^\V7Z*K?\`
MI4_\H*`5L^TROJQ:[360X<MG@5NRS]>!X.\5$!>!"2[R+!V*'\UBW<"Y!KV^
MQVS]CM=.H].N=W:>;FRYM8KGXV([2-KJ>+`TU`&E>W'17N*,,AYV\MA?367Q
M$UW92.;7QLBM#2M/%C3TRN@^]`O_`/0Q;?T[*?)1GO\`5L9_:Y_JP^'6']<*
M3^P6_P!</[,L=/@:2XV#Q6=>SXH>BC/1&_)L6O>=]Z,,M2+-("V[[L)]\"`N
M.SVNR7M=.O0/-G?\Z8?%^6,]O6NAULVO16DK!51AYNMSXYSDMKNFGM&W3J5K
M2MO,:5X56S1XH?BKK^'%8M.02.D$]N%VO#W.6.Z/?S4L8/X)/JXS!`J(5&S!
M("_">$W:$R/=]UTZ&[7DKGRUY8MY@P7<QO#:FU?&VG9=IJUAQK_O&4II[]:J
MV_.'G,[E3<V,`QXO1>,E=4S&+1V98*?[J2M=?>I3K4<>(7V@[1')#;%5TSM'
M4%CT5+[!E6=7J=F=6R+O5'>V27<$91$'8'I86L2-?":=K$;(+F:N6PN%"%6.
MD0W;#H-V<A\WM[%RY?&W<=[#`TO>P,,<@8T5<YHU/#M(XD5::#@">"Y;8OG.
M;:W;F(<%E[*3'7%R\1QO,@FB+W$!K7G1$6:B=(.EPJ?"+6U(@%X__AQ4#4;.
M!YEZ+JT;3H*RVEO4-VTZO,DH^OH6*>(Y<5K8<5%M2$9Q!IEXV482J:)4T5G:
MS58I`55<'4[KD5S!OLH]^T<U*Z6:./7;R.-7%C:!\1)XNT@AS":D-#A6@:!&
M7G-<J<9AX8]][=A;!!)+V=U$P`,#W`N9,UHH&ZB"V0#@7EA`U.>3J\Y954V6
M>W@%XX3K@SQLKG'E+C<CLHE?L5PGPM:FTSU4SKX63KJ;%K[C!0[`"/H(N>[[
M?I)N\Z=KLEZ],@W?7)AN]-PR9XY`VYDC8W1V.NFAH;75VK.FE>C@K,\M?.*?
MR\VG#M@8EMV(I)'=H;@QUUNU4T]@^E/;<5M)>&?SV6\0S2=NV^MK`FJ#5;9D
MGKP(%.VC<2O2QU;J]@"6]T35ZMBW%4;'W7<]R?L]SVNV/:Z%K3S%V.-A9F+$
MBY-UVML)=6CLZ5>]FFFM]?65K7KZ."N-RDYE.YH;?GSCK,61ANW0:!+VM:1Q
MR:M6B.G^\I2G56O%8EM\_:-'NE-X;ATZ7B2WL1=5;-O&NRV`VZ#Q8SA:=8Y&
M`"6&-#6;\(\9`&'>]SWZW==KL]LW3J,I8/S?F9G"VF7^-3'XU;1RZ?%P[3VC
M`[37MA6E:5H*]Q0EN7SJI-O[AOL$,(V7Q.[F@U^-%NOLI'1ZM/B[J:M-:5-*
MTJ5#'PL.0A^5OC;V[D.I50HY]IT'9LX:IEF1L!87T*E5*!!J$R,=$B_[P(<%
M>UZ,CT%3L]GUO4>OYFX`;7Y.18`2]L+:>)NO3IU5D<ZNFKJ>NITE</R:W4=[
M<_;C<YA\7-W;S.[/7KTTB#::M+*]%?6A9L_$^\6ISX<]^U72$-%);:+LJGSM
MJ-)*;#-2QAQA9IM$`Q!J6G6;TX'`..\[SO$NSTZ=D?/D.<MN5K>8%E<WAO3:
M^+RM93LNTU:FZJU[1E.Y2A4_\W^=;^5=_:63<<+T74+GU,QBTT<6TH(I*]%:
MU"AMQV^T@T/:^W]?:QV5QKF]:1&P+5"4Y&[PFR6EU;P,M9))"(AW4K!.*;5W
M2D.,@\1*Y60<'5;IB90J2O9[.==N#S?+[%8F?)8[(LN)8(G2=FZ$QES6#4X!
MPD>-5`:`BA/"HZ5P>T_.LQN=SEMB,KBGVD5S*V,2LG[72Y[@UI<PPQ^""07$
M.J!4AKCP/Y^T:\2M<2FAZWRZ@8",@]J4F\5JDW*;CFB#->[TBW>EQS!*P&1*
M3W3E:S8"-!9.%`,JFU<.$A,).[`CS?MU9"+.2;5GD<_&30ODC:341R,H3IKT
M->W5J`X:@T]-:O.HV1BKG;46];>-D>8MYV1RO``,L3PX#73USF/#0TGCI<X&
MH#::9QC`4IC#YB@)AZ!U'H`=1\@>4?)EO%0,`N(:.DE>B=X7NC:UP;\/[3T3
ML-Y'4Z?N00FQ-F2,RL1B1+86YY:$C:]`/E50*"<@P2E(6OD((^N<H``#Z[*!
M<R<U<[TWW=RV`=-##JBA#>/X*W:YSW#O$B27T"OJARAV]9\N^6=C%DW-MYY]
M$T[GT;^&NG,;&QW<<`Z&&G6X=]8;?M*_%OT=_ICF%7([HF](.D]H+MT0`H.4
M0D+%K:9>&)Y1.JC[K1ZBI_\`:-$^O[T,ESS=MS59=[3N'<1_U$(/<-&2M'H'
M0X#OO*@?SM-F^%8[XM&<"/%9R.Z-3X7&G=;VC7./4R-O<6J"K_O:GXA_R1RT
M2I0SUX]$+T]>&K1K(\+>++"0;-W[%]QDTJS>LWB*;IJ\9N-75M!PU=-URG1<
M-ET#B0Y#@)3$$0$!`<^;>[G.CWADWQDM>W)7!!'`@B9Y!!ZB"OK_`+!8R7E_
MAHY0'1NQ%H""*@@V\8((/`@C@0>I:)OBS<$G?!;E'-0%>CW!-(;2]T;WI:0$
MJAVS&'6>%]WZ`HX,)P-(4&3=%;D*8QE#QB[-8_KE3`%V>5F]F;UVTR:X</CF
MVI'<#K+J>#+3N2@5[@>'M'`+YR<\.6[^7>\)(;5I^(+RLML[J#2?"BK[*%QT
M]9+#&]QJ^BV=_LZ?[/$W^7K:?_)ZME;N?W^??S*'[LBN!YKGT8?_`.PF_D0K
M4IX;Z#@.4'/K5>BK:LNC4;YNB?3MI6JYVKMY5JZK8K;8(IJ[3_A6CF:BH%5F
M18OKD3+]LOE*&6FW=G)]M[&NLU:@&Z@M&Z*\0'OTL:XCK#7.#B.NE%278>VK
M3=_,ZSV[?$BRN+T]I3@2Q@=(]H(X@N8QS0>HD%;E?B1>(15O"AU;I.FZNT`P
ML?PS2GJ]K^NL')*+K"D0M';0IG#=VO%Q+]15ZN$XEZ+'MDTCK%(LL=8G8Z*5
M%Y>[#NN9^3O+O)7SH^Q+72O/X2:1TFJA&IPX#2:N-:<``>J^?-3F;9<F,-86
M.(Q@E;,U[(6-_!00LBT`@Z6GB=8TL&FM'$N!I6-/AS>.[&<NMSMM#;PU96].
MV.R1$Y)4NYP=P5>TV2>UZ-7F9"NSK>QM6#B#>+PS-PLU<`Z<)+J(BB)"'.F)
MNCY@<DI=J8@YO#7,EW;QN:)(W1TD`<0T.:6$AP#B`1I!`-:D`KDN5GG'VN^,
MZ-NY^TBL;J5CC%*V3\&XL:7N8X/]9X#7%KM9!(TT!(*P^>/MQRT)JS?.N]RZ
M`?T-O&;RC+5_.'4:'+P3N,B=@U)U$*.+,2'A'*B4&%RC;`05R`FFDL]8K+``
MJ+*CDL\C-P9S)X2XQ&=;.9+)S.R?*UP+HGAU&:G#PNS+30U)#7-'0`H(\YG:
MNV<1N&USVV76PCR#).VCA<PM;-&6U?I8?`[42"HH`7,>[I<5D#\`WPW->DUI
M'\Y]X5B,LMHLLA*!HF&LK1N\A*95Z^]<Q;W9!H]\4[52T3<PR<$CW"I!]SV+
M8KA`04<]M/@^>7,._.2=LO#2.CMHVM\9<PD.D>X!PBJ..AK2"X#USCI/!M#*
M/FU<I\7'AV\PMPPLEO9G.\5;(`6Q,82UTQ:[AK+PX,)'@-;K::O!;WW)#[2=
M2*%L^=I?'S0Q-O4VL2[N(<;)L]\5I\?;%8]<6SQY4(6/K$^Z]PE5TC^B/7:R
M9W*?94]&(4P=?#;WF\7M_C67F=OO%+N1H<(F1]H65X@/<7M&KNM`H#PU%9&[
M?.PQF*S$F/VUCA?6,3RTSOF,8D(X5C:V-_@'[UQ-2*$L'0LF/&'E/Q2\8/B]
M?6%OUVS]R(Q=*M[CU%L!1C).*7)2#)R[@[!$61NFT`S)XW076B9IL#%X@X:K
M!V4%41R.MR;9W/RGW+`^TN#VKAK@GBJ!(`0',<PUX@D!\9U-(<.)!4N;1WCL
MSGCM"X9>6S3`VC+FWF(<8G.!+'M?1O`T<8Y0&.#FNX-+>.EW8]&1?&KQ+*OI
M.O6V-O59HO*?4S2I6^*EHN91FZG)7RI35;7>/H9PYC_=QK$2*+>13(8!1?HK
M$$I1+V0M_;YJ7<7+J7,W$3H+F;&3%['-<TM>(WM?0.`.DN!+">EI!ZU06YVY
M!M+F]#@+2=EQ:6^6@$<C7-<'1ND8YE2PENH-<`\#UKPYO4MZ#Q'.;"O`7CL7
M?*.N2;1.:_U2D?!A2T#42@6RIRJ@R7NL$%8AZL_<SIW7H_K^W^^+T\M*^7^S
MAOG/_$AN/%AV#Y->C7ZPM%-.IG3JZ:]2^BW-/?[N6^U_\1MM1=GQAD79F3L_
M7->ZNK0_HT4IIZ^E8,8?[4`Q%\W+8>&K]&+%9,'BT'NQJ]D46PCT75:LY#6T
M:U=.$R^4B9UT2G$.@J$Z]H)IF\VV303;Y<&6G`.MZ`GOD3$@=^A]!5RM?/`A
M=,UMW@BV$D5+;NI`ZR`;8`T[E17NA98.=NFM&^([X=<YM&,B&KQVYTBZWWH:
M\2,6@SMM5E&M24N<;'*.0,=PQ:3K=`8R89=ZHW.54QNAE$45"1?LG+9KE]O]
MF-D>0T7HMKF,$ECP7]F33H):3K8Z@/"G02#-?,;!;=YJ<K9,Q%&'.=CC>6DK
MFALL;A'VH:3Q+0\#LY&U(XU]<UI&!S[,D?M\FN11P\@'T)#'`/QM@0XA_P"S
MKDV^<;_EW'_TT_BGJN'FCM+=V91IZK"G_P#6B4??M%O[0E[_`&-`:SZ?V/[=
MNH__`*1S>\@?\A?GLWW&+G/.A^E./^@V_P#*>MN7<7(=3B?P$7Y$IU0MZ4U;
MI/7D\6IGF1KY9L7#*K0_HQID(V8%AV/=/O.WZ,MU['3IY>H58Q.`&Z-\_$!E
M[`7-Y*W7IU::%[JZ:MKZVG2.E79S6YSLWEL-S"'Q@VEA;N[/5HU:A&RFK2ZE
M-5?6GH6#^B_:=Z6]L44SV7Q.L57JCE\@C-6.I;28VZ3A6"BI"KR2%;D:35RR
M_HB0B<R)7J)S@'0@B;H49FOO-OO([=[\=E(Y;D-):Q\)8''N%XD?IKW=)5>,
M5YWF/N+R.'+8:2"U<X!SX[@2.:">D,=#&'>AK;Z*GCXR7%S4'+7@C<>0D%&1
M#[8&IM;DW7JO94<T(A*2M&:Q[>SSE>>/>Z2>2-9L=/.LX1;+=00>E16(!3`<
M#\1RDW+EMJ[VAP,SGML;JX\7FA)X"0DL:X#H#VR4!(Z6U!ZJ23SWV?@=[<N)
M]S0-C=D+.T%U;W#1X3H0T2/:3P+F/B)<UIZ'AI'WP.$[B/\`:`G?%CC;J'CV
MGQ:0NQ-554E9+:S[?/`&G`(_?/O3!APUU+^Y_7TWL]WZ2M^]Z]KR]`F/=/(E
MFY=PW6=.3,)N9->CL`[3P`IJ[9M>CN!5[V7YSTFT-KV>VAAFS^*1%G:>-%FK
MPG.KI\7=3UU*:BMI/@!RW4YP<8Z?R)5HA-;GM4W<X@:F2Q#:2L@J5IE*V#@)
MD8:!%QZ>$=WW9]&)W?;[/4W3M#6C?6U1LS<<N`$_C`B9&[7HT5UL#Z:=3J4K
M3UQJKC\M-['F%M&#=+K<6IG?(WLP_M*=F\LKJT,K6E?6BG1Q6`Z?^TVOH.?G
MH3^INV<A"S<O#@Y'>2B0N`BY%RP!P*0:K4!(5@;]KL]HW9Z].H^?)RM_-Q9/
M`R?XW(UL#J>+#A4`_P#'"K3>>=U):7<EM\1-=V;RVOC9%:&G1XL?NK5]WGLP
MVZ=U;=W">'"NGVKLN\;%-`%?#*%A#7.R2-A&)"2,V9&D`CQD.Z[X44A5[':[
M!>O0+*83&_$^'M<2']H+6VCBU4TZNS8&:J5-*TK2IIT55.=R9@[@W!?9TQ]D
M;R[FGT5U:.UD=)IU4&K3JI6@K2M`K69LUI4PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+*IX)?[3OC%^?[)_5#?<C'G
M)]&^2]K#^/B4T^;U]+V']O/^JSKT0LH*OJ4M3+[4#Y^&/XV]?R=59:3S;/WO
M^;?EU2;SPOW#Z%Y]VV6IMEI%25,(F$6P1]FW_P`^_8'^K+>/UAZJR"/.&_R3
M!_>,?XJ96@\TWZ1[G^Z)OQ]LMC'G+X?'`;E;MB!V'RDN[NMW^)H<=4HEBCN2
M)UZ16J,IR?E6;KW%?F!5P8\I,.RBY#UI^SV/.3*^[+WYOG;&+?8;:A$EBZ<O
M<>P=+X9:UI&H=YK>'5T]:M;S#Y9\M=XYJ/*;QN.RR3+9L;1XS'%^#:^1S3H>
M"?7/?X0Z:4ZE#'_T7?!R^-B0_P#N?K7^ZSK_`/5_FUY*/ZF]<%_H/R)\M']=
MA]1:I_B`ZCU1HCEOO+4FCI(\OJFERT*RITDK96UP4=LWU)KDP^.:QL_[6DQ+
M+R+@O4OE3[/=CZX@Y9[8N5RF;VG9Y3--T929CC(-!90B1[1X!XCP0/1Z>M4O
MYDX3"[<W_?87;K]>&@FC$;M;9*@QQN/AMX'PB[HZ.CI"W</$C_8];J_U<:#_
M`,HI&4UY?_2Q:?WA+]R1?0KFC]"%[_=EO_*A7GJ9?9?+5;U7V<N=D9;P^I2-
M>JK*M:MR$V7"0Y5#&,1".=PM'LRJ"`#Y")>Z]A=*"`>3MJ&'SB.4G\X"".+?
M;9&`:I;")SN^0Z5E3_Z6@?87TA\U>ZFN.63XI"=$.2F8WO-,<#Z#_P!3W'T2
M5B-\.6OL*IX_VVZU%$32C83:/,M@P22`"I)-4E[B*2*12@!2II%-V2@'F`,E
M3F!.^ZY&6EQ)_O'VM@3Z)[*I4)\J[:.S\Y2_M8J=DR^R313H`'C``'H``*ZO
MVGG_`.J/$;_`';'_`(BI.:SS;O\`QV5_Y\'\F1;7SP/_`">$_P"1/_+C6L1`
M?_'X'_IR'_NDVRR5Q_N'^T=]PJGUE_W<?M@O0!\=#]EYOO\`/-/_`*WJ)E%>
M2GTE6/M;C\1*OIMYQGT/9+V]K^M0KSZ,O>OF`M]O[/A^S=I_^57;O_B<<HWS
MW^D*;^C0_P`E?3+S9?HJM_Z5/_*"M-8?!N\(*9L$_,3&U)!*7EYR8E99(.3-
M<;`E*24BY>R*0-C&[;<$WBYR]V/E)T[(^4,VEOS:YK0P,AAMAV3&-#?^D>>`
M``X]?!:6[Y&\C[BZDGN;REP]Y+O^MA'$GCP(KZ?'NJQV_?"(\)NAZ*W3>*-L
MY\]NM,U-L6UT]F;DA794KNT5ZH3$O`-C1:9A4DRKRS1(HMR^N6Z]@/*;-W@N
M:O-&^S=G97ML!9S743)#XJ]M&/D:UQKU4:3QZNE<WN?DGR5QVVLAD,==AV0@
ML9Y(AXY"ZLC(G.8-(%75<!P'$]`6'SP#A$?$TTT(^<:3N(1_!Y1UK.B/_P">
M2QSQ^CF[_P";!^.8H*\VH`<VK(#H[*Y_5Y5D+^T^?_4'A[_@=N3^[6O,X/S;
M?^QRW_-@_DRJ3O/`_P#(8/\`Y-S_`"H5JW-'SJ+>,Y1@LHW?1CMK(L7"1A*J
MW>,5TW35=(P=!*HBND4Q1#R@(99>1C)6.CD`+'`@CN@BA"IO;R20S-EB<6R-
M<"".D'J*]#3Q96B-Y\*+D/(32*1G*NIZ3<@!8@=6\Q&6BEV-`Z?4`["Q7C?L
MATZ#Z[I^'*#\KWFQYGV#(2=(NI(_1:62,^X5]2><T3,IR:R3[D#4ZT@EX]3F
MRPO].HHO/#R_2^6*81;N/V:G_,KVW_K+6;]7&LLIIYQ/^<;7^[F?CIE]#O-+
M^C^]_O9_ZO;K4[YW?Y[G+[_68W=^L6PY:/9'^3<3_=UO^*8J3\R?I!S?][7?
MZQ(LA7V?+]I'4O\`)%MK^Y<9G`\^?H^E_I4/\HJ5?->^E&+^B3_R"MGOQ$_"
M<U]XB5VUO=KGMV[ZW<ZWJLS5F3"J0M>E&\FA,R[>65=NU)DAE4ED5&X$*4GK
M1*/4?+E;M@\T+_8-G<6=G:PW#;B5KR7N<"-+=-!I5P>:')C%<T;VVO<C>36S
MK:(L`8UK@:N+JFI'=HHCZ>\`KAKQ=O%<Y`;3WE?+9!ZCEXR]@AL.2HM%UPRD
MZZ^;R,5+7!^G'MU#Q$;)(I+"BH^;MU3D*583IB9,W59;GEN_<ME)@L;90137
M3#'^"$DDI#@0YL8KZX@D5#21TBAH1P^"\VO8.SLA%N;+W\\L%D]LOX9T<,`<
MPAS72N/WH<`2-;0>AU6D@X_O'9\4/3/(6D5WBAQPM++8M=8W&/NVT]D0@JJU
M-T[KB#Q*N4VJR9BD1L:99!\+Y\];@=F0S9NFBJJ8RP)]WR3Y:Y?`WLFZ-P1&
MWG,1CAB=Z\!Q!?(\?><!I:T^%Q<7`<*QCYQ_.+`[DQL6S-JS-NK<3"6XG9_N
MR6M(9'&[H>/"+W/;X-0P-<[PJ8B?"ZXQ#RTYO:4UC(,!?TJ&G0V7LLIDS':_
M`/7RC>;D&#T0*8"-[+*E91'4?_>D`R5N9>Y/\+;-O,C&[3>/9V4/=[27P01W
MV#5)_P"A09R9V?\`XUYA6&*E;JQ\<G;3]8[&+PG`]Z0@15ZC(%L3?:2>4:]#
MU1I/C-4YPT79MBVQ/;-H.Q<BW?1U4UH[3^!X'`ARF(E*7U=-V@;\"L$/3S9`
M'F][:;?92\W%=,U6UO%V#*C@7RCP_<QC2>]*K6>=3O"7&86PVK8.<+JYF%Q+
MIZ1'":1@TX@/D)<TCH="LB+4M>\6;PHD"**1ZMAW=I4B9UNT@*5:WS1S@05A
M$.HLD8K:E8[0AZPYF)O]JIY>!<9^5W,\D:A;V=YWZOMI/NDPO[_A=\*3FMM^
M<_)H-?H-W?V%#W&7D/7U$-%Q'WB8SW"O//EXR2A'TK"33%>,F89[(1$O&NB&
M2=1TK&.%F4BP<IF`#)N&;Q`Z9RCY0,40R^T4L<\39H7!T3VAS2.@@BH([Q'$
M+Y=S6\MI=NMIVN9-')I<TBA!!H01U$=87H4VW<MTX\^#A1-WZ\7:H7/6'$?C
MY;H,'R!7+!VO%UW72CB+D$3`/;CYAB*K1?L]#@DL82B!@`0H5;8FSSW-J?#7
MX)M+G*W3'4-"*NEH0>ZTT<.^.*^H5QG+_;?(NTSV,<&WUKA;&1I(U#@R"H(Z
MPYM6D5!H30@\53W)75FJ/&;\.6$MNLE&*=IG($NR-,R3Y5O[H47;<$V=,)F@
M6)V4"BT1=/DW<!+!Y$NAB.R%/W2!LR-NY/*<HN8#[7(ZO%62=E<``TD@<06R
MM'70:96=?2PTJY8F[,-AN?/*QEYB=/CDD7;6Q)%8KA@(?"]W4"0Z)YZ/6R`'
M2TJW'V>^#F:QP,FZU8XM[!V*N<D-R0,_"22!VTC#S<.I7(^5BG[90`.W>Q[Y
MNHDJ00ZE.00S8<]YX;G>[+FW<'V\F/@<UP-0YKM9!!ZP0:@]Q:WS9[6>QY=2
M65TUS+F+*7#'M<*%KFMB#FD'B""""#Q!X%:6NL]TV[CGR<@-Z406QK7JW;;^
MVQ35\*@1\F#&?D$Y&$DNY$JP1L]%+KLG`D$#@BN82B!@#+@Y'#6NX=MR86]K
MXM<VH82.D5:*.'?::.%>%0*KY_XG<5[M/>46XL?3QNTN^T`/0ZCN+3_LO%6N
MI0Z2:$=*WH-+>(CX;WB0ZR94C8LGJY&8F4&JEBT!R)1K363CYT$>Z4"OJ6@B
M4#;#-U5U`:2$0L=SW8@8Q&Z@F3+2O,;!YA<O<D;RP;<F)A.BYM=9!;7[_1X3
M*\-37C37H+AQ/T8V_P`T>57-3$-L<F^S$SZ:[2]T`A]/_=F2C)*5\%\9U`=(
M8:M%H=V_9]_#_P!N1[U_K2.NNB)N00%>.D]>6QW8JH"RH`=)=>IW5:Q,G$>;
MJ`]RQ<L`$O[PY,VN&Y[;ZQ3Q'D70WL+30ME8&/IW-<>DU[[FN[X*TFX/-GY:
MYMCIL4VXQUR[BUT,A>RO=+)2_P`'O,>SO$+4G\0#P]]O>'GL]I1]@K1EHJ=N
M82$QK79U>9KL82YQL:HDE)-7#!R95>"M$$=V@#^/.JN"8+I*)++)*%/EIMB;
M]Q._,8Z]L`Z*[B(;-"X@NC)Z#4<',=0Z74%:$$`@A4FYG<L,]RTS<>.RKQ<8
M^<:H)VU#)&@@.%#4L>VHULJ=-6T<YI:X[KEA[6G?!BD!HX`S7J'AY`I#+LA$
MID7I]#D45E$5$P`P+>EN3NNV'E[8]KSY3RWIEN;[?'.+9<_X0/<\9];Z0#:*
M_EV78/D$]V/\%\.UZM(]D;.I=7NU)=7N\5YVQ"@0A"AYBE*4/]@```__`"#+
M]KY9.)<XN/22NT:3,RP8R,6PF)9C&3'HP3$:RDGK2/E@9BL+,)1DW73;2(-!
M<J"EWQ3]WWANST[0]?-\,,CVRR,:Z1E=)(!+:TK0](K05ITT"]HKJYAB?!$]
MS89::V@D!U*TU#H-*FE>BI5W.,12DY*<=2E*4I0WQI[H4H``!_YBUSS`'0,U
M.Y/\NY#^A3_BGKH-F$NWABRXDGXPM_QK5Z*G/;A96.>NB"Z)MMXL.OXDMWK5
MV]WZS'Q<E)"ZK2<FF@P%M+E,U]&=!)F$YOWX"0.GX<H#LC>%SLC-_'=K#'/+
MV+X]+R0*.+36K>-1I7U/YC;#L^8VWO\`#M]/);P=NV74P!QJUKVTH2.'AUZ>
MD!8=X/[,KQJ:2#9Q9>1N\IN+2<)JO(^.C:%7UG;4ABF5;!)&A)<[7O2@("H5
M,3%`>H=!#KDM3><;N-\9;;V%FR0C@29'4/=IJ;7T*J"K;S2-H1RM?=9*^DB!
M!(:V-E0.JI#Z5]!5OXCWB5<2N)O$"P<0>+EUJ=ZV,\U@KH:I5K7TTWM<)JBH
M&@`ITE,VVTL5WL:E-P\`95-LS%PK)+20D46(5,JJ@8?+WEWNG=.[(]U[EAE@
ML!<^,O?*TL=-)J[0-8PT.ESZ$NH&!E0TDT"S^:W-C9.R=BR[(VC<0W.2=9FS
MC9"\2-MXM'9.=)("YNMK*AK:EYD(<X`5*QO_`&90H%Y.<C"E#H!="PY0#]P`
MV##@`?\`LR0/.-_R[C_Z:?Q3U%7FC$NW7E">DV'Y:)1[^T6?M"7O^0'6?_++
MIF]Y`_Y!_/9ON,7.>=#]*<?]"M_Y3EMK[TX]R_*WP]7_`!Y@K+'4^7VCI#74
M$QLLLP<RD=$JMVM3F#.'3!FNU<N4SIQIB`!%"B!C@/F#IE6\+GHML;\&>FC=
M+%;7DKBQI`+JE[>!-0.FJNKGMLS;QY9_X:@E;#+=V%NT/<"0VG9/X@<>(;3O
M5KQ6`VA_9AYT9^./M/EA$*U--RF>8CZ#K1ZA8)%D4X"NRCY>P6A9A$+N4@$@
M.#LW8)"/:[H_3IDXWWG(0^+N&-Q;O&B/!,DHT@]TM:RK@.X'-KW0JU8OS0I6
M7C),MF6&S:X%S8H3K([@<]X:T]\M>!UM/0LG'C"<D=1</?#_`+7Q^AI2/:7;
M:.KDM$ZBUZB]*ZFD::K%-:C-6)VW%0SQO7JS3TED_3%0["SX44`$3J#V8YY3
M[>RV[-]19V5KC9VUSXS/+2C>TU%[6@]!<^2ATCH;J/0%+G//=>!V+RSFVS$]
MHO;NS%I;P`U?V.D1O>1Q(8R($!QX%Y:VO$D:"N7F7S+6_P"^`7^S,U#_`(:;
MD_6A9LHISR^D:[_Y,'XEB^G7FU_1)8?\ZX_'/6A=?O\`M[>_\-K;_P"(9'+P
M8_\`["#_`)+/Y(7S7S/_`)6X_P"<[[I5)YEK6IA$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+*IX)?[3OC%^?[)_5#
M?<C'G)]&^2]K#^/B4T^;U]+V']O/^JSKT0LH*OJ4M3+[4#Y^&/XV]?R=59:3
MS;/WO^;?EU2;SPOW#Z%Y]VV6IMEI%25,(F$6P1]FW_S[]@?ZLMX_6'JK((\X
M;_),']XQ_BIE:#S3?I'N?[HF_'VRK[[1=J_85TYKZUE*EK:\V^/0XWU5BO)U
MJDV*Q,47:>P]F+&9*OXF+>MDW2:2Y3BD)P.4JA3"``8!'7\@,EC[/9UQ%=W$
M,4AR#R`^1K33LH>-'$&G#I[RW/G28C,W^_[6;&6UQ+&,5$"Z-CR*B>Y-*M%*
MBM:5J*CNA8"/Y@-U_$9MO^BN[?\`4&3G\>X3RRU]]C_G*M7^&MV>17WO<GJ*
MCK72KA2>[97"GVBG.7C-=PQ:6BN3%;<.VQ!,FHX:-YADR5<($5]:8Y"F*!O(
M(]<R[:\L[QI=9RQRM::$L<UP![A+2:+6W6-R6.N(VY*&:&1Y!':-<TD5I4:A
MQ7H/>(9#R\_X1>WX:`B92=F'_':@HL(B%CGDM*/EN^I1Q29QT>BX>.E0(03"
M5,AA`H"/F`<H=L26*#FI:S3N:R)M_+5SB`!PDZ2:`+Z>\RH)[KDK=V]LQTD[
ML;;@-:"YQ.J'H`J>_P!X<5H;5SC!R7M\HTA:OQXWE/2S]PFU:,(W4]\<+++J
MF`I"=0@022`1,'4QS%(4/*80#RY=^XW-MRTB,US?V;(FBI)FC'#W2^;%KLC>
M%],VWM,9?R3.(`#8)'&IX=33_P#N6^#X;VD?_3;\.5B7D"^85*7KL=?-[[F[
M3QJX:U5S*)C**00NT5CM7TG"U>)8LE01.<BT@F<B)E`$@FI%S"S/^H7,!WQ$
MUTL4CH[:WX$%X'#52E0USW.<*@490FG&GTCY5;?_`-*>5K1N5S89XF2W=UQ!
M$9(KHJ"07MC8QI`)!DJ&D\*ZT?@Q;`?[9\89IM.42,A([*-R5OSUN8>T9LXN
M$-8[`HU$WX?1AD.[_P#V<L5S?L&8OE.<9&:QVXM(@>Z(W,;7[-%4SD)DWYKG
MD<Q(*273[R8CIH9(YGG[%25+7[3S_P#5'B-_@#MC_P`14G.6\V[_`,=E?^?!
M_)D79>>!_P"3PG_(G_EQK6(@/_C\#_TY#_W2;99*X_W#_:.^X53ZR_[N/VP7
MH`^.A^R\WW^>:?\`UO43**\E/I*L?:W'XB5?3;SC/H>R7M[7]:A7GT9>]?,!
M;[?V?#]F[3_\JNW?_$XY1OGO](4W]&A_DKZ9>;+]%5O_`$J?^4%I6;1T+N9?
M9^S%V^D-K+(+[%O*R"R.KKFHBLBK:I91)5)0D")%$E"&`Q3`(@(#U#+A8O-X
M9N-MVNO+4.$$=?PL?3H'^TJ#9W;FZ'YFZ=%97IC,[Z4CDI34:=2H8-`[L`0$
M-&;;`0$!`0U7=@$!#S"'2`\^9WQ[A/++7WV/^<M2=L[K(H;*^I_RY/464KP'
M6;N/\4+4S"0:.F#]C4]ULWK%ZW6:/63MMKN?1<M';5P1-=LZ;K$,11,Y2G(<
M!`0`0$,C3G>]DG+>ZDC(=&Z2W((-0096$$'K!ZBI>\VR.2'F[9PRM+961W((
M(H01;S`@CJ(/`A9+?M*U`OMUOO$E6F46Z7!*/J.WDY!6J52?L:;!1S,T`S=-
MZI#1[TC0[@J)Q("@E$X%'IUZ#D=>;M?V-E9947DT41=+!36]K:T;+6FHBM%+
MOG98G*9._P`*<=;S3AD-QJT,<ZE714K0&E:%80N'_AN\I.46Z*'24-*[,JM#
M<V:%5V%L.X4JPU.J5:FHO4'5@>'E[#'1S1_+*Q*2I&3%N95PY<G(4"@3M'+,
MV[.8>V=MX>>\-Y;RWPC=V44<C7O?)2C1I:20W534XT#14]/`UWV)RCWCN[/V
M]@;"ZAQID;VTTD;V1LCKX9UN:&EVFNE@.IQH!TU&UUX_N_*WIS@1*Z>;O&J%
MMY`S]9H5:A"*!Z82IU27B+=<9@B(CV_<V/8PS6/4/^!:31+Y>UY*O\B\'<9?
M?#<LX$VMBQ\CW=6M[7,8VO=)<YX[S"KI^<MN:TP'+9^$:X-OLE)'%&WK[.)S
M99'4]B-+(R>HR!:'F7>7S63"+=Q^S4_YE>V_]9:S?JXUEE-/.)_SC:_W<S\=
M,OH=YI?T?WO][/\`U>W6IWSN_P`]SE]_K,;N_6+8<M'LC_)N)_NZW_%,5)^9
M/T@YO^]KO]8D60K[/E^TCJ7^2+;7]RXS.!Y\_1]+_2H?Y14J^:]]*,7]$G_D
M%32^TL6:S5KD#Q9<UNR6&NN2:GNRY'$!.2D*N1=*YQHI+E5C';50JZ8AZTX#
MV@_`.<=YNUK;7.#R3;F..1OC+!1S0X4[/HX@J1/.RO[VPS^(DLI9(G^*O-6N
M(-1(:'AUJ;G@?>)&ORRU_.\1^2<TA<=P4BONG%9F[@*$HXW)JKLE9R,?8"R)
M5B6"UT\'!47QE045D8Q9)=0%%$GBH\=SFY>#:U^S=6WF&'$S2`/;'5H@FZ06
MT]:R2E6TX,>"!0.8%WWF]<USO?%2;+W4\3YNWC.ATM'>,P=#FOU5UOCZ':N+
MXR"=19(XX8_&S\-J/X9;<C-OZ=@CQ_'+=,D[)'Q#-(PQVKMCD25D).D(&#M`
MUKDZS34?PA#"`)$2=-2@";5(3R]R;YAR;NQ;L3EGZL_9M%7'IFBZ&R'NN::-
MD/62UQXO-(!\X7E-%L3-,SV!CT[8OW&C1ZV";I=$.XQPJ^(=30]@%(ZG+-]F
MSXPC4-+;4Y66"/[J:W#/!KVAN%TC%63U[0G:AIY^T4,``+:Q7E51!0`Z]1A$
MQR+?.&W)XWF+;;$#JPVC.UE'_P#%D'@@]]L?$?\`,*FWS3]G_%^WKO>-RW_J
M+Z3L82?^#$:O<#W'R^"1W85(W</BM^#/8K[.M-OM*=LJY4Y_)T=U8;+QDD]@
MJ$)6Y>1:+L(BS2='E1>0:4D+A1N9!86RG>F43Z@IU'G\3RQYNV]BQ^),UO:2
MM$@:R[$7KV@U<QL@HZE`:BHI0]"ZS/<X^0UUDI&9X6UW?P$Q%\ECVQHQQX->
MZ)U65)+:'2:DCI4J>$'B`>'[R$LLGHCB`^B:_)PL%*7]6C0^I9/4\*M'DDHN
M.FI6,9+5Z!AWTB#R3;"X*D!G!B&[PP"4IA#F-Y;%WW@;=N;W6U\D;WMB[1TX
MF=6CBUI.IS@*`TKPKPZ2NRY?<RN6>YKIVW=COCCECC=-V++<V[-(+6N<!H:T
MFKFU`\(CCT`TU-O'?XN?U>.<=LN4)'^B4/D?%GV]!&23[+1O;5U_<W9L40P%
M*3TCX3$+*G*'[Q.83#+1\DMS?'^RXK.9U;['N[!W=+`*PN]#1X`[\95*?..V
M;_ACF+)D;9FG'90>,,H.`D)I.WOGM*R'N"5H6R#R@_8'O?\`49TI_P"%->Y7
MK;GTX#^^KC^7*K7[H_\`^<!_]OV?\B!8+/`-Y]_U>MY+<7MD37HVG^0<TU)5
M'3]R)(^E;H530CH98IE![MK&[$:HI1;GS![H),#B)2]\89MYY;%^/L+_`(EQ
MS*Y:Q8=8`XR6_$N'?,1J\?[)>.)HJW^;1S,_PUN`[/RTE,)DG@1EQX17/!K#
MWA,*1NZ?"$1X-:XK=<J="J%&7M[BI03*"/>[?(7VU%8$%)*6M\M'1,9*SJR(
M#W2;V3;PK<S@Q`*"RP&5,`J'.8U.KJ^N[UL3;IY>((A$ROWL;2YS6^@"XT[@
MH!P`7T"LL98XUT[K&-L9N9W32:>`=*YK6N>1W7!C=5.DU<>))/GG>'/Q_P"/
MW*7GB.B.1CRSL:G?%MHH5=6JV-O5WSF_0[UQ/0\:YDG$?(=MK)0\;(I$1(5-
M15R*12GZ^M-?7F#G<[MK9'QWM\1FZ@[$OUM+P(G#2X@`CB'%IKQ`%:CK'S`Y
M5[8VQO#F5_A[=+I6V=P)A'V;@PF5HUM!<YKA0M:YH%`2XM`/49P^,%X/K;BN
M37VT.)>M[[9=)*U]S"[003>3FQ)VHW%G).'+"T3`"DZD6=9L,0\3;=\FF#-H
MZ8CW@IBY3[?%\I^;!W-V^,W5<01YCM`Z&H;$U\9`!8WJ+VN!-"=3@[A72:2+
MSRY%C9_BV:V-:W,F$[+1.`72.CD#B>T=05#'M(%0-(<PU(+F@V0\&F5YY%Y<
M:@KNBY#<">H$+G$+;MB9$;*KIIEK-%<!MIK`TF0-5(Z84B>\3BS(`E(FD#)%
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M0IA7[(#VB&Z<AS$QUYLKF7+D8V4C==MO83T!P=)VA`/^S(',/H5Z"%WO*?+8
M[F-R=AQ$CZO;8/Q]P.!<PMB,321W71%D@/14D=(--)/D/PFY,\7ME3&KMGZD
MO*4A'2;EA!62&JT[,U.]1Z3@Z#"?I\]','#&68RJ)2J%2*?TI`QNZ7335*8@
M7(V_O/;FY,:S)8ZZA+'-!<QSVM?&:5+9&DU:1T5Z#TM)%"OGUNOESN_:>9DQ
M64LIP\2$,>UCG1RBO!T3Z4>T](IQ%:.#75:-A7PI?!(I>R]"7[8/.W4MACI7
M9KR$1U#67\M9*/?J+5H=!\J]N+EK'/&#J*D+B_D4RH,I)%0Q6;`BJB``X*&0
M+S/YR7F/SD%ALFZC=%;!W;O#621R/=0",$@@B,`U<PCPG4!JU6@Y+^;WC\GM
MJYR7,6RE;/=EGB\9<^*6)C=1,A`+2#(7`!DC3P9JTT>"<*M]UMI73?B?5_5'
M'NQV2VZJUWRGU)482PVN1B9>6?2L+>JBTMJ192$C8F.D(Z,M9'K-JN1`HK(-
MRG$3";M#,-CD<QE^6TF4ST<<63GQD[W-8'-:`Z-Y9P<7$$LTN<*\"2%`&1Q&
MW\!SCBPVUY99L/;9:"-KY'-<XN;(P2"K&M:6MDUM:0.+0T\:K:L^T02$A&>'
MPDZC)!_&NB[ZU:4KJ.>.6#D"F;VD3%!=HJBJ!1$`$0Z]!$`_<RL7(2..7?99
M*UKF^)3<"`1TQ]U7/\YV:6#EGVD+G,D&0AX@T/K)EA[\$#Q3+=JK;$1Q6Y#W
M^8L.G]I2#:'UG9KG-O)5;5VQ'BH(1,*$Q*N'#EM2+LX4!H*)U!0829D%2=TD
MLZ-DL\YN65IDL6_<V`@9'E;9I=,R-H';1#BYVD"ADC'A5Z7,U`U(8%!/F\\Y
MK[%YEFSMTW+Y<-=N#8))'$]A,>#6U<>$4A\$CUK7Z7`-!D<9A^/9X9%=EJ7+
M<X-#5%I#VRI`#GD+6:ZQ2:M+75#F(E_.DE&M$R)A9*LL8ONRJ0G5Y&'%TJ('
M9G.KR?(_F/<0WC=FYN4OM9>%J]QJ6/\`^#4_>/'^['WK_!'KP!W7G)\H;6ZQ
MS^8&W(&QWT'&\8P4$D?_`!](X:V'_>FGA,/:.(T.+HH_9E?\YWD;_D&B/U@Q
M&=/YQO\`EW'_`--/XIZXKS1?\U9/^[_RT2CU]HL_:$O?\@.L_P#EETS>\@?\
M@_GLWW&+G?.A^E./^A6_\IRV@^<6PKSJGPH-A;#UK:YJCWFK<?=:OZY:ZZ[%
MA-0KQ16D,U',>[*4QD%3M7*B8B`?O3B&5NV98664YGP6&1B9-92WTP>QPJUP
MI(:$=?$`_85O=_9/(8;DW/D\5,^#(0XZV+)&'2YI)A!H1Q%02#3J)6DFZ\3/
MQ"7B"C9?F3R!!)4HE/Z/L"49+=D0$![#ED+=TD/0?.0Y1RY+>7&PV.#AB;&H
M[L32/2(HOGI)SAYG2,+'9O(@'N3R`^F'`J']NN5PO\^^ME\M=ENUIDS%-(V2
MW3LI9)Y^).H$]+EYET]?KE3`>A0,H(%#R``9UMI9VEA`VUL8HX;9O0QC0QH]
M!K0`/27!9#)9#*W+KS)SS7%V[I?(]SWGT7.))^R53>9"PEO^^`7^S,U#_AIN
M3]:%FRBG/+Z1KO\`Y,'XEB^G7FU_1)8?\ZX_'/6A=?O^WM[_`,-K;_XAD<O!
MC_\`L(/^2S^2%\U\S_Y6X_YSONE4GF6M:F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(LJG@E_M.^,7Y_LG]4-]R,>
M<GT;Y+VL/X^)33YO7TO8?V\_ZK.O1"R@J^I2U,OM0/GX8_C;U_)U5EI/-L_>
M_P";?EU2;SPOW#Z%Y]VV6IMEI%25,(F$61[PON<U;\/WD'9-TVC7T_LEA.ZJ
MGM=HP5=F8V$>MGDQ9J?/)RBKJ4;N&ZK5!&LJ)&3``.)UBF`>A1`8]YE;*N-]
MX&/#VT[+>1ETV74YI<"&LD;2@(X^'6O>4M<F^8MGRRW1-GKVVDN8I+)\`:QP
M807R1/U5+7<`(R*4ZQQX+/E]YXU!_HG;1_I!IW_5N09]6_+?VG;>]/\`YRLU
M];S;_P#9%S[\WX-/O/&H/]$[:/\`2#3O^K<?5ORW]IVWO3_YR?6\V_\`V1<^
M_-^#6#[Q6O$-JWB+[$U7=ZKK6R:Q;Z\HL[4'4?9)R*G5I)>7G22Y'K52);MT
MT$D4R=@Q3]3&'IT\@9,_+#8-UL#'W5E=7$=PZXF:\%C2V@#=-#4FJKSSGYJV
M/,_*V60L;62V9:PEA#WA^HEY=44:VG319G:9]I:U'5:?5*PKQ6V<[4KE:@H%
M1TG?Z@1-RI$1;6/.X3(:.[12+&;B8`'R@`^7(AO/-VRUU=RW(R5N!)(YU.R?
MPU.)IZ[OJ>\?YV>`L[""S=B;DF*%C*]LWCI:&U_W?>7>NOM/6JBMU3,>).R%
MW8%$4$7>RZHS;*'_``%6=(0,@JB3^R5%0?[&>#?-ORA<->4MPWKI"\GTM8^Z
M%D2>=[@PPF+#W#I.H&=H!^SV1IZ16&3Q`_&'Y$\\X/\`FV=1$-IS1Y7[:1=Z
MXJ4D^EG]L>,'`.HQ6^6UXBP5G6T:Y(59!DW:,F(+D(JHFLJFD<DO;$Y2X#9$
MWQBU[[O,T($KP&A@(H>S8*Z21P+BYSJ5`(!(,!<SN?.Y^8]M\4]FRQV_J!,,
M;BXR$&H[60T+PT\6M#6-K1Q:7!KA'+PZ^6L'PBY45#D/8J9,7Z+K-<NT&K68
M*38Q$BZ5M=?<PJ#A-](I+-2)LU%^V<HEZF*'0/+G0\P-JS[SVS+@;>9D$LDD
M;M;@7`:'AU*`@\:47*<J-\6O+W>,.Y;R!]Q#%'(TL:X-)UQN8.)!Z"ZO0I#>
M*WXD-2\1BUZ9LE4U=9M8IZMKUQA'K:R3T1.GESV>2@7Z"[0\2V;E;$9EAS%.
M!^HG%0.G3H/70<K^7MWR_MKR"ZN8[DW,D;@6-+=.@.!K4FM=7VEU/.SFO8<T
M[NPN+&TDM1:1R-(>\/U:W-(I1K:4T]]8I(YT5C(QSXQ!4*RD&3TR91`IE"M'
M23@R93"`@4QP3Z`(^81R4)&ZXW,'26D>F%"4$@BF;*14--5L:<__`!S];\S>
M)VQN.$!Q\OM%E;NM2E6EGF[E6I6-CO@K=:]:E@<L8]@B[<>F-X0Z!.P8O9.H
M!A\@"`U^V)R6R.T-TV^X;B^AFBA$E6-C<TG7&]@H2X@4+J^@%:_F?YQ6'WYL
MFZVK:XZ>">X,)#W2M<!V<T<AJ`P5J&$=(XFO>6M_EA%4M;#_`(;_`(VFO."W
M%^#X_P!BT+>=@RD3;KG9E;)!6VNP\<NE:989)!JFRDF2SHBC1,>P<1,(&,'4
M/(/0(!YA<F\AO3<K\[;WT,$3XHV:',<XC0*5J"!Q5K.5/G"8CE[L^+;5WCY[
MB>.:1Y>V1K0=9!`H6'HIW5/'[SQJ#_1.VC_2#3O^K<XCZM^6_M.V]Z?_`#E)
M'UO-O_V1<^_-^#7]^\\:@_T3]H_T@T[_`*NQ]6_+?VG;>]/_`)R?6\V__9%S
M[\WX-8&N+_/&M<?O$4M/-Z4UY8;+7K#=-[6I*A,9N,:3[9+;ZEE.Q:+S+IN:
M.67A0GB]^<$P!44Q$H!U#)OW+L>YSNP(MFQ3LCN(X;9G:%I+3V&BIT@UH[1P
MX\*JM>S>95GMGFE/O^>VDEM9;F[E$0>`X"Y[6@+BT@EO:"IT\:=2SR?>>-0?
MZ)VT?Z0:=_U;D(?5ORW]IVWO3_YRLI];S;_]D7/OS?@U1EY^T\PON(Y3UGQ(
MF1L:B1RLW=]V='I0;-80$"+.6%<K3J0DDBCT$4RN6@F\W;#SYF67FW3=L#D<
MHWQ<=(CA.H]X%SZ#T=+O06OR7G?6@@(Q.&<;DC@99_!'?+6Q`N]#4WT0M;KE
MARYW?S1VN]V_O6RIS,\=H2(@(2*;GC:E2JXBLHNWKE2A3+N?<^.(NJ955111
M9T[7,95=510>N6&VMM3#;/Q;<5A8]$-=3G.-7R./2Y[J"IZA0``<&@#@JF;X
MWWN'F#F79O<,H?/ITL8T:8XF#H9&VIHVI)XDN))+B7$DQGSHUQR819Y?"W\8
M6A^'OHFXZAM&DKGLF0M&TY;824W7;3`0C)HSD:Q4Z^G&*-)1FNX.Z15KAU3*
M`;L&*J4``!*(C!_,OE-?;\S<.5MKR*WCBM6Q:7,<XDA\CZU!`IX8%.\K,<FN
M>F+Y8[;GP=[8S7,LUXZ;4V0,`!CB9IH6.XUC)K7KZ."P]<A-FLMU;ZW5N&-B
M7<!';4VI?=AL8-^Y0>OH=I<;-)3[>+>/&R:3=TZ8I/@3.HF4I#F*(@``/3):
MP&-?A\'9XF1X?);6L41<!0.,;`TD`U(!I6E5`NZ<O'N#<N0SD+#'%>7L\P:3
M4M$LKGAI-!4@.H305[BDEX;W,*!X+\GX?D!9*3-;!C(NEW*K&K<!*,(>057M
M#5HW1>%>R2*[4$6@MA$Y1#M&[0=!\GEYWF'M*?>NVWX*WF9!(Z:-^MS2X48:
MTH"#Q78<I-^6G+G=K=QWD#[B%L,C-#7!IJ]M`:D.Z/05Y/%8\1.J^(IL+4EV
MJNLK)K)#6U,L%6>,+).Q,XM*+34XUEDG;56*;MTVZ3=-N)#%/U,8Q@Z=`#RZ
MCEAL"ZV!8W5G=7$=PZXF:\%C2VFENFAJ36JZ#G5S5L.:.0LKRQM9+5MK"YA#
MWA]:N+JBC6TZ5CRT]MN^:&VC1-R:PFE*_?==6)C9:W)D`QT@=LS"5=A(-P,4
M'T/,,5%6;UL8>PY:+J)&\AASOLOBK'.8R?$9)G:6-Q&6/'>/00>IS31S3TAP
M!'0HJV_GLEMG,V^>Q,ACR%K*'L=WQU$<*M<*M<WH<TEIX$K8TY/>/)QRY=<<
M[SH';7$C8@-KW6$VJDO%7NH.1J=U9I)/82WU@SZ+(X!Q6[$BFY;]YV#+(D%)
M4.PHH4:^;<Y(;AVKN"'.8K*0:H)*Z71O&N,\',?1U/#9P-.@\1Q`*MANWSD=
MI[VVK<;;S6'GI<PTU-E:>SE`JV1E8Z^`^A`/KFU:[@XA=?4/'PU9ISA]&<9-
M%\;]@5*<J&DUM8T.ZR=SK"C.,M1ZTO%EOTE'L&(.G#M2PNE)==-,P&5<G,':
M#M"(>MUR.R>6W8[<>:R$$L$MX)I(Q&^I9K![($NH!H`8">@+QL_.5PF"V*W:
M>WL;<0W4&/,$4KI6\)3&6]LYH8*N+R92`15QZ>-5K)>N'RG.90X^4ZAS"8YS
M#Y3'.8>HF.<WE$1\HB.6/`IP'0J>N<7.+CTDJ4W"KD[-\.>3NJ.0\,P=325$
MFG`62N-'B;%:T4V=CG<':J^1TL15NBX>Q+\YFYU"'32=II*"`]C.9WCMN'=N
MV[K`RN##,SP'D5T2-(<QU.F@<!6A!+:CK7:<O-XS[#W?9[FA:9&6\GAL!TZX
MW`LD;6A%2QSM-00'4-."R8^*3XL6D_$5T[3:5&\?;UKS86O+I\):E=9JUUN9
M8MXF5CEHJV5YVSCV:+P6TVB5HN`D-ZURP1$?6@/6..6G*[,[!RTUY)?0SV%Q
M#H?&UCFDN::L<"215OA#T'%3%SBYU[<YGX.WL8L=/;Y.UN.TCD,C7#2X4D81
MH!HZC'<#TL'557)VQXVNN]C^'@XX2--"7J+L"V@*)ID+ZYMU=<099&H0U:BU
MYT8I%B61]!>J01CD1[7>%*H`"/4!'-=B^3>0Q^_1O%U]"Z#QZ6X[,1N#J2.>
M0W5JI4:NFE."VV7\X3$9'E>-A,Q\[;H8V"V[4R-+=438P7:=`-#H-!7A7I6O
M$DJJ@JDN@JJW704360<(*'17072."B*Z"R8E41614*!B'*(&*8`$!ZAD^N:'
M`M<`6D4(55&/?&\2,)#VFH*VM-$_:4V--T_KZI;IT#=]B[/K-;8P5MOL!<Z[
M%Q]Q?1919H6-2/DF!W324EF*22KXO:%,7IE3)]$S%*6L&;\W>2[RT]UA[Z&W
MQLDA<R-T;B8P[B65#J%K34-Z]-`>/%76VUYV5O98*UL\_CYKG+Q1!DDK96@2
M%O`/(,9HYS0"_C374B@(`U=VEUGH&_I;&ITK*56S15Q-=:Q-13LS68KTRWFC
M3<0_8O4>R*3^,=`0Q3E#IVR>;IY,LJ^R@GL#C[MK9;9T79O:15KFENEP(/41
M7@J<LRES:Y89?'O?#=LF$D;FFCF.#M32"*4((!!'7Q6T=QN^TN'B:I%5_E7H
MF:LUGC6R+5YL73TC!M2V,44B)^Z$G0[&O$,HJ2<&*)UQ9R0M3G,(I(($Z)A6
MC</FZ]K=.GVQ>LCMG&HBG#CH[PD9J+@.K4RM.ESCQ5Q]J>=LR*Q9;[RQ\DMX
MQH!FMBT=IWS$_2UKCTDMD#22=+&C@KY77[35QX80ZYM<<;]SV2>[I3T1I<):
MC4N%!P8#=V9U(P\O=G_=`<>I@(S$PAY`$!\H::S\W+/OE`R&0LXX*\3&V21U
M.\'-C'_M+HK_`,[K:L=NXXO%WTES0T$KHHFU[[F.F/\`[*UE>;7.#=7/';?\
MZFX7<>R0B6"L'1:)72N4:I0ZZHY]*5CXE-TJLZ>R,BX`JK]^X,+AXH0@#V$4
MD44K&[-V7A]D8KXLQ(<YSW:I)'4UR/I2KJ4``'!K1P:*])+B:A\Q.8V?YDYO
MXWS1:V-C2V&%E1'$RM:-!))<>E[R2YQ[C0UK?KPIYU[YX';+7V%I>79K1TZD
MS8WW7EC(X>4J_1+)515JWF6;9=NY9RD<+A464BU43=M!5.4!.BHJBI_-Y;)P
MF]\<+'+L(D94Q2LH)(G'I+2000:#4T@M=0=!`(_7+SF5N3EME3D<$]I@DH)H
M7U,4K0>`<`00X5)8]I#FDFATN<UVS+1_M-?'I[!ME-D<<=SUNS`BF#UG2Y6C
MW*!.X`@`J9E*3,S29$$3J=1*51F!BE'H(B(=1KG>^;CGV3D8_(6<EM7@9&R1
MNIWVM;(/2<K=8_SNMK/MFNRN+OX[RGA-A=%*RO71SW0G_P!G[*A/S/\`M%.Q
M]NTJ<UMQ8UO)Z086-DZBI?:-JFV,MLA&+>)G0=(U&+A2'A*A(KH'$@2!G<@Y
M0`PF;@@L!%B]CM#D!88J\9D-S7#;Q\;@YL+&EL51Q!>7>%(*_>Z6@_?:A4*/
M]_\`G3Y'-8^3%;-M76,<K2UUQ(X.F#34$1M:`V)U.&O4\BITEK@'+7GU5<T-
M>;4UIL1\R<R[:B;$I5X>QR#@B+R40JUGC+`Y9(NW!54TG3]-@9,JB@&`IS]H
MP#Y<GO*69O\`%W&/C(8Z>WDC!(X#6PM!IW!6M%5O!Y)N+SMIEYFF1MO<QRN`
M-"X,>'$`T-":4Z.'<6<OQ,?&CU_SVXUAHBM:*N^NY(-B5&[!8;!:Z],Q_H]:
M3ETUF`LXQFBY[]U[I!V#=KLE[(]<A7ESR?O]D;B^.[F]AGC\7?'I:QS35Y::
MU)(H-*L?S;Y_XGF-M/\`P[9V$UO-XRR36Z1KA1K7MI0,;TZN[U+7V`1`0$IC
M%,40,4Q#&(<IBCU*8ARB!B'*(=0$!`0'RAD\D`BAZ%5IKBUP<W@X+:+X^?:+
M8VI<>ZAJ7D?H"U;KN4+55J1;;DRM-<;1>PH%)!:*9NK%$3D<X47EY&OF(A*B
M<RB3UP"BWD[X4RUISW("6ZSTN5V]?1V=H^42,C+'$Q.KJ(8YKA1H=Q92A:*#
MJJ;E[7\Z>VM-KP87=>.DOKYD)BDD[1H;,RA:"]KF.JXLHV2I.LU<::B!CU\/
MSQ%]*<!>3?(/;=0TKL&?U7M*`6K>OZ"I;(!*RT>'/;&MF:1LQ.+M5&,RC$HI
M"S15(4JJB1"'4]>)L[S??+[,[XVY88N[O(&9.V>'RR:':)'!A82UM06ZJZB.
M@&H'!1CRSYK[<Y;[OR>:LK&XDP]Y&YD,1D;KC:9&O`<_0=6D-TUH">D\5'OQ
M,N9E?Y[<D5MZUFC3>NHY;7-5HXU^PRT?-/P=5YQ.K*R'I<8B@V!NY++E`I.@
MF`4Q$1\H`&^Y<[/N-D;=^)+F9D\G;ODU-:6BCPWA0DFHHN6YM\PK/F+N]NY+
M.W?;PMMXX]#G!QJPDDU#6]->XLHW*#QTM;\@.$EVXG1?'R^UN9M>L:M06]QD
M;C6GT2R=5Y>NK*2*\<U8IO56[CW$,!2%,!@[8=?,.1KMODID<%O*'=$M]#)#
M%<OE,8C<"0\/%*EU*C5]I3%N[SC</N/E_/LZ''3QW$MI%$)#*T@&,QDFF@<#
MH[O6M;O+#*I"81,(MC'P[?'#UUPBXK4KCO8=`7N^RM5G+O+.+-!V^N1,:\);
M+;+61!)!C(LE7:)F:$B5(_:,(&.03!Y!``K[O_DQD-Y;GFS]O?0P12LC:&.C
M<XC0QK3Q#@.-*]"MCRL\XC#\O]F6VV+K'3W$\+Y7%[96M![21SQ0%AI0&G2M
M>>QRA)RQ6&;21.W2FIZ9F$VZABG4;IRDDZ?$04.4`*<Z)7`%$0``$0ZAD^6T
M1@MXX2:EC&MKW:`!58OK@7=Y+<M%&R/+J=RIJNFSV6*F$3")A$PB81,(F$3"
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MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8195/!+_:=\8OS_`&3^
MJ&^Y&/.3Z-\E[6'\?$II\WKZ7L/[>?\`59UZ(64%7U*6IE]J!\_#'\;>OY.J
MLM)YMG[W_-ORZI-YX7[A]"\^[;+4VRTBI*F$3"+*YP.XW<3M@<8>9?)GE5$;
MEL,%QHD-*HQ<#INTP-;FI%MLV:F:\]!0MA8+Q[M5N_(T5*)UT`(B10`[1A*&
M1=OC<.Z;'<F(VYMA]I'/D6W%73L>YH,+6O'K""*C4.@\:="F_EIM/961V?G=
MV[R9?2V^*=:!K+9\;'$7$DD9_P!XQP-"&GI'`'I-%<K5VA/"MYF6='1G'BS<
MJ^-_(&V-WC?43W?LAKVZZEO%L;LG+QC3)MU4TQGH%_-G;]TW6`Z91,/0@+K=
MVV6UV3SG,W:%L<UGX\9D,%$09Q;"6.>-E0#(T2'2X-K4CI[ND5<-SA]M<F=_
MW8V]M>7,8O<LH(MS=F"2WEDH2V-QB:'L<\BC7>MJ0*.<6L=$SBMP7LV\=W[:
MUWM6QDT=K_C%#7.V\H]@2K,))76M=U](NHF?C8V/*8J<Q:Y.58K-F"`")3@D
MJN!52I=TIU.Y][6^&PMK?XN/QR_R3XV6<333M7R@.:2?O6`$%Q[X'"M1P^S.
M6MWN#<5[C,U+XABL0R62_F<-78LA=I>T-!\*4N!:UH/34C5I(,@:M(>#/?KG
M&Z@'6W,+5T!8)5*LPG)ZP;1I\W(QC^06+'Q%JNVJ480("/JXO5$UGJ;111PW
M;&,/9`2B)=!<Q\W;&T=EO&,5<SL;K=9MAD:"!Q<R.;5J+Z<&Z@`31=;9R<A,
MG?MV_P"+9BTMWN[-M^^>)S@3P$DL`B#!'6A?H>7::TXT5M4-3\,N*>Z]^Z.Y
MK1>Y=TR='M,+':VNG%J]T"-J\M7%H]U)N)>9-.NWY/399A(1QP:)+'4CG!'+
M981.3J.R=E-W[HPUCFMGNM+..:)QECO(Y2]KJ@!K=-.#2'^$11XTN;P*TC,+
MR_V3N#);=W\V^OYH)6-@EL)8!&YE'.+G:P_BYKHSI!)8=;7>$%-7D+HSP?N.
MM,XV76S:PYR3K#DSIQAN>K-(':&LO2Z_!R"S=!.)L'N@P9HC+)F<`)O1C+(]
M`\A\X[`YKFQN"\R%E;7.&9)CKLV[RZ&:CG-^^;1Q\'T:'O*0MS[=Y&[6QV*R
M5Y:9^2'*V3+F,,FMJL8^M&OK&/"%.-*COJ%+KC;H2R<!>2'+RCM=AQ<M3.8\
M/J75<39+#&NR,-162)B9N*:7!DPC?1Y6Z-6<H!'#QNNF@90O4B?9\_8MW%G;
M;?./VI>FW=%-B3/,YC7"L[7%KC&2[A&2*AI!-.DJ/CM';%[RSRN]\>VZ9-!G
M/%[=KWL-+=S-;!(&LXR`$!SFN#:]#50?AI<<M><M.:>G]`[64L25#O2=]--G
MJDJC"SQ35O7-KM,;Z%)+L9))N496&1[WJB;MI=HH=D1[09_,;<&0VML^[SF+
M[/QZ'LM.L%S?#E8PU`(KX+C3CTT6FY1;5Q>]>8%CMO,]K\77';:^S<&O\""6
M1M"YK@/"8*^">%1PZ5"RR,$(FR6**:]YZ+%S\U&M>],!U?1F$FZ:(=Z<"E`Z
MG=(AVAZ!U'R]`SL;:1TMO'*_USF-)]$@%1_?0LM[R6".NACR!7IH"NESV6*O
MX(]`$?*/0!'H`"(CT_``!Y1$<+^@$F@Z2LP=AXT\+N#E,UTCS>C-Q[OY-[+I
MT)L=QQWU';8G6]4T[3+(FJO7VNSKTZ8R,XZO$FV3[PS)D0I6W0Y3D%,$G"\2
M0;BWAO2\N#LUUI9[<MYG1"ZG8Z5\\C.#C#&"UHC!X:G'PND&M6MGV?:/+[ES
MCK4\PFWM_NV[@;,;*![88[>-XJQL\I8]YF<.):P#16CJC0Y]+WWBOQ=Y"<=-
MF\F>!\AM&LS.@&D?-\@N,6Y)*'L]FKU'DW"R">RM:7:%;M!M%5BC(G%^B[3%
MRBDDJH<4A(DFXRK#<^Y<!N"VVYO=MM)#?$MM;R`.8QTC17LIHW$Z'N^]+3I)
M(`K4EN'EMD[.W5M6[W=RW==13XT!UY8W):][(G&G;02M#0^-GWX<T/:*N)`T
MA]%ZRU+P>U9QLUYOGE)9-B;COVZ++;8NE\?^/FP:+6)77=2I;U&,DKAM^<E6
M5CE(69FWBQ5(F+%JV](;'(H)E"BJ*.9D\KO3)[AN,)MF."TL;..-TEU=12/;
M*^0%PC@:TL#FM`I(_4:.J*`TU:_"8/EQA=J6NX]Y3W%[D[^65L=G9S0M=#'$
M0UTERYS97,<XFL4>ENIOA5(J&VZYP<9:!Q_G=,7+3%KL]LT5R6T]"[MU.I?6
M;!AL.N0\F]=1LI3[NE%)I1+V8@)!L``]:$(V=)JAV`$2&,;8[+W)?9Z"[L\O
M%'%FL==NMYNR),3W``B2/5X0:X'UKO":0:]-%I^9&S,=M:YL;_`RS2[>REDR
MY@[8-$T8<7-=%+I\$O8YI\)@#'`C3T*F^%O':C<BMGV9AMC9)-4Z=U3K"Z;H
MVM:6AHE:V.*=1FS=9Q6]?1,PX0;3=WL3MVD@T0`JXD)WBO<JBF"1\C>.X+W;
M^-C?B[?QK+75S';PL.K0))":/E<T$MC:`2X\.H5%:C!Y>[5QFZ<M,W.W?B>"
MLK.6ZN)!I[0Q0@$LA:X@/F>2`QO'K=I=ITF6U9X^<%.7E`W\TXDQ7(_3V[M"
M:CM>](>`W7;:5?JAN#76OS-5+BT5>UN$A7=)O+>/>)K-TB'<,E%#]CUQ0,=/
ME+C/;WVI?6+]TNQ]WAKZ[9;.=;LDBD@EEKV9`>YPDC)!!-`X=/>/?6^U^6N^
M,9DF;)&3LL_C;&6[:VY?%+'<00:3+4QQQF.8--6BKF.XC_:%OM7\>^,&H^+.
MO.5O,AIN"[AR`N%RK6@=+:<L5=H[^3J^N73>+O&S[G<+#$S9VT4VGG'H#!DU
M;E.LJ!5#'.F<W<9^3S^Y<MN6XVQM$VD/B,4;[FXG:^0!\H+HX8V,<VI+1J<Y
MQH!PH"..KPNU-G8#:%KO'?PO)W9*>6.TMK=[(B60$,FGEDD9)1K9#V;&-94N
M&JI:3IMMS,XP4+4".A]P<?K!;[CQQY44F1N.I%KTVCB;`K$Y6YP*S>]7W(\(
MDC#R=AI\\JDEZ6U332=%6`"E$2"HIL=H;EOLJ;[$YZ.*+<&,F$<_9D]D]KVZ
MXIH]7A!LC:G2XDBG'IH-+S`V9C<&,=G-KRS3[7S$#I+?M0WMF/C?V<T$FCP'
M/B?0%S0&N#A0<*F6$WX5ZVE."W)W?O(FPM(;D7K>.TO*5/0E=M<.^G]70&R-
MC0]=2G]UL(T)(&DO<(==X$7%`LB=H5L998YU!%%'EX>9HS.]<;@\!&7X"X=<
M!]R]C@V9T,+GZ;<FE6L=IUOH0:@-%/"/:W/)D;=Y<Y?<>YY6LW5:MM'1VC)&
ME]NR>X8P/NF@.TND;K[..K2`"YQ)\!L6N*&@^/=BU5NGDQRINUNC]2Z<DJG4
M875>J)"M,]N[?V'=!7/&Q$0ZLA7;.N5.$:HE7DI$[54>[4$$A`Z1BFZ;=.=S
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MHZGQ&P]V:<U_81>!`7O:VNJ9.C'+E:R`0UIN$-!2@L'1TG!&ST&+]3NE!3.!
M%.@B4W3H/;9N[EQ^&N[^WIV\%K+(VHJ-3&.<*CA45''B%&>V<?;Y7<=AB[K5
MXK<7D,3])H=+Y&M=0D$`T)IP/H++[R-UYX-7'#?6S>/UPUASW?S>L;2>ISEH
MJFR-3.XU9<C1D\4D89K-M&;APDFD]#LD<)$$QBB`AD3;>O\`FYN'"6^=M+G"
M-AN(M;6/BG!Z2*.+20.CJ*GO=F+Y#;3W'=;9R%IN)UQ:RF-SXY;4CT6AS!]B
MM%"_FUP]I>A(736\]`;'D=Q<4^1\-+R>JKO.QJ$1<J_8*TX(TMNM]A1K1-!H
MWM-=<J=GO4TFZ;@4UBE2**!C'['9F[;S.37>%SMNVTW/CWM$T;271N:\59+$
M3QT.'422.%3X7"/.8NP<?MFWL=Q[8NG7VS<I&YUO*X!LK'QD-EAF`\$2,<:5
M%`[CI'@E1>B./N^[!1'6TH'2&WYO6;)-1=WL*(UK<I*DMT$>WWSE6T,X9:%*
MV0[LW>*=]W9.@]H0Z9TLN?P4%Z,;/>VC,B301.EC$A)Z`&%VJIZA3BN,@VGN
M>YQQR]OCKU^*:*F9L$IB`%:DR!N@4H:U=P4AN*W'C7NY="<[ME6]2?"Q<<M'
MU78>N@AY5%C&J3TU<C0+L+`U.R='E8_T$`["9%$!*?J/:'\'/;HW!?XC.X7'
M6G9^+Y"\?%+J!)TMCU#2:BAKUT*[#8^T<5G]L[ARN0[47>,LF2PZ7`#4Z5K#
MK!:210G@"WT5&K7&D=S[B&4+J/46SMHC!I=]-#KRAVFYEB$Q3%4#29Z[%R)&
M(G2*)B@H)3&*'4`'.ER&:P^)T_&MW;6VOUO:RLCU>AK<*_87$XG;>X<\'NPE
MC=W@C'A=C#)+I]MV;74^RJ)"N6(9_P""85^=&U^Z8PGP7"'D1LGNT"WHXP_N
M$#;W5]U07]9Z/W7?=OR=GKY,S/&;;Q?QOM&>*Z=6O4-&GIU:JTI3C6M%@>(7
MOCGQ?V4GCVO3V>DZ]5::=-*UKPI2M>"N5L/CMR!U'#L;#M;1FX=9P$F=%./G
M+]K6Y5&'>*N`$R"*$G/0S!D9=8"B)$^WVS=/(`YKK#<&!RLQM\9>VEQ.WI;%
M-'(X4Z20UQ-.^MMD]I;IPD#;K,8Z^M+9U*.F@EB:2>@`O8T$]X*1.S>#MWUQ
MPFT=RT<1>Q'CO;5LV4VL%>6U_-,(#7%&IRL6PJMHG)E1JHH#>^NG_I#)XOZ*
MR6;*)%0%4PBH//8[>MGD-XWNUVNMPRUBB+7=JTNED>'%[&MKTQAM'-&IP-:T
MZ%V.4Y:7V,V!C=YO;=.DOII=;.Q<&0Q,,;8WN?Q_WI?5CCI:12FKB5<SFCP&
MLVN.1,WK3BSJ7=^T:76M1:=O5A>0U7L>R7<'*WNAQUGF/=:4K%=]&8-3.G)S
M-T52%.5'S"8`ZYKMG[ZM\A@69#<UU9VUW)=3QL#GMB#FQRN8W2'OJ30"I!Z5
ML^8/+*[QFY7XS9ME?WEC%9VTLA9&^<L=+`R1VHQ1T:*N-*@<.LT6,UPW<,W#
MAF\;KM';1=9J[:.D5&[IJY;J&1<-G+=8I%F[A!4@D.0Y0,0P"`@`ADD-<U[0
M]A!814$<00>@@]PJ'9(Y(I'12@MD:2"#P((Z01W5D'X7\9](W_6?(CE)RCL.
MP&''WC,A06$U4=2(Q8['V/>-G3#J&J5:C).;*>(K<(DX:]I^]6`#`54@)F((
M&,'`[QW)F;#(V&VMM1P.SN1,I:^<N[**.%H<][@WPGNH?!:.X:J5>7FSMO9/
M$Y/>.\)+ENV\4(0Z*W#>VFEG>61L:Y]6L;5IUN<.@C3QZ)!5?4'AJ\R(#9-/
MXY1VZN*&_P"EZ^LFPZ`SW9LJKW;4VUD*@S]-E*>_GG1F<C5K7*("46ARJD;%
M]>?HJ"8ICH+G+<Q=HW%O=[@=:9/!S3LBE-O$^.>'6:"0-%0]C3Z[AJZ!PK5=
M7;X/E)OVTN[+:S;W#[DM[9\T(N9HY+>X[,:G1%Y#',D<!X)KH'$FO`+$:^JM
MIBX&`M$K6+%%5JU@^&L6&2A)-C!6,8M8K>4+`S#EJE'3)HQR8$W(-E5>X4'L
MG[(^3)7CNK66=]M%)&ZYBIK8'`N9J%6ZF@U;4<14"HZ%!$^/OK:WCNYX9&V<
MQ<(Y"TADF@T=H<11VD\#2M#P*_85*UC!1]H"KV0:S+S)ZY$V,(*5&!E;"D0J
MBL!&3`-/<Z0FTTS`8S1%0[@`$!$F?SQNT$[K;M8_&6,UN9J&IK?9%M:AO?(I
MWU_1C<@;9EX()?%))-#7Z':'/I72'4H74XTK6G%7`O?'G?VK:_'6S9FCMOZ[
MJLL*)8RRWC6MRJD"^.X_XNFVEYR&8L#JN/\`@R=YVC_@`<P;+/X+)3NM<=>V
MEQ<MZ61RQO<*=-6M<2*=?!;/);3W1A[9M[EL=?6UF_UKY8)8V&O11SV@&O>)
M[JD9=^#UUI?"'47+E6*V,\=[,V'>8:7KHZ_F6D!1==5:-9*05YF)L[5106%S
M?/`.S>J@VCSMQ("1E3&[6<[9[UL[O>=UM4.MVLMX(RU_:M+I)7EVJ-K:],8%
M'-%75Z:+L,CRUO[#EW9;V+;ETMU/(',[%P9%"P1Z)'.XU$A?5KO!:1T%W&D;
MJ3H#?&RZ[*6_7&D]MW^IPG?>[%GI6N+A::_&"W_XP5Y,0D.^CT#M^O\`"%%3
MM)AY3`&='>Y[!XZX;:9"\M8+I_K622QL<:]%&N<":^@N-QVU=S9>U=?8K'WM
MS9,]=)%!+(QO=U.8TM;3OD<./0K?1%;L=@6E&\#7IV<<0D5)3LTWAX>1E%X>
M$AB@>8F95%BV74CHF(*("Z<K`1%N`_PABYGRW-M`UKIY&,:]P:TN<`'.=ZUK
M:GBYW4!Q/4M7!8WMR^2.WBDD?$QSWAK22UC>+GNH.#6CB7'@.LJO+3HC>-&A
M:O8[KIC:]0K]W6:MJ;-V?7=O@HJV.GP=6+6N/Y.':MIET^+Y4$FYE%%@\I`,
M&8-MG,+>S26]G>6LL\()D:R5CG,`Z2\-<2T#K)I3K6TN]K;EQ\$-S?8^\AM[
M@@1/?#(QLA/0&.<T!]>D:2:CCT+A[%TSN#4"L2AMK5.R-7K3[47L$EL*CV6F
MGF6A2IG.XBPL,9'>GIIE6()Q2[78`Y>UTZAG[Q^8Q.6#SB[JWN0PT=V4C)-)
M[AT$T^RO'*[>SV"T#-V5U:&059VT4D6H<.+=;6U'$<1PXKNX7CGR$LE&6V?7
MM$;EGM;-T57*U_AM8W63IA&R`'%=T-E90B\09J@"9NVJ"HID[(]1#H.>$VX<
M!;WHQMQ?6C,@33LG31B2IZ!H+M53U"BRK?:&ZKK'G+6V-OI,6!4S-@E=$`.D
MF0-+`!0UJ[AUJS0"`@`@/4!\H"'E`0'S"`YN%SO1P/2F$60GEUQ:H6FM.^'_
M`''6S>W25OY0Z!+L.[Q[Y_[NE=W-Q+0T<S8U&+9QK=TS;NCR)B)M0%RHH<2`
M41'S\!M/<]]E\OG;3(F)MIC;WLHR!II&&DDO))!(IQ/`=*EK?NR<9@,%MN]P
MXG??Y;'B65I(=60NT@1M:T$`]`!+CWU%N.XY\A)B"M%HB=#[FDZU27TA%W*?
M8:ON[N'JLG$J'2EHZPR*$&=K#OXE5,Q72*YDU&QBB"@%$!SJ)-PX"*>.VEOK
M1MQ,T.C:9HPYX=Q:6`NJX.^](J#U+AHMH[IGMYKN#&WS[6W<YLKVP2ED;F&C
MFR.#=+"TCP@X@CK5MJS6+-=9R-J],KD_;[-,K>CQ%=JT-(V&=E5^R)Q1CHB(
M;/)!ZH"91,()IF$"@(CY`S87-U;6<#KF\DCBMF"KGO<&M`[I<X@#[)6ILK"^
MR-RVSQ\,L]V\T:R-KGO<>F@:T$D\.@"JJ/8FJ-I:@FDJYMG6U]UA8%V_IC>$
MV#4+!3I1RTZ@7TILRL$?'N'+8#&`!43*8@"/01ZYCX_*XS+0FXQ=Q!<P`T+H
MI&R-![A+20#WEE9;!9K`S"VS=I<VEP14-FC?$XCNAKVM-._14!F>M4LF?AM\
M;>/.^QY8VSDFSV5)T;CCQRFMX$B]66*+KEEE%*Y)$&18(N)A@]8.#N8PAR(D
M4,B0%A`3'`,C?F'N+/X0XNTV\;=M[D,@VWU3-<Y@U@T-&D$4-*TKPZE,?*7:
M>UMQQYK([K;=/Q^+Q<EUIMW,:]W9EI(&MKFDEI-.CC3BJL"Z>"AY/_(SQ".G
M^5'3WF_]@9B^)<X_+<%[U<>JL_XR\WVO_8;D]^M/YBQPH5!_L;8DM6M)4B^6
MI&6GIQ6BTZ-B'MQO8UD)%PI"MI!E6F3M61E642=$KQ9!+N16`Q@Z%$,D-UVS
M'8]EQFIH(G-8WM)"X1QZZ#407D4:75T@FM%$@Q\N8RLEKMNVN9HWR.,40:9)
M=%26@B,'4X-I72.FM`N3LK3&X-,/F<9N#5.R-5R$BFJM',]BTBRTM>120`@K
MJ1Y+%&Q_II$`5+VQ2[8$[0=>G4,_..S&)R['28FZM[EC>DQ2,D`KT5T$TZ.M
M?K+;=S^!D;%F[*[LY'^M$T4D1=2E:![6D](XA<LFB-X*PEFLJ>F=KFKE+C8Z
M:N$]_-W;PAJK#2[$)2*EK%)##@SAHR2BQ!T@X<'325;""I3"F/:S\'.8431V
MYO+7QB9Q;&WM6:GN:=+FL&JKB'<"!4@\#Q7[&V-QNMY;MMA>&U@8U\KQ#(6Q
MM<W4USW::,:YOA-+B`1Q%5V=:XW\B+D[G6%1T)NBT/JNP8RED90&K;Q+.X".
ME&*4I%O9ENQ@UUHUM)QBQ'+8ZP$!PW.51/M$$#9YW&XL!9M8^[OK.)DKBUA=
M-&T.+3I<&DN%2UPH0*T/`\5[6FT-U7[Y([+&W\TD+6ND#()7EC7-#FEX:TEH
M<TAS2:`CB."J3C_5M72TON!AN:B[OM`U_2VQI*G1^GH@'4K5-IPY6)*Y8=G-
M7:(JQNL(!QWY9Q00(HAVB=>@]0S&SMUDHHK1^(GLX^TO(A(9W4#X75ULA(Z9
MG"G9CH/%9FU[#$S7&0ASUM?S.BQUPZ-MLUI='<,#>S?.'=$##7M2/"%116VJ
M6H-MWQ>LM*1JW8MR=W-650J*%4I%FL![4O`&0)/IUP(J,=>[0P2CI,'OH_>>
MB"H0%>QV@Z[&ZR^*L6R.O;FWA;"&]H7R,;HU5TZ]1&G50Z:TK0T6IL]OYS)/
MB9CK.ZG-P7]D(XGO,FBFO0&M)?HJ-6FNFHK1=)<Z/==<6%]4MAT^TT.U1G8&
M1K5SK\M6)YB54!,D=U$3;1D_035*`B0QDP*<`Z@(Y[6=]99&W%U8313VKNA\
M;FO:?0<TD'TUBY#%Y+$W1L<I;S6UXWICE8YCQZ+7`.'V0JZ4X\<@$JE`WU71
M>XTZ-:GT=%UBXFUC=0K%BD9A9)M$,82<]Q/<Z4=2[E<B;0B"AS.5#E*EVC"`
M9A#<&!-T^Q%[:>.Q-)?'VT>M@:*N+FZJM#0"7$@4'2MD=I;H;91Y$XZ^&/F<
MUL<O82]F]SR`P,?ITN+B0&AI))X!4[5=3;5O5R<ZZI.LM@V_8#)9XV?4:L4R
MQSMO8.(YQZ)(HOZY&1KF78J1[K^"7!9$G<J>M/V1\F9%UE<796@R%Y<P16+@
M")'R,:P@BHH\D--1Q%#Q'0L6RP.;R5^[%X^TN9\DPD.BCB>^0%IHX%C6EPTG
M@[APZUP;WKK8.K;`M4]FT2Y:ZM+=$CA:N7JL352G4VZIC%2<C%3S)@]%LJ8A
M@*H!!(80'H(]!S]V.1L,G`+K&SPW%L337&]KVU[FII(KWJKRR>(RN%N?$\Q;
M3VMV!71+&Z-]#T'2\!U#0TX<56?'K15[Y,[KUQH?6C9NXN>R[&A`Q:KTRI(V
M+;E17?S,_+J()JK)0]=A&3A\Z,0AE.X;F`A3'$I1Q,_F[+;F&N,WD21:6\9<
M:=)/0UK?]ISB&MKPJ14T6PVIMK([PW#:[;Q0!O;J4,%>AHXESW=)TL:'/=0$
MAK20#T+(E=VGA#Z`N4KI:8HG*CE%+5"3<U78._*KLRK:RKZMDBGBK"PNM44(
MD<]0EX.->(G3;&E'8E<F3$Q5E4C$5-'UF_FMGK1N8AGQN-BE:'Q6SXGS.T$5
M:)Y-0TN(XG0WA6A`-0)<OV<C=KWK]O7%OE<M/"\QS7;)HX&ZVFCW6\1C?J8#
M4-[5]'4J'%I#C&#F_P`9M<<=[AKV;TCMEKN'0V\=>1NT]4V-ZM%-[W"0T@8J
M;ZG[+@8Y0HP]KKSA0A#J"@V3=%/ZU--5)=)/IME[DR&?M)X<U:FTS=E.89FC
M48G.'1)"X^N8X='$D=T@M)XCF-L[$[7OK6XVY>"^V[D;9L]NXEHF:UW`QSL:
M:MD8>#O!:#7@`0YK;#3O'O?M7H[79UET=N"NZW?$259W^<UI<XFF.$5^QW"R
M=E?PJ$.*"_>%[L_?`13M!V1'KF\AS^"N;PXZWO;23(-Z8FS1ND'=JP.+N'7P
MX+F;C:>Z+.P&5NL=?1XMPJ)G02MB(-*4D+0PUJ*4=QZE1L!0+[:T&SJJT>XV
M=J]L#*I,W-=J\Y.-W=KDFZKR.K#9>,8.DE["_9H'619%$7*J1#'*02E$0RY[
M^QM7%EU-%&YL9>0][6D,!H7FI%&@D`NZ`30E:^TQ.4OV-DLK>>6-THB!8QS@
M9'`EL8(!J\@$AH\(@&@517'2.ZM?6J)HEYT_M&GWJPB@6NTNST&U05JL2KM0
MB#1&!@)**;RDRJZ<*%33*V25,90P%`.T(!F/:YO#7UJ^^LKNVFLHZZY&2L<Q
MM.)U.:XM;0<34CAQ6;=[8W#CK^+&9&QN[>_F<`R.2&1DCBX@#2QS0YU2:"@X
MG@%DKYW\5M!</=+ZJH;;1W(.3WK<M6ZCV%9^2=KFY*#U!%6V[-5IZSZNC:8:
MNI1;B4B8J/<(E15>)R#4>AU04$A^L<[)W/G=V9FZO77MBW"PW,\3+1C0Z=T<
M9TLF,FNH#B0:AI:>@4J%+_,?9>V=C;:LL<S'9)^XKFTMY7WLCBR!LLK>T?;M
MB[*A+6@M`+P\4-:T*QQS''W?=>HC;:,_I#;\'K-XFDJUV%,:UN<;2ET5^QW"
MZ=G>PJ,,+=?O"]VIWW=G[0=D1ZY(<6?P5Q>G&P7MH_(@\8FS1F0$=(T!VJHZ
M^'!1'/M/<]MCAE[G'7L>*(!$SH)!$0:4(D+=!K44H[BJ<J.K=F[`%D%#US?+
MM[I3Z-5CS5*H6&QIO;0Y8K2;>N-58B.>)+3JT8V4<E:%$5Q;IF5[/8*8P9%W
MD\;8:O'KB"'2S6=;VLHP$-UG411M2!JZ*D"M5AV&$S.4#3C;6XN`^41M[.-[
MZR$%P8-(-7EH+@T<:`FE`N=%Z:W!-WYWJF&U1LJ6VC'K+-I#7$91;0^O<>NW
M!,7";^I-HM6>9&0*L03]Z@0"@<HCY#!U_$N8Q$-B,G-=6[<:X5$ID8(S7HH\
MG2:T-*%>L.W,_<9)V&M[*[?EV$ZH&Q2&84I6L8;K!%14::BO%=-=]>W[65C<
M4_9%'N&OK8U(DHYK%VK4S59]%)8QBH*GB)QDQ?@BN8H@0_=]DX@/01SVLLA8
M9*W%WCIXI[4]#XWM>WAT^$TD<.OBL;)8C*X:Z-EEK:>VO`*F.5CHW@'HJUX#
MA6G"HXJNH+C7R,LXVD*WH#=D^:C&(2Z%AM57J1/4E5&B#]-&R)M()4\*X48.
M4URIN`34%!0J@!V#`(X,VX]O6W9>,7UG&)O]WJFC&OB1X%7>$*@BHKQ%.E;.
MWV=NR[,PM<9?R&W-)=-O*[LS0&DFEAT<"#X5.!KT*TT;$2\S*LX*'B9.6G9%
MZ2-CX2+CWDA,/Y%53N4X]E%M$5GSI\HJ'9!%-,R@F\G3KFUDFAAB,\SVL@:*
MEQ(#0.Z2>`'?6DAM+JYN&VEO&]]TYVD,:"7$G@``.))/`!5YL?2NY-.+1C?;
MFI=EZM7FD1<0R>Q*+9Z8:60`A5#*1OPBC(X'Q2$.`F[KM"4!#KTS!Q^9Q&7#
MCBKJVN0PT=V4C)-/HZ'&GV5L<MMS<&!T?'=C=V?:"K>WADBU#AQ`D:VHXCB.
M"Y],T!OG8]9E+KKS26W+Y3H7OO=>UTW6]QL]<C1;?\9!W-0L,]CD3-O^%`5.
MJ?\`[W3/Q>9[!X^Y;9W]Y:P7;_6LDEC8\UZ*-<X$UZN'%>V/VKN;+6CLAB\?
M>W%BSUTD4$DC&TZ=3VM+6TZZD4''H5I!`2B8I@$IBF,0Q3`)3%.41*8ABCT$
MIBF`0$!\H#FU!!%1T+0N:6G2X4(7\POXF$3")A$PBRJ>"7^T[XQ?G^R?U0WW
M(QYR?1ODO:P_CXE-/F]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC^-O7\G566D\V
MS][_`)M^75)O/"_</H7GW;9:FV6D5)4PB819D.&O[)GQ<?\`I'B)^LM]D1;O
M^E+:WM;_`/$A6`V#]">]/;8O]:>H4\`:C:;US?XFUREMW;FP'W_JZ:3%B14Z
MS&*JMMB[/8I=44`$Z+*'K\0Y<KJ?O2))F$<[+?=W:V.S,I/>$"#Q&9O'K+XW
M,:WCUN<X-`[I4=\K\??9+F%AK>P:YTXR5N[A7@UDK7O=PZF,:YY[S2>@+-,^
ML<%MY7[1;3]5@E+VRSOH#8%?"%-Z0ZL-&U%LV=3VB[BBMNTH^9=I,ZJG=]H%
M0>%\_;#K#C+>?%#8-WDZMM8VNB=JX!LD\#>Q!KT'J'<T]Y6(EN[;./YG66&H
MZ]E=',S3Q+XK6[D=<.;3B6T<'$CI#@M:F.8O)=]'Q<4T<24E+/6<;%L&21W+
MN1D)%PDT8,F:"0&4<.7KI8B:1"@)CG,`!Y1RQDDC(HW2RD-B:TDDF@``J23U
M`#B2J@PV\]Q.VV@8YUPYVD-`)<2>%`!Q)KU*[_(3CUL[BSM:Q:1W#$Q,%L&J
MMX=U-1,-/P]D9LTK!$M)V+`TC".730KAQ&/TE3(F$JR8*!VRE$0ZZC`9[&[F
MQ<>8Q#G/L)2X-<YKF$Z7%KN#@#0.!%>@TX%;[=>U\QL[.2X'/-:S)PAA<T/9
M)36QKVU+'.%=+@:5J*\0%D<\4+_Z!^$W_J'UO_E\9D?<M?\`SVZ/[[?]PJ6>
M<7^5-F?_`&]#]TJ]W#;:M*TWX//(VZ7[1E`Y#U]+FY1(P^NMDNI9G6E7DAKV
MFD:S1EH80>^GQ)B"9$`'LB)QZYI-X8N\R_-G'V=C>SV$YP\A[6(-+Z"5]6^%
MPH>OT%TO+O-6&`Y&9/(Y*PM\E;#/,;V,Q<&5-NVCO`(-12G3T$J^_A3<QM";
M5YYZ/HE+\/3C=H^RS1-C#';0H<O<G5LK/N=J^Y23KW*0ECF8']UV;11BMV_,
MW<G$/7`&:7F=M'.8O9%[?7F>R%Y;L[*L,C8PQ]9HP-6D`^"2'"G6`NBY-\P-
MM9WF-CL9C]M8VPNY#-IGC=*9(]-M,XEH<YPJX`L-1ZUQXK6\N_\`VVNG^%]G
M_NX_RPUE_P!E#_RF_P`D*I>5_P#)S_\`-=]U3L@.)7$*4U!&WZ5\275=?V"\
MU\G:WFFW.E]FO)N,MAX$90VNUK(@Z)#K2B4H'N>9X0GHPJ_PA0$G3KQ$^Z]U
MQ99UA%MZYDL!<:!<"XA#2S5I[70?"II\+3TTX=*DJUV)L>?`,RDVZ;6+)NM>
MU-L;6X+FR:-78F0>`7:O`U#P:\>A0,ITE'1%LJ,S-M^_AXJSUR5F6@AWG?1<
M?,,GLDV$H=>WWK-$Y1#\/7.XO(Y);26*$TE=&X-/<):0#Z:C3&RPV^2AEG&N
MW9*TN'L@#Q%.^%E1\;:!L"OB-;-M?]L35<W'6-07S4\TU(JY86ND2VN*K`1+
MBNK%*)'S4DS#N6I02[754G_ZP=8RY-SV[>7]M:\&7-I)/%.TT!9(V9[G!W<.
MES3QZBIE\X6SO'\TKN_%9;*_BMIK9PXB2)UO$QI93I&ICFBG26E72\,#76P]
M$2OB0VG=M*MVM*KK/@;MZF[+A;[7I:L./A-L,T2G1*H^CYEHT6]T[$>&=^A$
M[(BKY.QU`X".LYDY''YN+;UMAIHKBZN,W!)"Z-S7C1%J[5X<TD49J;J[G7T+
M<\G\/EMMR[JN]P036ME:[<NH9V3,=&>TGT"&,M>`0Z0M=HJ/"IPZ5C&UTQFN
M.DWK#;VX^-,5LVA7ZM3$UKZM;A9VN&U[LA@W.A&J6:.>5V0A9"?90#Y8O0I'
M'HQE3E!4IR#V1D:_?#N&"YQ.)R+K>^@>ULKX#&Z6(].@AX<&EP[HK3HH>*BC
M&-N=I7MKG\]BA=8NX8]\#+@2MAE%2W4TL=&7AI[CM-0-0(X'(9XII(S=FJN$
MW.VM#-5"K\@-<6?6#'0\BZCEZOI-;0LPG63P&HTXV(@D&VL)%=PNNV0,W%5)
M4>\.H(K]VEP?+(RX;*9C95SHEN;&X9,;D`Z[CQENO5/5SB9@``XUH1P`\&ID
MOG,V#<&$P',6S[2"SR-K)`VT<6]G:^)O$6BV#6L`@))<QM*M))))?1N*;5VJ
M[_NW8-3U7JRIR5WV!=)9*(K-;B42*.WKTY#JJ*G56,FV8,&#5)1=T[7.FW:M
MDSJJG(F0Q@D_)Y.PPUA+D\G*V&QA;J>]W0!]TDF@`%220`"2H4P>%RNX<I#A
M<+$^?(W#M#&-Z7$\3W```"7$D-:T%SB`"1E.V7;M1^')I7:G&#35RA=P\Q]Y
MUI?7/*/=U4<&<Z\TOKURJ0]CT!JB2Z$-9+'-+I=Q8I7LE23`G=@4JZ9$VL98
MZTRO,',VVY,O"^TVE92"6SMWBDMQ*/67,P^\:T<8F=/&O%IJZ:LQ>X'E1MR\
MVC@IX[[?61A,%_=1FL-M"2.TLX'??N>1IGDX#AH`U`EE(<Y$S/\`@CX2<_&A
MVZX32V^ZKWJ7KFR-LK^VVI;(T4$O4J3T5%2',4>AA+Y>G3,K9)[/>VZ;>3A<
M>-VSZ=98Z#P#Z'`K"YEGM^7&S+J'C:FSO&5'0)&71$@/<-7-7WY-'4A_"H\,
M&,D#F0G)'8',"X0*9E!(]1JI]A1+)%^B4!!5%J[DP*9(X=`.).T4?)C;8$W,
M_<DL?&!L%@QW<+^R<:>B&]*;P<;;DOM&&6K;E]QDY&#H(9V\;:]X.<"1W5V?
M%:1D9CPQ?%VEY>0?2TM)R?#%Y)2DH\<2$E(O%MS2AUG;]^\46=O'2QAZF44.
M8YA\XYY;GCCAYC[5BA:UD36Y`!H```%N.``X`=X+TV=<3W7*'>UQ<O=).YV*
M)<XDDDWCR22>))/%08XN<5=J\NMF%UWJYE%-21<4YLU]O]K?$A-?ZLHD</;F
M;O?;(N46\/!1R0"(%]<NY4#NTB&-U$O:[FW/B]J8[XPR1<7.<&11,&J6:0^M
MCC8.+G'TATD@*.=E;*S6^<K\5XD-;"QIDFFD=HA@B;ZZ65YX-:T=?$GH`)H%
M*KECO_2&O](Q7`KAY).K;J&$NC?8.]^0$FR]S9;DGMV):#',7L%'&$ZL+J:H
M%`0B&QC&]*.1-?UW8])=\QM;`YF_S+M\;M:(LJ^'LK:V!JVT@<:D./WT[_OW
M=0JWKTM[;?.Z-OXG;S.6NQ7.FPL<_:W=XX:77MPT:06-Z66\=3V;3Q<?#/$:
MWQ!XJ?YT?&G_`%@M+_K)K6=9NG_+.1_H,_XIZX#8_P#G/$_WE;?CF*1OBP"`
M>(]S!ZB`=-NO/./_`/`('.?Y7?1]BOZ*/Y3EU_.\$\U,S3RMW_[%/[7NNH"?
M\/#PL=&[D(,>PY&>),ZLL,QDE#M':^E'DD%(M#YL!Q(NVB)Z0FT@36+V2*$?
M)JD$0,4P\%?Y">#?VYLUB/"?8;>T.+>(%P!VK`>HEK6FHZM)!Z"I2QF*M[CE
MAL_;V>\!F2W3K:UU6N-K5MO*1T$`O>"#T&H<*BA4F^3.\]?TGF[;YEIXNVS]
M".]*[%3I%8XU5/BMNAUJO7E=HKMI#--8!6:[9V-"N<,\8L`2<N@CCI295N\3
M`$Q1`G.[<PE]>[-BB?M6VOFWEOVC[M][;B:5T@U&;6]AEC=4U`UU92AXUKUF
M[=R8W&\P)IF;UN\:;"Y,4=A'CKLV\+(26"'0R5L,C`&T<[1ID]=2A"C\X>Z;
ME)#QY9SC_'2<1JBQZ$UQ9ZY#2U-F]?.X=[8K=$S-JC"TRQQL/+U]DUMSQ\#9
MNHU1(5N)!2*"0DS=AF7CCV3#G7-?E([V5CW-D;*'!C'M8>T:7-<2P-J:GC6O
M&JT+9,#/-S#GVTUT>&DLH7L:Z-T):7RPOD'9O#7,`D<\-;I`#0*"E%9'FWN7
M:_%W0OASZ.XY;)NFH=<3G$.A<C+%(ZMLDI2'NP=Q[0EI=W;;)9YNM.HZ2GW4
M$O%(H-DG2RI&A3=D"@4$P)O-FX?%[ESFX,SN"WAN\@S*RVC!,QL@B@A:T,:Q
MKP0T.U$N+0-1X]VO)\P=Q9O9VVMK8#:MS/8XN3"07SW6[WQ&:YN'2&5TCF%K
MGZ=#6M#B=`%!3A2O-!;/YX<@N3DGR0)0=':)V&PX2`:X<I]ST^T4ROPFI2L0
MKP<M8^1</5O=K;4XT1.T92T8T<,7#=!1(&Q4$U3!@YW&[(P.W&[?,][>V#LS
M^#L[>1DCG3UU^(D`#3`TD.=&]P<"0=6HA;';&8YD[HW<_=(M\?CLFW;X,M_=
M121-;;T[/XR:XDZKEP!8R6-CF.`+1'I#B+_:2?U&=XR^)-K]SXBM_P">+@W#
M38-^F:;8:+MI/6M-GZW(1SN%N\-=]PS+M\\M:4P)"I(L&+9)8I17,H8S=+IH
M<O'=0[CV]?#`081OQO%$V1DD':R,>'!T;HX&@!A;6I<XD=``U%=9@IK.;:.Z
ML>=SW.XGC!W$SHGPW'8121.C<R5LMRZID:XC2&1M#JEQ<2P4AGR5W%MQYX._
M`J,>;2V*ZC;?L?D]3[9'N;K8UF5HJ5*L<2WIU7L+521,A,UVI(,T21C)P51L
MQ(D0$2$`H=.NV]B<4SFQG)&VUN)(K>T>PB-E6/D8\R/::5:YY)UN%"ZIJ2N$
MW1G<V[D?MF)UY=&*:ZO(Y`99*/CBEB$3'C51S(P`&-=5K/O0%>?Q9^:_*75?
M*[7%$U1NW8&KZEK+27'^QPL!0K))5B*EK--4B*FI&>M[&)7:M[>[<)&18]W)
M`Z0*P;$1*0"F.!M3RMV=MG*;9N+W*6<%S=7%Y<M<Z5@>YK&RN:&L+JE@'%W@
M4.HDUK2FWYU\PMXX/=]GCL)?W-G9VMA:/:R%[HVN>Z"-Y?(UI`D/$-\/4-#0
MVE*@Q.\:Z(BXGQ(M[*Q4<SC`L$/J&V2B+%`C9NXL%EU!292=DNY3`"@XE))=
M1=8WG464,<PB8PB/5<G)99>7MD)7%W9OG8*\2&LGD:T>@&@`=P`!<-YPD$,/
M-7(NA:UG:,MI'`"@+WVL+WNIW7.<7'NDDGB50O#G:?*_BGJ3:W*#6--H6P>,
MLQ:ZUH[?E&V>PA+IKNX2SYJ,]68NWT!22;6%%%!*2,1I,)%2036>"W,HIWID
M1S=W8S:^Y\K:[;R4T]ON-D3[BVDA+HY8V@Z7F.6A94T\)AJ2&ZJ"@*P>7^7W
MMLW!7N[L/;6]UM*29EK=PSM9+#(2#(P20Z@^@!.F0`-#G%NKPBTS+T:AX?/B
M>WIIQS;\1UN&G)>]0ML>:TV=HZX25AU$_M=;KDE:?<^Y:UF&S5I!P"[*(7$Q
MF:!U`Z`0KE$QBFSC\U_CSEO9'/NR@R^W('L$T-Q&ULX8]X96.5I)<X%P]<:=
M>DJ0=N/Y8\W\@-L189V"W;<1R>+W%K*]]N7LC=+IE@<-,<9#'5T<>H.;6JLK
MI1!]R4\-#DWQB<IFFMK<)[ZTY2Z>9-.\D'[[7$R^4I.]*O""F)C&B8EX\"9$
MA"B"SEVF/GZ9N,RYFW>8N.W(SP,9F(#9SD\`)FCM+9[J_?.`,=>IK2M!MYCM
MW<ILKL^0Z\M@;AM_;#I)@>1%=L;2IT,U-G(`\)Y4K;ANRN\'.6/AT<9W>OIO
M;%4X'Z_^%^[*;2XA*Q6!YR(WO5G]JV/<(:*;@HWFIW4Z=ACWD;Z08O<*-SIB
MHB(=HO,6N&N-Y[7W!N-L[+6YS<^BWDD.EHM;9X9$QSNEK9]+VOITAP-'=![2
M\W#:\O=Z;7V@^V?>6FWK;M+J*(:G&\NXS+.]H]:\V^N-T6HU:Z,MJWB14@,+
MMN:A\GAX5>)V/,=AL[3E]D]G<4>7<+=$-EFI:!BS,U,:_C+D]7J;[8E2;$`[
M&0BV<>BV-T$ABB"/8QM=EB+[&C>&W!B9+>[B$-[8NC,.L^"ULIC`>(GDT<U[
MG$]?77-[+(YW%YAVPMVNSD5U83&?'Y%LHGT-\)[XA*71OGCI5CXA&&GBTBC:
M1@VIM?:<SX0G!FMO]O;%;P%XY%[MUG;"JW:QBQD]<PAX9C`5B;;'D!0DJG4V
MA""QCURG9LRI%!-,H%#ITF,QF,BYK9FXCM;<SPV%O*S\&RHE=K+GM-*A[SZY
MPHYU>)*Y+,Y?,2<D<!:37MRR"7(74,GX5^DQ1]D&1N&JCHX_O&&K6CH`60CG
MQ8=1Z<Y%1.G*OXINT>$M:XW4S7-6UMQ_UAQZW'(U>GL4ZC$3J5CDYZCV>$J^
MR9.X*R0O73QTW<`H186RO;$BPGX38]OE<MM]^7N=LVV8N<A+*^6ZFNK</>=;
MFZ0V1CGQ",#2&@BE-0I44DCF1>X7`[ICP5GN^[P%GBHH(X;."RNW,8WLHWZG
M20R,CG=*7:W/+23JT.)H:]/I[:VII'Q.>1.]]"+FGQD_#/VCL6\/I_4<]JN#
MM^XX.N0![39TM;7*+9J%KM[7@6<JJ3NUV;I5XM_"+&%0X^V6Q>59RYL,)G!V
M8;N.&*,-G;,Z.!SW:&=M&3X<8<Y@-0X!HX#@%XX3,X63FQE-Q;;/:N=M.XGE
M<^W=`R6Y;&WM'B"1HHR4L;*10M<9'<7<2HM\&>:O*2Q<3_$\O=XW3>-D6O7V
MJM9;-UW,;(F'%Y7UWLB<NDM6E+Q0T[*,DWJ$_'-'I5F9V!$$VKEJW42*4R)>
MG2;TV?MJWW/MNRLK.&WMKBYEBE;$T1B6)L8?V<NBG:-)%'!U=0+@:U*Y+EWO
M[=UYM#=V0R-]<75U:P030.G>93!,Z8Q]K#VA=V;VAU6N932YK2*:12TBFV-H
M;Y\'?=DCNF\6_<<[KCG!J,E$E]BS\O<K'")6NF.RSD1'3\RY?3I(V7.\6[38
MJPD`[@XD*`FS:_%>-P?-FSBP\,5I!<8:;M&Q-;&QVB1NDEK0&U%!QI6@'<6C
M9FLON;D9?3[@N)[ZYM<]`8G3/=+(S7#)J#7O)=0].FM*DGI-5/Y]R$I_)/>>
ML]F<=_$6V-P3WQ7V.K:K7^#W(VL7NL\?Z_-0<!"P;6A0ZT$\C*3\";6LBGVF
M[YFY=/BO>V!$1.DDEPK,%=[>PMSCL_@+?-821TSW9&U?&^Z<USG.,K@X&3M&
M5Z6N#6Z:5-"3)C]R66Z=Q6F4VQN>ZV_N&)MNQN*O&3,LV%D;&"%CF'L1"\BI
M:^-SGAY)#:M:W77Y0U+8U#Y&[NJ>X(.LUG:$7LVVC>(2F-&D?36=ADI5>7>#
M4&+$J;-I5W?N@5>/22*0A&BJ8`4G3LA8#;-WC[[;UE=8E\DF-=;,[-TA)D+0
MT-&LGB7BE'$]+@>)54-ZX_+8W=F0L\Y%%%E67<IE;$`(PXO)/9AM`(^-6```
M-I0#H5B<WBY99].1XB5AX`!BB)3%U9J82F`1`0$-NZ\$!`0\H"`Y!.W?7[Y_
MI$WXB16HW9P;RX(Z?%;?]88KD[)YK<HFGCA1]`B-TWR`UG`\R:EJ1GJV"L$A
M$ZU6I4S<H2#L[*2I#!9O795_:S2;IZ_>N6ZKQ9^X,OWH'*02X&.V=MI_)EU_
M+9P/R+\2^<S.:'3=HV-SF$2$%[0RC6M:"&AH#:4K7/S','=\?G"1XNWO[B+$
M,SD=N+=CW-@,3KAL<@=$"&.,@+G/<6EQ>XNKJH1T4\Z5XLZO\9G=''\A:)M>
M+YQ-N.=<N57(#"RZCT_8=CV>2F"4R1;`1:JEM#LB<:+AMW2A`01[HQ#I)B7U
MMVC<V2VCA\[^'Q;L-XTZ-_%D\[88PWM`>#]`)?0U!J:@@E>5R?\`!V&WUN#;
M7_3YIN>-FR6/@^VMC<3EPB<.,8DT-C);0@-&D@@%8R+7RCY6;JX@2FJME15A
MW7J776W8:XM-\7QA<+O<-16*P1:L4A0V>T9"0=-H2O70O;4&-?F5,NMY4>SV
M2=F2;7;.U\-NQN3QSX[/*7%JZ,VT1CC9.UI#NT,(`+GQ]&MM*#IZU#5]O3>N
MX=B/P^7CER&%MKQLHO)FRRR6[WM+>R%P7%K&2<3V;J@N%6\0H*@(#Y0$!#^P
M/7.W49$$=*S<^#18:[4H'Q)K1;Z5'[(JU>X*W:8L6OY63?0T9=(:.DRNI&L/
MY>,*:1C6DTU2,W470`54BJ"8OE`,AGF[;W%W<[>M;29UO<R9J)K)6@.,;B"`
M\-/`EIX@'@:*QG(2[M;#'[JO;ZW;=V<6WYWOA<XL;*UI871ES?":'`4)'$5J
M%:$><G!`2B!?"-TD41*(%$>0.XA`!$/((@#8IA`!_<$!_LYMALG>_P#]4WG]
M5MUICS+Y=?\`T79?UV[]553X?4?R"C..?*NYT+<>G.'&B+'/T6D[/Y970;@W
MVI$/6SH)J,T_IB1I)W-G75FF\BDM*-VK=)99!1,0<`8`*3%W[)@9-P8RSOK2
M[RV;C9))#91]F87`C29[@2491I!#"20#7P>[F\K(MT1[6S%_C;VQP>VY9(HK
MC(2=J+EI%7BWM70ETE75#I&M8"64J[@%)3D'(5&T>$#NIE&<OK]S>)K+E;J;
MW%V1L*@7>IHT*5L$`];R]8H4MLN:F[I-PCR,?&77,KZ(BDHZ$"(@!Q$>:P;+
MJVYJVCY,5!AC<8R?5%%+&_M&M<TM?((6MC:X$4%-1-.+N"[;<$EC?<E;ML6;
MN-P"US%N63S0RQ]DYS9`YD1G>Z5S2.)J&`5!#/"J:-\7_ECR"K%JU7Q]IFT;
M;2M02'"/2!;=1JM*JPT'?W-\HHMK(\N[9F"0V59W"1K./(#HRA46C8")@3MJ
M=K-Y4[7P5U:7>=O+:*;*MS%SHD>W4Z(1R58(R?64<7/\&E7.J:T%-3SJWMN>
MPO\`&[:Q]W-!A),'9B2*-Q:R4R0MUNE#:=H2W2SP]0#6``"IKWOBN<S^4&I.
M4NJZ5J7=-^U?5:#HGCM;H^!H-AD*M%SMMEZ1%O9"Q71G#K-$;H_<,FS:/[,F
M#I(L<U30*0"=H#>7*_:&V\MMNZN\K9P7-S/>W3"Z5H>YK&RN`9&75[,5J[P-
M)UN+JUHO3G1O_=^"W98V.#O[FSM+?'V<@9"]T;7R&"-Q?*&D"5U*,_":AH:U
MM*5!F!>XB*A?%0\6P8>/:Q1)_P`+S:UJE4&")6S=S/V;2&GIF>D3(I@!>_E)
M5<[E8WE%1<YCF$3&$1Y2QEEFY9[5[9Q<6;E@8TGB0UES<-:/0:T`#N``="[?
M*P0V_.#>I@:&"39]U(X#@"^2SM'O-.ZY[BX]UQ)/$K']9.0NX]'>#9PIC=/W
M^R:T>["WIR7BK+9Z5*.JY<%Z]"V()'X,L;5%*-IV)@9:4<HN7R#5=$KM1DW[
MWM%3Z9W%M@<1FN;>8?EH([AD%E:%C)`'QZG,(UECJM<YH!#20=(<ZE*J.LAN
MC.[<Y%8-F#N9;26XO[YKY(G%DNALC#H$C2'M8XN#GM!`<6MU5HI,Q\>PY91/
M@"6?DC(&V+8MB;#WQ0M@VNXK&E)G8%8UIM6.6I%4MTFZ,=W/(.5V9&)A<'.H
MX],5[8F.NH8W.R22;6EWS;;>;XO;V\%M)$R/@V)\T#NT>P#@VE=7#@-(IP`"
MZJWCBWO!RXO=UN\9NKFYO(II)#J=,R"[8(8Y'&I>""8_"))UN)-7$FQ&AN>?
M,F;\72IL)S:.PGD-;.61M06#2CV:E'6N(F@'V*ZJ1JI'Z]<*J5N("C1"(.6C
MI)J1TU>,@=&5%3O#FW>;V/M&'E5+)#;0-FBQG;MN`T"5THBUZS+Z]W:.X.!=
M1S7::4H%S>W>9._)^=\-O/=W+[6;,-MWVI<XP,A=.(RP0U[-O8M]8[35CFA]
M=52;BUGD%J2@;9\4K2>UMD[UXL([HYEV]W$\R=)5B;G5Z^XK&P;B=35MW?U\
M$;`C7YHC@[P&\<X37<@JOWADR``GUUS@<K?XO;68Q=O99,VF(C#K"X>UH<'Q
M1_AHP^K-3:::O%!PI4]&WL-T8/&9G=^"S-S?XAM[G9M.3M6.>6ED\Y["7LRV
M30[5K#8S5U#J\$4,:_$'I>]E>,6@[J]Y5ZTYS\7ZGL6WT/6_("(;38[AK-ML
M$6%@=ZSV@[MKR2M+5D,3%>DL62[IP+<J)`/W9?1@-T>P;S"#<E]9LQEQA=QR
MV[)9;5Q;V#XVNT":$,`83J=I<X-%2>%3JIR/-6PW$[9^-OWYBUW!M2&YDAAO
M`'>,LD>T2&"?M:RM&ANMC'/=0>Q&@&E_`_GHB%\1C53.3?-HM];J7M^EU22=
M*=R1G<)[74[[B=VKYR.7GHBK9+IZXRBX%#RF#,OG/!--L"Y?&"Z.*:"1X'6Q
MLK-7V!74>\*K6^;K=00<S[2*5P9+/#<1QN/WLCX)`WCU$GP1W2X#K6+"U5^=
MJ%HL]3M3-U&V>K6&;KMECWZ9T7K&>A))S'3#5XDJ`*)N4'[90IP-Y>H9)MI<
M07=K'=6I#K:2-KV$=!:X`M([Q!!"AC(6=U87TMC>M<R\BD<Q[3TAS26N![X(
M(/?"S">&EPHL\)S+X-6_?U#A7.O]XU3:&\]05B2DX>0>WL^JJ+.V6KFG:J*B
MLG',G$\BP?M`>-P0D$"E%,5"]X4L2\Q=XVT^T<U:8*=XO[.6&WG>`X"/MI&L
M?I?2A(:7-=I-6'IH:*>^4O+Z^M=];=O=S6['8W(0W%U;1N<UW:^+PR21ZF5+
MFM+VL>W4T"1OK=0JOCPCYY<OMK>(;JAGLK;-]V16N0FWV>M]MZ?M\S)3^KY>
MA["D7$#9:W_-M)*N*I%1-6AWZJC4B#1'T4K3H(]@50/_`'>6Q]IXO85T_'6L
M%O<V%J98)XVALS98AJ8[MA1[G/<`'$N.JO=I3\\O>96^LWS0M(LM=W%W9Y*\
M;!<VTCG/MW0SN$<C>P<3&UK&.):`T!M.%!4&_L1>;/Q!X'>)C'\=+8_IB]3\
M2-#4M(ND"X%&S5BH%2EJ^=Q4Y[U[^#F7=7C31II!LHF[*T<K%(H43B.:&6RM
MMU[WVZ_/Q-F;+M_MY(W"K'OJUU'MZ'-#W:])!;J:VHX+JXLC=['Y<;J9MB9T
M#X=SFWBE82)&1CM6ZHW^N8]S&:2]I#M+G`$55F[;NO;VR_!OK.VK[LR\VK;6
MC/$59U[5&U9JTS3[95+A9/2;BT+,(>].'JEF0(C/`5RB?TGO43I)=DP`BD!-
MQ;X;%8WFS+B["WABQ=[M\OFA:QHBD<+C15T8&CUE6GA0@FO2:\[-N+.9GD=;
MYK)W=Q-F<?NIL=O<.D>9XV.M.U+6RU[2G:`/'A5!#:>M;3(;91D>0?BW^'QI
M;=-WM5TU$/&/1NZ'6M;99IB<I-CV?6-(WRW,)Q_5I1XYA)&PR\W'$.[<*H'7
M?)@=)4QRJ&*/!6_9X'E;GLOAX8H<K\8W%N)F,:V1D+[F.,M#P`X,:T^"`:--
M"*$*4+HR[EYS[7P6>N)KC#'$VMR8))'OB?.RSEE#S&YQ8Y[GM\(D$O!<TDAQ
M"MMK[E%J:/Y9K[5O?B[;?W'&VFZS4/L;C%(\0-]R.O;U2YET_BIS3C#73F=G
M*S%M4HQPHR8]Q$**M5DRJ=@YN\`^PO\`;64?M88RRVK:VDD4+717@OK82QR-
M`+9S*&->XZ@'.J\!PX5`I358S>.&CWJ<MDM[7E]#-,6S6#L9>F&6)YTOMQ"Z
M1\;06DL9^#.@D$"O38F@[JFN-?AK<\[!Q6MEBH\<[\1:.HNM+DW:R%<O-8UW
M+5XYV#B)&4;H3]1LKNI12<<X4$J$@W0<KIB)#B/3=7V'AW#S#PD&YHHYI!@#
M)-&2'QOE#Q4.H2U[`]Q<!Q:2UIXA<_C=P3[4Y4;CN]GS2V\9W-V4$HU,E9"8
MWEKFDT?'(Z-@:X\'@.<VH)5R=%6Z"8^&5([WV)S3N_&7<'+'E5;8+<W)F&UM
M?-M;4NK&B5Q9"O:F<V:DRT18:<P=,F0RQU2N$S.DQ51#JFH<N:_-6DS^8S<)
M88>')8G%XQCK>T=-%!#&9'^%/HD:YDA!/9TIP-#T@%;3;]_!'RC=N3)Y^?$9
MO,99[;J^;!-<W$C8X_`MB^)[9(VFIEKJJX5::MJ%'SE;M#0E\X,52D?UM]@<
MU=PZNY"U][J_<%ST#MBBRM3UY88A-G<M2S.R[LM.MIUD+LC>7:-7DB#M,4TR
M)$%(I`+OML8W.6.]9;P8J##XFYL'":".Z@D:^5KJQSMBC#2TTK&XM90\236M
M>7WEE]M9/ES%8NS=SG\W:9%IM[F2SN(71POC(DMW33%^MNH-E`<^H(H/!X"]
MGB?<U.4>M/%/+2=;;KOU`I6MK'H,L/3JA8']?JTP[M-4H=@M4E<X&+5:1MV?
MV1Q.K-W:DJF[,HR*FWZ@F0H!I^6^SMM9'EGX[D;.">\N([G5)(T.>T,DE8P1
MN<"8PT-!:&%H#JNZ35;[FYS!WAB><?Q;BK^XML?:26NF.-[F1O+X(9'NE8TA
MLI<YQ#C('$MHPU:`%=#8+5AHCE=XZW(G54?&P>XM(46B'U))-(YHL]HDAOAU
M7F6SMBUE!1!5*-L+%%TLX!X0@&1%RKU'L*J`;66+WYK:^R\!DW.?B;R:3MP2
M:2"V#C#$_NL)`&D].D=8"WN2CCV[O/F#N;#1LCSEA!#XNYH%8W7CV-N)HQ3P
M9&AQ(>.+=9ZB5B-HW*;EENC16WN/5_<6_D#IFSVW5UMOFQMFA>-GS?&Y1*X)
MLAV#6+H\E71:`6Q^DJ-':KXRC-=(%$TR%,JL)Y6OML;6P^;M,[8"*QR\<4S(
MXH>SA;=U97LGQAH[7134T-HX&A)(`I!F*WKO;<.W;[;>6,V2P$LT$DL]P);A
MUD6R4[5DI<1#VE=#]=6N;5H`+G$YHN>=KU/J/DREJNL^*CM'A/`\;JY0*CK;
MCOK3CKN5_4*!',ZA!S"$G(2E.L\/5MD/+8:0].=.W;5P59%?T93M@0_:A_9%
MKE,KMPY.YVS;9B?(22R2W4UW;A\A,CFD!LC'/B#*:0T.%"-0I4*?>8U_AL%N
MYN%M-X7>`M<6R&*"R@L;MT<31%&X5?%*V.9TE=;GEI)#]+J@+"WXHUJTQ?\`
MEO/[#TBN^=0M\HU`LMV?/-96;4*$QM)>&%A=[-%46UL(^3C(VX.H]*6[92J(
M*N'JIBJJF[9QF'EG;9>QVLRPS(`E@GE9&!,R<MA#JQL=(PD$Q@EG40&C@.`5
M?><UY@,EO1^3P!<Z*YMX9)7&!]N'3E@$KVQ/`+1(X=KU@N>>)Z5COSOU$Z81
M,(F$3"+*IX)?[3OC%^?[)_5#?<C'G)]&^2]K#^/B4T^;U]+V']O/^JSKT0LH
M*OJ4M3+[4#Y^&/XV]?R=59:3S;/WO^;?EU2;SPOW#Z%Y]VV6IMEI%25,(F$4
M]N(7/2<XEZ[W=J@VC-,[WU_OQY17EXJVY6$]*PR@Z^7E7D&BE'1,K'-7*7NA
M)@X-WY5!*LW2,3IT'KPV[-C0[IR%GE!>W=E?6(D$;X"UKOPH:'<7-<1P;3A3
M@352?L3F9/LG%7^%?C['(XW(F$RQW+7O;^`<]S.#7L'KGZN->+012BO)(>+'
ML&M5RRPW&KC)Q+XA3UPAW=?GMFZ*UBNPVG[AOT^Z>1L)<)R7DE*^FN3_`(1N
MAWR9P*HF=-4A#EU$?*VQN+B.;<62RF5@B>'-AN9@8=0Z"Z-K6ZJ=\T(X$$$A
M=!-SNR-G:S0;2Q&&PMS/&6/GM+<MN-)X%K97O>6`CV(#@>+7`@%04X\\B=L\
M6]L5_=.FK(-?N\!Z8W,H\;DE8BP0\H0$INN6F)=&[F<@9M$`!PBH('[92*IG
M36335)VV?V_B]S8N3#Y>/79OIT&CFN'K7L<.+7-/01Z!!!(,:[5W;G-G9R/<
M&#E[._CK6HJU[7<',D:>#F.'`@]XBC@",@$9XI%)I]G5VSK#P[>&VN>0??N9
M*-VO%Q%QDXFL6-T5436FH:OD9D:I7IUJNJ*S95(X@BKT'H8.H#P<G+*]N[?X
MKR6?RUQ@J4,)=&'/:/O))@W6]I'`@](4J1\Z<;97/QSB-LX6VW-74)VLE+(W
M^SB@=(8XW@\6D`Z3QH5B^OU\N.TKM:MC["L,C;+Q=YR0LEJLDLH560F)F36,
MN[=K]V1-%(HF-V4TDB$102*5-,A4RE*$EV%C9XRSBQ]A&V*RA8&,8WH:T"@'
MJDU)/$DE0ME,ID,UD9LME)7S9">0OD>XU+G.-2>X./0!0`<``."OCR$Y46_D
M73.-U*L]:K,"PXS:>8:8J;N`-*B\L,%'JME4Y:Q>Z3UV@$NH9L':]&*BCZX>
MA/-TTN`VQ:;?O,A>VTDCWY&[-P\.TT:YWWK:`>#Z-3WUTFZ=ZWNZL;BL9=11
M1Q8FQ;;1EFJKVLZ'/U.<-1Z](:.\D%RGM\#Q$OG#IM6JRO1[_N.O[IDK6N:5
M^%C*>KL-%PK6)8E3>EAO<A9O%%.?O&YENV<W0X!T`$^V+2?=<&[722"\@M'6
MX8-.@M<XN+CPU:JGJ-.\O[:;VOK38MSL1D4)L+F^;<ND.KM`YK`P-'A:=-!7
MBTFO6N'Q%Y-VSAWR"HG(FCUVN6NST$EF)&P5L&4+`/?A15)NI.S/1AGD?(]I
MJSG%%4NPJ4.](7M=2]0'][KVW:[MP,^`O))(K>?15S*:AH>UXIJ!'$M`/#H7
MAL7=]YL3=%MNBPBBFNK;M-+)-6@]I$^(UTN:>`>2*.'$"M1P4?)>15F):5EU
MTTTEI:3D)19)'M=TDM(O%GBJ27;,8_=)G6$"]H1'H'E'KF^AC$,38F\0UH'I
M"BY>YG=<W#[AP`<]Q-!T<5U^>B\4PBR-ZH\1BQUW4M3T-R$T/IWEYJG7)Q'5
MC3;J$]$[`U8U$0,,+1MHU-\RLT770,0G89J=\"14DTTSD2223)'N5Y?6]QE)
M<W@+V[Q63N/]\8"UT4Q]E)"\%A?_`+0I6I)J229>P/-JYM,+#MO=..LLUA[6
MH@\8#VS0-/WD4\;F2-C_`-@EPX`"C0`),;7\9![R2U):^.7(#CG7U="O*U#-
M*#$:LV;L6O["I%MI;=\I2)N=O-LF+6&SH5K(+H^EQTNT[H2)%63_`(=,@CSF
M,Y1MV]E(MP8/(2?'8D<9730Q.BD9(1VC6QL;'V+B`=+F.KQ(/@DKK<SS[_Q5
MA9]J[DQ<1VXZ%HA;!-,R:*2-KNR<^61\W;M#B*LD;3H<"'-!43M0\]3U?2-8
MXY\@./&IN66HM>3<M8M416RI"XU:U:M?V!11U/QE3N](EHZ8)4IJ04%RYBUR
MJ)'5Z>O`A2$)U&6V-XSF9-P8*_NL7E9V-;.8A&]DP;P:7QR-<W6T>"UXH0.K
MI)XO`<T!98&+:^YL9:9C!VTCWVS9C*R6`O.IS62Q/8[LW.\)S#4%W'A0*TO*
M?EUL?EA.TM:U0U,H5!U76"TG4&GM90QZ]KC6-4`Z*BT?7XQ5R\=N'\DHV2,]
M?.5E7#DR28=2IIIIEVVV-J8_:T,PM7S3WUU)VD\\SM<LS^ZXT`H*G2T``5/6
M23S^]=]Y7>UQ`;R."VQEG%V5M;0-T0P1UZ&-)<:NX%[G.+G$"IH&@5AP=YLV
M3@Q?+OL2H:JUKLV>NU$=:\4'8Q+`*<#7Y1Z@[GBP:M>E8IRV=3Q&B*#A03B;
MN$^P40`Y^UB;TV;!O6RAL+JZN+:"&82_@M/A.:"&ZM37`AM20.[QZ@L[ESS$
MN.760N,E9V=K=W%Q;F&LP>=+'$%X;H>P@NH`36M*@4J:WFM'B*:NL57L=<:>
M&EP+K#F>@9B%;62`H-E;SU>7E8]PQ2G85RK8%"(3$4HX!PV4,!@*NF41`<TU
MKR_R=O<QW#]Q9N1L<C7%CI6%K@T@Z7#1Q:ZE".X5T=]S7PMY936K-J[=B?+$
MY@D9!('L+FEH>T]L:.;6K30T("M/H3FT?6&GW7'7<6B-9<IM#DN"NPZM1=F/
M[379;7UY=LQ82DS1KQ2Y&.L$*RGT.GN@PZJ-G)P$P`F9145-KG=F#)949_$7
MMSC<WV79/DB#'-EC!J&R1R-<UQ:?6NX$='$`4TVV.9'Q1A7;8S^.M<MMSMS-
M'%,9&.AE(H712Q/8]C7"FME2UU`:`ZB;7\H>4=XY3W*N6&SP=2HM4U_3HK7.
MJ-5:\C5H?7^L*#"BH=A7*VP<N';M4ZJZIEG;MPJHX=K"`F$I")IDV>V=LV6V
M+22"V?+-=3RF6::4ZI9I7=+WD`#O-:``T=\DG0[TWKD=Z7\5S=QPV]C;0MAM
M[>%I;#!"RNEC&DN->)+G.)<YQ-32@'\UER<M>KN._)3CA$URMR57Y.*:I4M=
M@DC2H6&N#J2TN+9#!6RM'J$88)5XX%)UZ4BOT2`.[[!O+C);;M<GG\=N"621
MMSC>WT-&G2_MV:':Z@G@!44(X]-5_,/O&\P^U<MM2&*)]KEO%NT>[5K9XM*9
M6Z*.#?")H[4UW#HH>*D'Q+\1&3XI:2VCH=+C=H7=%0W)9F%AV$IMAE:GSFQL
MX9I'(0%6DFL-.QL<]K<$[9*NVZ"J1O[8>+F-V@,`!H=U;`CW1F;;-G(7UI=6
MD9;%V)8`TN)U/!<QQ#W`AI(/0T=Q=5L;FM)LK;UWMP8O'WUG>S-?,;ALCB\,
M#>S8=$C`6,<'/:"#1SW&O<Z7>W-S7^YM93NO(+@?P\TC)S*\.LWV3J6FS\/>
MX(L5+LI19&(?O)ITU22ET&AF;D#IG`S9=0`Z&Z&#UP>S+_#Y)E_/F\M>1,#@
M8IY&NC=J:6^$`P'P2=0X]("\-S<Q<5N##2XJVV[A+">0L(GMX7LE9I>'$-<9
M7`:@-+J@U:3U\5#37%U?ZUV'0=CQ3-G(RFOKK5+Q&Q\B*X1[^0J4\PL#)D_%
MJJBZ!DZ<QY4U>[.13NS#V3`/0<[#(V3,ECY\?*2V.>%\9(I4![2TD5J*@'A4
M44>X?(R8?+6V6A:UTMK<1RM:ZNDF-P>`:$&A(H:$&G6LK%U\7"$V#<IS9%P\
M.+@-:-B6*2]VIBWVK7=IL<E*S0)I)$DICT^S?\ZJ@1`@""INA@(`#Y,B^SY5
M3V%HS'VFX,Y%81MTM8R9C`UO<;1G#["F[(<\[7*7TF4OMK[<FR<CM3I)+>1Y
M<[NNK-X7V5`_DER^WKRJV=#;6VG9VZ,Y48^*A==PM+CDZC4=804$X([AH;7T
M#'*"2`:QSM(BI5>\5='5(0QU3=@G9[C;VTL)MC&OQ>-C)AE<YTKI#KDF<[@Y
MTKCZXD<*4#:=`%2HTW9O[<F\LQ'F<M,&S0-:V%D0[.*!C/6LA8WU@!X@U+NZ
MXT"F6KXJ#:S6:O;CVWPHXN[=Y1U9"#&-Y"6)M>(=[-359111KUMO>N*]/L:3
M<K5%E:H&(Z530`#()]@B92$*7CQRQ=;6\F)Q68R5KMJ4NK:M,;@UKZZF12N8
M9(V&IX`GI-2:E2#_`*U17=Q'G,W@<5>[QA#=-X]LK=;V`!DDT+)6Q2R"C?"+
M1ZT4```49X[G1N42<R'EO+"W^T<W:TRKFU;;8"OF\G$D8V#W?;NZHTBG3.,9
M`W$J;1!LHDHU;,D4TDB%*0,Z.39&(KB66FN"VP\A="QE*.JS31Y<"37BXD$.
M+B2225R,/,[/TSC[X1W-WGHPV>1^K4VD@>"P-<UHI0-`H6M:`UH``5=:RYZ-
M(G3M&T7R&XRZ;Y8T?42TRIIAULF0NE5N.MV<^Z]T).L-+71IB,>SU'7D@!<(
MIX4Z91`"`?NB)$3PLEL9\N6FS6`R-WB[R[#?&!$(WQREHH'EDC7!L@'#6VG=
MI4DG983F@RWP=OM_=.*L\Q8V1<;5TQE9+#K.IS!)%(QSXB[PNS=45Z"!0"L8
M;Q5=\);SV!MJX4K5%[HNSM/->.]HXY2<`_C-+M-$11%25S6U1BXR2)+5=E6!
M<+J,W*;A58%72YE`4[SH7$FY880X6#%VDUU#?6UV;IEV'`W!N7>OED<1I>7\
M`X%H%&M`I19MMSLW$W<=QF;ZWLY\7=6(LGV186VS;1OK(8FM<'QB/B6$/)!<
MXFNHUYT1XFH:\INXM4:(XB\>-+:>WIK.VZYV+48A?8-LMEA/:(Q2*9V:2VK;
M+,^N*SNG-73KW)CTC(12*CQ8ZK=8XD,3\2\N#?W=IE,WE;^\RUE<LEB>[LF,
M;H.HL$+&".DA`UN(+R&@!P%0?1G.%F.L+_";<PN-L,#D;.6":-O;22O[1I:'
MNGDE=+6,%W9L!;&TN<7,<2"+&Q7-&4#APKPUNNFM5;%K4'-VVQ:HV58VTVCL
M;3\Q>5VSNRNZH[CY%&+<B[=H&4*"Z'3^&,53O2%3*3<S;-C.[1NVSO+JWN'L
M8R>)A;V4[8P0S6"TD4!IP/5PH:UT%KS(F9L8['O["SNK6.1[[>9X?VMN9'-<
M_0YKP"'%H-"T])K44`MURJY,6OEIMK^=^YUZNUB;^!5#H_N55S29HKW/H%>:
M5R,=]9=X^>>F/6C0IU_X3L=X(]D`#R9L=L;<M=K8OXJM)))(>VDDJ^FJLCR\
MCP0!0$T'#H6CWKO"\WMF1FKZ***8011:8]6FD4;8P?"<XU(:">-*]07[Y;<F
M[9S`WK9M]W:NURJV.T1%.AG<)5!E#0;9O2ZG$5"/4;#,/'\@*KIC#)JJ]M4P
M=Z8W9Z%Z!C:NV[7:>$CP=G))+;Q/D<'/IJ)D>Z0UT@#@7$#AT)OG>%YOK<<V
MX[^**&YF9$TMCU:0(HF1"FISCQ#`3QZ255_$OFOM/B&[O4=5H.A[*U?M>*9P
MFV=);;KP6O66P6$<HLI&+2T0*[99K+Q8N50;NT5`$H*"50BA0*4N)NK9N,W6
MR"2Y?/;9.U<707$#M$T1/3I=0U:Z@J".KA19^Q^8F8V,^X@M8[>[PUXP,N+6
MY9VL$P::M+F5!U-J=)!%*FM1P4E)/Q04:A6K;&<5.'/&OB-<;Y7Y&K67;FNH
M^=L>S6E?FD3-YJ,H\]9%P3HZ,F@;L',W2543``,D)%"D4)SD7+1UU<12;GRV
M0REI!('L@E+60ES35ID:P?A-)Z*D`]=14'L[KG.RSM)H=F83&8>_N(W1R7$3
M7OG#'BCVPO>\]D'=!TBM/6D$`B[/@_:ZV?I[8:OB"V5:$J7$+4%5W%7MO6Z8
ML58.%S,G1CE3T]'4]S+A8)6Q6BP2D.HS*=IZ.HH0@D,HIV4CZOFQD,;EK`;$
MM@^7==W)`Z!C6/\`P?X7_?F0-TM8QK9-1U5`K6@XC<<BL5F<%DW<S;TQP[)L
MXKAES(Y\?X8]B:6S8R[6Y\CWQ:6Z=)-""2`TX^ZOS+WA2N6TCS3JDXA'[DD]
MBVS8CI9^W&2AGAKHO)%G:K*QXJH^G5EY"RJD:=`ITC%:@7NCIG(F<O>7.T,-
M>;5;L^Z83B6V[(A3@X=F!I>#U/#FAU:'PND$$@Q?:\P=PX[?#]^V4@;FW74D
MQ)JYA,I=K86FE8W->YNGA1IHTM(!$E)+Q(X*NQ.Q7G'?AAQVXT;6VS5++2;K
MN&AO+]8)]A7+F7L6YEK2O6J=>5K69YQ`3)&48HJ&02-T2[)@*8O.1\NY[B:W
M;G\O?Y'%VLK)(X)!$UI?'ZPS.8P/FTGC1QXGIKT+L;CF]:VUK=':V"QN*S%[
M"^*6XB[9S@R04D$#))7,@U#P:L;5K20TMZ196L<T)&,X?2_#>Y:6U1LRGM[!
M;+9K"]VEM.HW_3MENC-!I-RM0>QLD@P<'$R(K)$<(]`45,"@JI@0A-Q<[-CD
MW8S=MG>7-M=&-C)HV%O93LC)+0\%I(Z:$@]`X4-2=!8\R+B#8\FR,A8VEW:B
M1\D$L@?VMN^0-#BPM>T'BT&CFGC6M10"]C/Q*F-PKVOD>3_#_CWRLV)J>MQ-
M1HFWMB.+Q7;DXK=>[(UZ'V4C49IE$[290X`)2%D4BBJ4QQ5$ZBBJBFG?RZDM
M+B<[;RU_C,?=2.DE@B[-T8>_USH=;2Z$NZ]!X<*4``&_AYOP7UI;-W?A,=E\
MI9Q-BAN)>U9(6,%&-G[.1K;@-X@=H*D$ZB223;]AXD&^3\A=V<E+<QJ%TO>[
MM*WG0LG&/F<E$U2FT*Z0\?`MXZCQ$1((&BT*G%QI$V"*JJY#&,HJX[Y50ZAL
M]_+S"#`V>WK1TL-E9WD=R""'/DDC<75D<X'47N)+B`#T!M``%J(^;>Y';FR&
MZ;YL$]_D,?-9N:6N;'%%*P,`B:UPTB-K0&`EPZW:G$DV*TUR4M6E=2\D]00-
M?KTO"<FZ/5*';)68&3"6KT=4K$I9&3RN`R>-V8O73M3L*^E)K$[L`[(`/4<W
M>7VY:YC*8[*SR2,FQLSY&-;32XO9H(?4$T`XBA'%<]@-YWNW\+EL+;Q1/AR\
M,<<CG:M3!')V@+*.`J2*'4'<%]:UR;N%6XN[`XK1T)!!5=A;=I>Y'MN%652M
MT18J-&A&Q3*).@]3C$V"A0[PYCHF7*IY2G#H'3\W.VK2ZW+!N:1[_&8+62`,
M\'0YLAJ2ZHK7JZ:4ZE_;'>M_C]G7&SH8XO%+B\CN#)X7:-=&US0&D.#:'4:U
M:3WU-)WXI3"XV*L[<W5PHXS[KY.5%G648[D#:5=@Q#^>E*8@V;U>S;"U]7[$
MSIMWL46FQ;_PRQ$"&!`A2D(0A"%X]O+*2T@DQ6'S&1L]MRE];9G9.#1(27LB
ME<PR1L-3P!)XGB225()YTPWL\6:S^!Q=]N^%K`V\?VS2]T8#6/GA9*V*9X#6
M@DM`(:!0``*UFG.2E:M<[SQVIRA0UM?+MO?1>QPA9.XU,9FZANVWN?0*4\TZ
MV0CG,-4'4))297+UVJ=J2/@XWNVQA5[L@[/+[=N;2'"8S;1N(+.RO8M38WZ8
M_%XQ603U(=('-%&M%2Z1P+N%2M-@=W662DW)F-XBTN,AD,?/H=+%KE%S*:1F
MWHTMB+'N#B[P0V)K@SPM+3COR0%$BF9>^:]]OR/"]"2I].9%X25VM5N@BQ-.
M"-P:5FRP5G:KW'OY)3LKN7D"FFIZ#Z,7NU#]D`'LB''6.S+&P.7,<LSOCA[W
M2UT^`7L<P]G1O4'<-6KBI&R?,C)9,8$2P0-^(8V,BH'_`(01O#QVE7GI(H=.
MGAW%3,]RON5@YD'YINJS5T;XIO&'WN:HHFEO@>-BAK!'V)"%[1WPS?N(NZCB
MIG_MCO\`NS#T.`]!#*@VM:6^T?\`![9)#9>).MM?@Z]+F%A=T:=5#7HI7J6!
M=;YOKO?HW\^&$9`9!MWV8U=GK;*)=/KM6DD4]=6G77BKJT;Q"=D5#<_)C9DO
MKS6FPJ#R]GK)-;ZX^79E,R.K;66>L\E;6!&1D9-&Q0LM3I>56/#R23HSIJ)A
M$W>#T$-7>[!Q]WA\=CH;BX@OL5&QMM=1EHF9I8(S7P=#FR-`$C"VCN\MWC.:
MF5Q^X,MEI[:UN<9FY9'W=G*UQ@?KE=*VE'A[71.<3$\/U,)K4E=+OWFP[VKJ
M>)X]:GTEK/C#Q\C[E_.-*ZUUDZL\Z\O%](R]SF=DO]XN<G)V*S'B&/\`!,FY
MA2;MP[(B4YDT12]L%LQN,RCL]E+RXR6>=#V399@QHCCK4LBCC:UK-1XN/$GN
MBIKX;IYC/S6&9MC!V%KB=LMF[9T,)D<Z6;3I#YI97O?)I;P8VH:T=1(:19/D
M9NQIR"V<ZV0RU+J[2:#F!K\&%#T]!&KE);F@67H1I9",.HJ8LI+_`.^.U.U_
M"*!U\_4<W6WL,_`XX8^2ZN;QP>YW:3NUR'4:Z=7#@WH:.H+F]V[BBW/ECDX;
M&SQ[#&QO96T?9Q>"T-U::GPG4JXUXDDJ[G#'FG8^&<OMI[#:LUIM^%W3K9?5
M=WI^U&TT\K3^J/)!-](-%6<-(QQG9)$A!0636$Z1D3B'9Z^7-3N_9UON^*U;
M+<W%I-9W`FCDA+0\/`(!JYKJ4K44XU6]Y?\`,*YV%+>F*SM+VVO[4V\L=PUS
MF.C<07`AKV5K2A!J*$\%(S_U+]3_`/\`BV\/7^CJT?XQ9SW^G&5_^I<][\S^
M8NM_U?P7_P!([:_J\GPRMEJGQ`?@'!;WU9<N-.E=I\:]\;-4VV_X\2:UOJ57
MUQ<4G/:BG&J[/5I=O9JJTBHQ)!@0@G7.+1JF4#DZJ][LLIL/QZ:RR=GD;RVW
M%8VP@%T-#WRQT\(3,>TL>7.J[H'A$FAX4U&#YIC&0Y'#W^*L;O:>1NS<&S/:
M1LADJ=)@?'(V2,-92/USB6-:VHXZOWL_Q$['L#C7?^(M>T#HS4F@[38JA:ZE
M5-=1MG:RE`L=7E#2+^PFM4S/RT[L"PW!/NVTB\G571BMT$R-BH%(`9_,;R^M
M['<,&Z;B^O;K.1QR,D?*YA$K'B@;H:QK8FQFKF-C#>))=J)7[RW-JZR&V+G9
MMGC<?9[=EEBDBCA;('1/C=5SS(Z1SY7RMHQ[I2^C6@,T``*//*;DK:N5][KM
M^N-?KU9DJWJC7VHVK*L#)F8N(7740K#1<HX&6>/G'NH^;J]I?LF*CV@#L%`.
MN;_;.V[7;%C+86DDDD<MS+,2^E0Z5VH@:0!0'HZ^Z5R>\-YWN\<E;Y.]BBBE
MM[2&`!FJA;`T,:3J<XU('&A`[@"^G*CDS:^6.U&FV+E7J[6)EI0Z#K\D95S2
M8Q9HS7L$C`1CTPRSQ\[].>MD`.OT4[OM_O2@&-L;<M=K8TXRTDDDB=/++5]*
MUE<7D>"`*`GAPKW5_-Z;QO=[9=F8O8HHIF6\4.F/5II%&V,'PG.-2&@GC2O0
M`I+V#Q.-L6+D1R+Y(.==ZY;VGDGQNE^,UI@&Y[/\'Z]4YBF56DKV"O"I,GDC
M6)&.J:*I`=++-N]5/U3$.R`<[;\M\9;X#'[?;<7!ML=D6WC''1J<]LCY`UW@
MTTUD(X`&@'%===\X,Q=[HRNZ7VMJ+K*XE]A(P"30R-\,4)>S\)JUAL0(U.<V
MI/@]%(R7'DK:KIQDTCQ;?U^NM*AHNY[(NU>L;,9,;+,R&S'23N6:30+O%(L&
M<>=("M^X12/T_?B8<Z*SVY:V>Y+S<K))#=7L44;F&FAHA!#2V@K4UXU)[RY+
M);SO<EM"PV?+%$VSL)YY&/&K6XSEI<'5<6T&D4HT=^JNI!\E[3M>L<&.-<S9
MJOHBL<9]CV4]/WZR)8%YJINML[&AK4^OML1)*`@#77\LS2<HBP(V.5ND8QQ.
M8.N:R?;EKB[G-[BBCEO;G(V[-=L=.EX@B<P1L\'IE!(.HD5/4%N;/=]WFK7;
MFU)YH<=:XFZD[.[`?JC-S<,E=+)X?1"1J!8&D`=9H5L/:O9\SJ3RPKV[=V\9
M.#M`J-6M3>>W3XFT-'TR-;[.U!#"9>:M=1>+[`DJ_'7#;M<;`Q6<Q\*G,`1\
MHF(-NR<Q8"R3MHWFV),-ALCF9[N6(MM\0XR$PSNX-8\"(/,<#SJ#7R&/P0:N
MX5M7B6[[L-WQ9_/XS;]MCX9P^YSC6Q@3VS35\D;C,8Q+<Q@L+XX1+X9%(_"I
M@Z:^(DZJ^RN7\,^U3KSD'Q?Y/;XN>VI?3>V&\\Q8IRCFY2LM5;M59^O/XVQT
MFWA"K-T5UT3&$Z29"&(!DRF":'<OVW6-Q4S+F>PW+C;*.!L\):301M:^-[7!
MS)(]0)`(X$U!XE5RCYKNL,QG+:6TMLGM#+9&6X=;3AX`<Z5[V21N8YCXI=+@
MUS@>(%"#04LSR,YFOMUZUIFA]>::UKQNX]T6URE_C=4:R6LDN2=V#+L!B'%W
MO%OM\G)S]JGVT,86;4Z@I$0;&$G9-T()-SM[9[,-D)LWD+NXR&>FB$1FFT-T
MQ-.H1QLC:UK&EWA.`K4\>ZN=W=S"?N+%0;;Q5C:XO;%O,Z9MO#K=KF<W1VLL
MDCWOD>&>`TDBC/!HHC5JR6"FV*!M]3F9&NVFK3,98:Y/Q#E1G*PDY#/$9"*E
M8YVD(*-WC!ZW(JF8/,8H><,ZNYMH+RWDM+IC9+:5A8]KA4.:X4<".L$&A7!V
M5[=8Z\BO[%[HKR&1KV/::.:YI!:X$<000"".(/$+*9,^*+5=ERS/8'(;@#Q%
MWKO%H@T!YMV7B[94'%OD&"9$FLSL2EUF4)5KE)"1(@*BH1%(Y2@0I$R`!0C&
M+EG=8Z,V.!SF4LL*2:0-<Q_9@]+8I'M+XQW*$D=-2>*FR7G18Y609+=&W,/?
M[A`XW!9)'VI'`.GBCD;'*X@#55H!Z``."B_LKGIR9VAR8JG+*6NZ$'MC7CF#
M#69:K%-HBGZX@JV9?W'IM2JIA=,&M220=KI.&BXK^GD<K>DF5%4XCTN.V-MS
M&[<EVO%"7XRX#NVUN+I)7/IJD>_@2\T!#A330::4"XK+<S]W9?=T&])9Q'E[
M4L[`1M#8X61^MCCCX@1BI!:=0<'.UZM3JR6_]4HE>L,_M[4W#+C!IWE+:6DX
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M&2%+NSF*.%C-EXG'X2\P$VNXQU[/-)()*?\`OS5S06@4`/K3ZX'C6H"V.9YD
M9S*;BQ^Y[;1:93'6UO#$Z*O_`/;@!CB'N?4FGA#UKN@MH2%*1/Q5&T/<9/>E
M&X2<6:'RSF$I5=SR)AFEX=J1UEGF*S&9OE<U5*V!W0X2[R'I2RQWW86[2ZQS
M*$4`YRFYD\L'RVK<+>YG)3[686TM7&,58TU;&^9K!*Z,4`TU'```B@IV@YUQ
M07;MPX[`8FWWJ\.)O&ME(:]X(=+';NE="R4U<=>D^$22#4@PQ+RJOJO&C9'&
M:4CXF<A=I;XB.0EHOLLXEG5X<72+AUXE9$S@SWW,<,Y4SE1RY450.X.N<1`X
M`/3.P.UK$;BM]Q1.>R6VLG6K(VAHC$9<'=%*@B@``(%.I<!_CK)OVC=[3G8R
M2&\R#;R29VHRF0,<RE=5"#J)-6EQ/6JZXU<V;-H/7U\T;;M7ZXY#\=-ES$?9
M[5I7:Z$P6(:7"+11;,[K2;+7GT?8*3;/0VR:"KMJ<W>HID`2]HH&S"W'LRVS
MM_!FK2YN+#/V["QEQ"6ZC&34QR,>'-D94DAKAP)K5;#9W,:[VQC+C;M_:6V3
MVO=/#Y+:<.TB1HH)8GL<Q\4E*-+VNXM%"#04YG(;G!.[FUM1]#:[U%K?C=QT
MH%M<[`C-.ZN4L3]I8K^Z2.U-==@6RTR4A8;E8&T:H9JW56,F5%`>G9,)4Q)^
M-O[+AQ&0FS>0NKC(9^>(1&>;2"R(&O9Q,8T,C:7>$0*U/&O$U]=V<R;C/XJ#
M;>)LK7%[6MYC,+>#6=<I&GM9I)'O?*\-\!I)%&\*<`J`Y,\K;ARAY,S7**VU
MBKUNVSDC0))Q6ZT:7-6D5=>P-<K\:FB:6?OI;NW[:M)*..TN(]XH?L"4.R`9
M^W-KVFVMMLVU:R2R6K&R@/?IU_A7O>?6@-X%Y`X=`%5J=W;WOMW;PDWA=PPQ
M7DCHB6,U:!V4;(Q34YSN(8"?"Z2:4"O,'B1;E2Y=;>Y;(5+7*KW?D2[JFXM,
MS,7)S^H=@4.3@8.`EZ5/Q,C)&EG$8]1@$'!%0=%<(.>HD-W9CI'T_P#IYB#M
M2TVL9;@-L7!\%PUP;/%*USG-D:X-TU&HBFFA'2*T(Z#_`%;SHWQ>[T;!:DY&
M,QW-J]KGVTT+FM8^)['/+BUP8#774.'`TJ#PMN<[$K1I>U\>]!<<]2\3]4[*
MF8*>V_':TD[I:+3M-W65@>5Z(LERO$Q)2;>G0DGU=-HIL5-)-<1$3B4QRG_6
M)V.;7+Q9[.Y"ZRF3MV.;`91&QD(>*.<R.-K09'-\$O-21U=%&?YG-O,%-MK;
M&,L\/B+I['W(A,KY)S&=3&OEF>]W9,>2]L;:`.XU-2#<I#Q,&5SB:$ZY-\.^
M._*?:>K:]"U6F;DV&M>*_;9""K79^#K#:$?4YIE";43B0+V0]T4B"L43=[VS
MJ*'/KG<N)+26=NW,M?XW&7,CGR01=FY@<_UQA+VET.K_`&#P/10``;:+G##?
M6]N[=V$QN7S%G$V.*YE[5LCF,%&"X$<C6W`;T>&*D>N))),(N0_('9O*+;UM
MW;MV7;R]UMZ[3T@L<S+&P<+$Q;1*.@ZW7(HBBI(NOP4:@1!LCVSGZ`)U#J*G
M44-VF`P.-VUBHL-BF%EG$#2IJYSB:N>]WWSG$DD\.X```!&NZ]TYC>6<FS^<
M>'WTQ%0T:6-:T!K6,;]ZQK0&M'$T%22XDFRN;E<ZF$3")A$PBRJ>"7^T[XQ?
MG^R?U0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC^-O7
M\G566D\VS][_`)M^75)O/"_</H7GW;9:FV6D5)4PB817IT#QYW#R?V1&:GTA
M3'UUN<DW<2*K9%=K'Q4)",12"1L=FG9)9K$UZOQO?$!9TZ53)VSD3)VU3D(;
M3YW/XG;6/=E,S,V&T:0*\27./0QC0"YSCU-`)Z2:`$CHMK[4SN\LLS#;?@=/
M>N!)`H&L8/7/>]Q#6,;UN<0*D#I(!G<?PC=U3K2:8:>Y`<->1&S:W&OI6<T?
MI'?T;:=K)-XMNHYDTH>%?PT+&V)W'I(F!5)H[,;O``A>T<Q2CQ'^JN'@<Q^6
ML,O88V1P:VXN+8LAJXT&IP<XM!ZBYHX<30*2O]#<]<LDBP64P63R\3'.?:VE
MXV6XHT5.EA8P/(`-0Q[C7@`2L6#MH[8.W3!^U<L7[%RX9/F+U!5J\9/6BQV[
MIF\:KD37;.FKA,Q%$SE*<ARB4P`("&2:Q[)&"2,AT;@""#4$'B"".!!ZBH6E
MBD@D=#,TME:2""*$$=((/$$+CCY`Z_N9^E^%.N$\._D#/[AXP:.8N->A=>7&
MGH;>.J#KV=Z2$2I,[`V2Q,26R0)!J+0TX$?570*-DD712JB0H*#VA$O$S;_P
M,&)R6:>)_$\5=NMIZ,&KM&N8PZ!J\)M7MH21PKP4E6W*K<UUG</M^-UMX]F[
M%EW;UD.D12,DD;VAT^"[3$ZK0'<:"O%0=>M%6#UZP7['?L7CIDOW9NTGWS1=
M1NKW9A`HF)WB8]!Z!U#.T8\2,$C?6N`(^RHYEB=#*Z)]-330_87&S]+S3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?3O
MENY%MWRWHPJE<"V[U3T<5RE$A5Q0[7="N4@B4#].T`>3KTS^:6ZM5!JI2O71
M?H2/#.S!.BM:=_H^XOGG]7Y3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(OL9PX.V29'<.#LD3BJBR,NJ9FBJ/G42:F.*":@_[8I0'/SH
M:':Z#6>OK]->AFE+-!<=`-:5ZST^FOCGZ7FF$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PBRJ>"7^T[XQ?G^R?U0WW(QYR?1ODO:P_CXE-/F
M]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC^-O7\G566D\VS][_FWY=4F\\+]P^A>
M?=MEJ;9:14E3")A%F/XTR#K6/@_<]-FTA4T??=E;STWH.T6!@(I345JIRTBY
MN2BT'R71PRC+4YG7;%T4IBE<)J]@W7LEZ1%N.-N2YL83&WOA6-O93W+&GUIF
MJ6@TZW,#0YO<(J.M6"V?(_$<B]Q9?''1DKJ_M[21X]<VWIVA;7J;*28WCH<.
M!Z`L4^L-CW/36PZ5M36TTO6+WKRPQMHJ<XT324/&R\4N59N8[98AVSQDN4!2
M<-E2'0<MU#I*E,F<Q1E#)8ZSR]A-C,@P264\98]IZVN%#QZ0>L$4(-"""%".
M'S63P.5@S6*E=%D;>5LC'CI#FFHJ#4$'H(((<*AP()"G+QFM>JMV;9W[N'DC
MJ78_+?D+;4U[;JC0&M:K.Q58VQM&TSBZMLLNPW.IV364KU<K9%B.Q91[5%*0
M564*<Y3`4%.)W);9/#8JQQ&WKJWQ>!B\":ZF>USX86-\!D0G):YS_6ZGDEH`
M(!ZI-V;=X?<6;R>>W;97>:W/+^$M[.",M;<3RR5DDE\7#7M;'77HC:.TJ02T
M=,VN0_$R/M/A^;PY(;%\/W^H/M_1UUU82HJ0#V^1%=W!3+]8VM3GHV2U_?YN
M:E8F0JB[Q%<7@E1.LHLF!3B4%D\XW;^Z9+7?=GM['YWX[Q-[#-KU")SH)(F%
M[2)8FM:X/H1IXTH21T%2%NS9<%[RSO\`=>4VV[;V<Q\]MV9:9V,N(YY.R>TP
MSO>YIB):XOX:M0`/K@I>:O\`VC_@5?\`^N76?ZK=UYRN3^C[>O\`]P3?CK9=
MEA?I2Y<__:UM^K7JU:+-_P!IK)_A%.?W5=Y9BU_[:/VC?N!4UR'_`'LOMS]U
M=)GNL1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBRJ>"7^T
M[XQ?G^R?U0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC
M^-O7\G566D\VS][_`)M^75)O/"_</H7GW;9:FV6D5)4PB819$>"_*;5&JJYO
MCC7R=@K18.+7*.O0,7>GE'*U7N^M+Q3GYY.B[2J;-Z`H2#F">J?VTV#URQ4T
M3]E8$1;+Q_O;;.4R=Q9;BVV^-FY<;(YT8DJ(YHY!IDA>1Q`</6GJXCAJU-EG
MEMO3"8>TR.T=X1RR;0R\;&RF*AE@EB=JAGC#O!)8XDN:?7"E=6G0Z0^K=<>%
M7QJV%7]^V;FE:.6,;KV9:7.A\>Z1QVN^O;'<++"*A*5>.V)9KRY^"T5",IE!
MN9^DF/9<D(8`$4Q%%309/(<SMQ6#\%;X>/%R3L,<MU)=1RL8QW@O,3(QK<XM
M)TD^M-.OB.KPN*Y+[1RD>Y[G/39F*V>)8;.*RF@?(]IU,;+),>S:P.`U@%VL
M5`KT&M.,O/;7MR8^()&;,VVZX4;FYBVJK7.C\B-<TRP3,50HBO2SAT\U`X-0
M4$KS`5Q]%=TT*_8%(JX[U99P?O2E*KA;CV-D+-^"EQUJ,QB,3&^.2UED:TR.
M<T`3CM3V;GAU7%KN`H`WAT;/:',[$9*/<D.6O#@,YFY8Y(KV")[A$UCW.=;G
ML0)F,<TA@>P$D5,E2`'=3-;SXB:\X/<U>-D1RDV9R+W[O!;3-K+MNR42_1>O
M+@[UQ?6LNWU]35+@YE;LU4AHGT]VYEYM*.;/UWJ22!`!$3&]8,)NN_WGA]PR
MXRWL,'9"X9V#)8G2QB6(M,K]%(SJ=I:&1EY:&DD\:#'O-R[%QO+_`#NU8<Q=
M9/<F0-I)XR^&5L,IM[C6(6:ZR@M:7N,LK8P\N:UH\'4:^HW.SC-!\T/"LW%(
MW:51H'%_AC2-/[GEBTZTJN*WL"%H6S8.0B&46E%GD;"V1E+*S3!VQ37;G*H)
MBF$"&Z85]LG<<^T-SXF.%IOLEEY)[=O:,H^)TL+@XNU4::,<=+B#PI3BLS&\
MR-HVV_-F9R6X>,;A\#!;73NRD)CF9!<L<T-#=3P'2,&I@(-:@T!6!^<<HO9N
M;>MC"=N\F)5VW.)3$$[=T_<+HG$A@`Q!,DH`]!\H>8<F^!KF0,8[UP:`?L!5
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M5/!+_:=\8OS_`&3^J&^Y&/.3Z-\E[6'\?$II\WKZ7L/[>?\`59UZ(64%7U*6
MIE]J!\_#'\;>OY.JLM)YMG[W_-ORZI-YX7[A]"\^[;+4VRTBI*F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+*IX
M)?[3OC%^?[)_5#?<C'G)]&^2]K#^/B4T^;U]+V']O/\`JLZ]$+*"KZE+4R^U
M`^?AC^-O7\G566D\VS][_FWY=4F\\+]P^A>?=MEJ;9:14E3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%E4\$O\`
M:=\8OS_9/ZH;[D8\Y/HWR7M8?Q\2FGS>OI>P_MY_U6=>B%E!5]2EJ9?:@?/P
MQ_&WK^3JK+2>;9^]_P`V_+JDWGA?N'T+S[MLM3;+2*DJ81,(F$3")A$PB81,
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MM[YK=,.Z\1MK;=U#:NOX[DN?)$)0#"P/'`\>(J.!'$@GH4[\M-O;)FV-G=X;
MOLI[UN-EM&L9',832XD=$>(!'`Z7=!X`@<2NE>[S\(M5F[39<!^139ZHV7(T
M<J<JY%4C=T=(Y6ZYTC,CE4(DJ(&$H@("`=.@YZLPG-4/!?G+$LJ*CQ,<1U_?
M+RDW-R.,;A'MR_$A::'QX\#3@?\`==U4)9N.NI;;X:FO^5NJ8J4C]JZKW=+:
M8Y3,UI^2EV,@TM3<9C5M]CH9V91O68U5!5K&JE0[*;A\X4_V@`7.MMP96TYB
M3[8RCVNQES9MN+,Z0T@L.F:(N'KS6KQ7B&@=U:J^VI@LAREMMYX.-[,O97[[
M:_&HN!$@UP3`'UK0/P1H:.D)[E!U/AU<<]9[WVKL:T[]0E3\<>.NE-@[OW.,
M/,+UZ0D8Z`B%F54JT;-MA*X9RUAM#Q$R)$Q!5PFT53+T$>H>W,#<&1PF,M[7
M!EHW!D+R*WM]3=0!<ZKWEIZ6M8#4G@"02L7E1M/$[CS%U?[E:\[6Q=A-=7.D
MZ2X,91D;7=3WR.;I`XN`<!Q4IM5ZKX$Z\\/?7W+SD/QUV9M:R[+Y([&U*SA*
M+NN>HB%?B(AC*V"#(?MF<-GQ(V/C!:F4$GI"YS`H<PCU#.7R>3WSD-^3[5P.
M0M[:WM\?%.726[9"YSB&N[E*DUZ:#H`7>8C"\L\1RRM][;EQ=Q>7%UDY;<-B
MN71AK6LUMZ6NJ``1Q%3TDJ.>U-P^&1.ZZN$/J/AAO.@[,D(5RVI5SL/(]_:H
M.N3IQ)Z+)RE=5:`G,-$.@]I`1#M]?.'GSH<7B.9$&0BERN7LY\<UX,D;;4,<
MYO6`[5X)[ZY'-;@Y/W.*G@PN!O;?*NC(BD=>%[6.ZB6]F-0[U0I=Q7ADZTV]
MX6^G^1&FEY(.7KNN[>VK8]?KSS^1';NJ=6;-FZ7<C4NLK`9NSGZ3&.HAR4C/
MH=V(G2,0ZKE$2<K+S'R6)YEW>!RX;_A0200LE#0.PFFA;)'VC^MLA$@\+HX&
MH#75[2#E%AL[R<L=RX,N&]S%=7#X2XDW-O;W#XI3$RGKH6F(T;4N%1I+G-I"
M?@=Q^UAOR&YK/MCQLG)JZ3X2[?WAKTT9-OX8K#8-0<0"<!(ORL3D"6CD"R*G
M>-%NTBKU#M!Y`$.RWQGLE@YL.S'.:T7F9M[>6K0ZL4FO4!7H)H*.'$*.^6^U
M\3N*VW#)EF.=)C]OW=U#1Q;IGB,88XT]<!J-6G@5(7A,/AH;JNG&_CKL;B1N
MN5VSLNP4W7%KVE'<AI6(J[FU3KE-@]M#6H,DD%&,4*Y^\!FFH!B%]:!A'RCS
MV\AS&P]ID,_896T;B[>.25D)M6N>&-!(87DFIX4U$+LN7KN46X+[&;7R.$O'
MYFYEBADG%V0TO>X,+Q&&"@%:Z=70.DE='S'DO#6UG/\`(?0FK.)&ZJYMO7-P
MN^LZOM"8Y"2=@K#:PT^S.8(UE=5!XBJ9[&O"QZARM5%!,4%``3=0ZY[[2BYB
M9&&PSF2RMI)BKB*.9\+;4->6R,#M`>#P(J!4#J6'ORYY28F?)[;Q.$O(LU:S
MRP,G==ES0^*4L+^ST<0X-)#=7"HJ:JS_`(6G'C6'*KF_J31FXXR3F->6^.V*
MXFX^'FY"O2"RU<UU9['%&1EHM1%ZW*E*Q:)S@0P=X0!*/D$<W',W/Y+;&S+K
M-8AS67\3H@TN:'`:YF,=X)X'P7'T.E<YR8VOA]Y<P[+;^=8Z3&3-F+FM<6DZ
M+>61OA#B*.:#W^A7M+M'P:9*PJ52R\/^5FMH<TNXAI._U?D.G<)>N(HO%&2L
MXVK$XU,PE4VG9%8R(@J<Q"B!2*&Z%'1_%O-V.W\:M\KC;B4-U")]J8VOX5TE
M[345Z*\._1=4,SR%GNO$+K"96TB<[298[L2/94TU!CX])ITD5/1PJHJ<Z.)2
M_#S=B-%B[<CL?6%[I=;VWI'9K9N#5*^:INJ2ZU>EW#<@`BA*M56JS9T5/HF<
MZ0+$*1-8A"]5LG=0W9AC>RQ&WR4$SX+B$FO9S1T#V@]PU!'<K0U(*X'F1L<[
M%SXL+><76&N8&7-I.!02V\M3&ZG4[@6GNENH``A9"]<>&_IJU\$&CV1+8PYZ
M[)X_[)YE:G@23;UM$JZ-UO=*Q#MJJK51.#.4GKY45GLE&J@F*YS*@!3=E`Q<
MX'(<PLO;;W+(^S_P3;WT5A,[2-7C$L;W%^OI:V)^ECQT"G=<%*V*Y3X"[Y;A
MTPE_U$NL;/D[=NKP?%8)8V"/1]\^:,22Q4XGT&D+%SQGN?%^G66PR'*/2U[W
M?4WT`BWK$)0MDKZS?P\_Z>BLK+/I-NDJ>19J1I3H@@/0"G,!_P`'DDO<EGN6
M\MHV;9O(;.Y$E7NDB$H<VA\$`D4-:&OV%#FSK_9V-O9G;SQ\]_:F.C&QS&$M
M?J'A$AKJB@(IWUF`V=2/"9UIQ/XT<JW7#+?4K$\DK!M.`C*<WY-3K:3JJFKY
MY:"=.9"54!5I))S!T>\2*DFF*11Z&ZCD2XV]YI9'=&1VPW+V39<?'"XR>*-(
M?VS-8`;4$:>@U)KU*><M8<E,5LO%[S?@;YUOE)+EC8_''`L\7D[,DNT'5K]<
M/!%!P/%6BXOZEX`[1UMXAW*:X<>=J/=.\=4M$RNKM0M-UR\?;8R.O;N4JUF8
MR=U:E12FUW4\U(^24<)G]';@*)>HCVLVVY<IOK&9#`;9M+^V;EK_`,9;-.;=
MI8XQ!KV$1D^#1I+30\3Q6AV;A>669QVY]X7F+NG8'&>).@MQ<D/:)G/BD!DT
MC5X0#Q5O`"@J>*M.?>WA""0P%X!<C2F$I@*8.5\EZTP@/9'US%0OD']TI@_L
M#YLV@P?->O\`YRP_J0_G+2G<_(RG#;>0K_3W?!*.W"'2VOMP[.V5,;9CI!]I
MG1N@=U;YV$P83+N">/65*JKEI2(%.;8]';5>:V+.0S;^#$%%RB<A1#M"(=%O
M3,7^)QMO#BW-;E[V^M[:(EH<`9'@R.TG@0V)LCN/`<"N0Y<[>Q>>R]W<YECG
MX/'8VZNY6AQ:7"*(B)@<.@NG?"V@XFM!W1D@X#4CPL>9.\]4<:7'#_>%7NER
MKDVI+WQSR1G7D$$Q3J+)VB:>)0+`K1RFVF',*J1!,B@=SWQ>O4"B&1WOF\YF
M;2PMUN(9:SDLXI&Z8Q:M#M,DC6-&HDBK0X5-.-"I=Y:V/)K?>X;+:?Q)>QW\
M\;M4WCCBW5%"^1SM&AIHXL(`!X:AT@%0+Y'[)\/:;HMAK''?BAN+4^TFM@:-
MX^\W'?3R^P#>.BY<4YQLO6'#<"+JRC%$Z:)^T`H',!NH].@]QM[';]AO8[G/
M92UNL86&L;+81N)(\$AX/"AXGAQ4:[MR_*VYQLEEMG#7=GF!(W3+)=&5H`/A
M`LT`&HX>NX=]3KN/`?C7#^,#H;ATPK=D3T7?Z=1)FQP:ERG%IQP_L&I;1;I!
M1O9SK^Z[1,\U%H'`B9R@4A1(7H4PAG$VF^=Q2\J+[=CY(_CJ":1K'=FW2`V=
MK!5G0?!)Z?14C7W+/:4//#&[*CAD&W[F")SV=H[42ZW,AH_I'A<>'H*#GB6<
M:-=<9^1C6.T@:27T!M?6M%V_I9Y*R+B8>C5[)&FC9F->2KI19PZ>Q%QA9!,Y
M53F613,F0XB(=1[;EUN+(;BV^7YK2,[:W$D%P``T:V&K2&CH#HW,/#@36BC3
MF[M'%;3W0T;=U';5[:PW-J22X]G(VC@7=9;*R04Z0`*\>)EI'<!=&P'A#WWE
M3=6<\ORC4C*)M6I()V&78Q-7U!L7=K+55)<25:3,2*DE+8RK$X];JJE,H*:Y
M#`(=T4,Y23?.:N.:T&VK-S!MK5+"_P`$$OGBMS/(`_I&@OC:0.%0>ZNY9RSV
M[9\CKK=V0;(=XZ8+B,:B!';37;;:,E@X'M>SF>TGC0@]2[*RZS\.'C3Q2X0;
M,WAQCV_N/8')O4U@O$[+T_?,U18YA(UF9CXQV7W(.#AH0CXLJF8A4"ID3!,>
MH"(]<\K;(\PMQ[GS..PV2M;2QQURR-K7VS9"0]I</"J#PH>FM:K-O,1RHV?L
MW`93<.(N[W(Y6TDD<YETZ(`QO#3X.EW34=RE.M0CY`[2\/BV:X=P_'+BAN'4
M&S3RL0X9W.Z;Y>;`@F\.W<]N9CUJVX;$(LXD6OK$E>H"B;UW]@>SP.,W[:Y`
M3;@REK=8W2X&-EL(G%Q'@G6">`/2.M1QNK-\KK[$.M]K8:[LLN7M(E?=&5H:
M/7#08VUKZ/!1#M6N-@T6.J$Q=:/;*C$[`@4[31).R0$G"L+E6513!.P5=U(-
MD$9R&4%8G9<MA41'M!Z[RAG6VN1L+V26&SFBEE@?HD:QS7&-X^]>`26N[QH5
M'U[B,KC88+G(6T\%O<QB2%SV.8V5AZ'QEP`>T]3FU'?637PHN)7&[EC/\FHK
MDO.2-0J^OM,1UAKE\9S[J$:T6S6"U(55C9Y5-(Y&,JPCG,@B<R#W^T^A1%42
MD[1BQOS0W3N':\..DVZQLMS/=EKXBT.,C&L+RQO6"0#Q;X7<J>"F+DILC:6\
MWY:/=LCH+2WL=3)@[2(7ND9&V1W40TO!H[P>Z0.(AQ=^,]RT3RV:\8MV1"C2
M<@MO4ZD60C0[AJUL%:L%EB&K2Q5YZ8I%QAK56Y$CMBX``.5-8O4"J$,4.ML]
MR6F;VH=R8=X,3[5\C:T):]K75:X>R8\%KAT5!ZN*X6]V;>[=WVW:&X(RV1EX
MR-]"0'L<X4<QWL7L(<TT!TD$@'@IJ3?AX5O8WB=;]XFZTFE-6Z)TM,VJUWF^
MV%T\LHZRTM1H&$EK18'CI^KZ3+R0KR16S0%U`*+AR05#`DF<0XZ#?USC^6]C
MNC(L\9S=XUC(XV@,[:XD<YK&@#@T<*NH.@&G$@*0;KE78Y7F]D=G8M_B>V[!
MTDLTKR7]A:P@&1Y)H7'B&CCZYS:D"I'`>[M\(""F%:!$<(=^7W7K=V:-/R`E
M>24U7MPRK,BG<&ML3K-E&(:\;F63`7"#!RH@!@$I5`2$3$+Z,PW-B>#Q^7,V
M,%\17Q5MHU\`/3H,Q=VI[A<`>]7I/G+N#D7:W?Q5%M_(7&-:=)O'7SF7)IPU
MBW#/%ZGI#7$#HU$<55:O"?C9I3FMQ.BMB6*9W/P-YC1\;,:GV4C+O*+94(B[
M%"O12%L>PP-2Q]GUM=I6-+,$*1)!5DOVCI(*"HBCBC>6XLSL[*2V$;+/>V)<
M6SQ:1(PNC\,E@=6K)HP_LS4G4.!<*..;_IWM+;W,##19.22_Y=9QC76\U3%(
M&RUC`DTTTR6\KF&84IIXD-)TMQL<D],3?''?FXM&V3O!D=5W^R53TM4@IC)Q
M,>]44K\X0HE+_`3M>6:O4QZ``IKADB[=S$.X<%:9JWIV=S`Q]/8N(\)OHM=5
MI[X40;NVY<[5W1>[;N*F:UN7Q@G[X!Q#'^@]M'#O."RMUW@UQTKV[?"SXP;"
MKEAD=O\`(F!:[1Y5J(W*88>Y=7V4G,26K:!&1K)5).JS,5"QYCR"B?1TH=,@
MB8"J],BZYWIN&?#[EW)821MQ5A(8;/\`!M-7PT$TI)]>USCX'52O6%.-CRYV
ME;9W:&TLI#(_-Y*(7%_^$<VD=PXFWB#1P8]D8_"#UU2T\`51^T;_`.$3K'9N
MQ]:.N"/(:6=:ZOURH;F5;<J)9LWE'%/L<E75I%!LJW45;H/E(X52)F,8Q"G`
M!$1#KF5C+#FMDL;;Y%F;L6MN((Y`TV;20'M#J5U<:5I5869RO([#9>ZQ$FW;
M]\EK<21%POG`.,;RTFG9FE:5I4^BJ6XA:HX9\QO$6U[K6N:<V'KKC38*+>Y"
M8UW,;0E;'<!G*1K*X6IQ)-[LR%G(E;/).*;'(V*8``$S$$>R<0#+W7E-W[2V
M!/D+B[@N-Q,FC#96PAC-,DT;`#&:BH:X\?L]2UVR,/R_WWS3M<99V%Q;;5D@
MF+X73E[RZ*VEDJ)`UIXN8#2G>JHX>(;QVI_&?D]9J=J]1ZZTI<JO1MOZ.E'[
MMR_6DM5[*K3*=@SC)/3'<R'N;("\8BLH8QSBUZF$1$1SHM@Y^[W%MN.ZR=!F
M(9)(+@``:9H7EKN`X"HTNIU:EQ_-3:MAM/=\EGAJG`7,,5S:.)J76\[`]AJ>
M)`)<RO66$J:VR.!.C=7^$M$<D9MM.*\LI%SJ"\3)#6&32AZMK?>5PG4==QKF
ML%5"*,_F*)`E?"=5,'!!=E-U[(DSC,?OG-9+FD_;\)8-KM$\;?!&I\MNQO:D
M/Z:-D=IX</![M5(^3Y9[:Q/)5FYKAKSO-WB\SJ/.F."Z?)V`+>BKXH^TX\1K
M'515CNC7'AD\2]6\.EMK\4]T;:O/(#BKK+>=BL56Y"S=.BT)JRQJ2$TV3AEB
MN$T"KRJ"JY"H@1))-0I`#UO7,3$9#F/NG*99N+R=I:V5CDYK9C'VK9#I8[P3
MJJ/O2!QJ2159^;Q?*/96#P3\WAKR\R&2PUM=O>R[=&-<K3J&G0[[YI/4`"`*
MT*B9S'XZ<;67&K2/-;B0.R*IJ[;5WN^J+/J+;DI&V"S4385+:.)(7%>LT>!?
MA%5I)@T5$3+=ZH@<$NJG:5.BAU&T=P[A=N&]V?NGQ>7)6L$<S)X`6LDBD-*/
M8?6/::='`\:"@J[C-^;/VF-L8[?NS/&H</>W+[>2VN'-<^*5E"#&]H&N-S36
MI&III4U=I9,KE50/"OX:6G6&L[SQ"WCLVS6S0VK-M2EGKW)"=K4:=U>HQV=T
MR3BG9'1D3H/(Q0_4@E3[*@%*4`+G([8ON9N[K:YR-EE;.WMHKZ:`,=:M>:1N
M%#J!'41W^"[K>..Y-["N;+%9/"7EU>3XVWN'2-O',%96DD:=#NL'KZ^A8U.0
M]\X2WUG1XSB[QOVCI&;2M)/AC*7S<CK9;2>K[I--JA&1S)=NE[E/$7JG>BN4
M>HD#L]!Z^21<!8[SL7S2;ER%O>0&/P&QP"(M<.))()J*<**)-UY3EUE([>':
M&*N;"Y$I[1TER9@YI'``%C:$'KJLE'-^H^%CPJY'6[CO)<)-R[%>5*%I4NI;
M67+&TUMM(!<:I%6@B)(A:`E5&YF!9,$3&%804,03`!0'LA'>S+KF9O';\6>C
MS-I;LE?(W0;)CR.S>YGKM;:UTUZ.%:*6N8=IR<Y?[HFVQ-M^[N9(&1'M!?OC
M#NTB9+ZWL7TIKT^NXTK0545N4_&KC)-</=:\[N(D?LR@46<W'*Z`VAIO:UA8
MW"0J=_:P#NTQDI3[>V;-7,W7G<.T`%O2.\4`ZZ8AW1B+)AU&V-Q;DAW9<;)W
M6ZWGO66C;F&XA:6!\1>&%LC"2&O#CPIPH#TU!7%;XVCL^XV-:<QMD-NK:PDO
MG6<]M.YLACF$9F:Z*0-:7,+!QJ":D=%"!&K@_P`9F7*_D#"ZTL5F<4C74)6;
MAM#;MV9MR.GM6U9KF%6G[9(1R*J2Z`RKQ--)DT,H11))P[(H<AR$,0W1[TW&
M_:^"?D;>,39!\D<,$9-`^:5P:P'O"I<ZA!(:0"":KC.7.SX]Z[E9B[N8V^)B
MBDGN90*F.WA87R.`-?"(&EI((#G-)!%0IC5;4?!/FI5=Y4GBGJ3</'_>6F]5
MVS<NLG%[VT&T87?].UT5)W;J_9H5>"CAHVP'T$L#Q@E&++,@5`Y#G,0@]KD+
MG*[VV?=65YN:ZM+_``MY<L@F$<'8NMI)>$;F.U.[2(.\%Q>`ZE"!4\)$ML%R
MXW_99+';.L;W&;BQ]I)<PF6X$[;N.``RLD;V;.RF<RKF"-SHZAP)H`38K2-X
M\,=CK2GQ6\N/7*^];@!)TC:9_6VUJM!56<?.IA\:'+7J^]1-(-A"(6:H&3-V
MCJ.2',7J!@S=9JSYCOR,LV%O\9#B>!8V6%[GM`:-6IP-#X537J%%SVW+_E%%
MBX+3<6-RT^?!<)'0SQ-C<=;M.EKHR11FD&I/$$J\'B>:#X<<;&^E]>Z0I>W*
M'R"GJXQV%NVA;&V!'7@=4P%FBBNJC0Y]:-:(LD=ANTUR/G:"!SD9-@(4QC]^
MF8-5RVSF[MPNN[_,S6L^!9(8K>6*)T?;.8ZCY&ZB3V0(TM)'A&O1I*V_./;>
MP]J16&,P%O>6VYY(A-=0S2LD\79(T&.)Y8UH[8M.MS0?`!;TZ@1B4R55!2R-
MZ,U_PSUGQI;<E^3S6P[YNETV9,:\UKQBUOM2,UR\BX:M1J3R;V/MFP,&DW;X
M.*>/%?1HMN@U2!P)2GZJE5$S>/<W?[OR6XCMW;998V<-NV66\EA=*"YY(;%`
MTEL;G`#4\EQIT<"/"E[;6*V!AMHC=N[P_)9">Y=##80W#(2UC&@NFN'AKY6`
MDZ8VM:"34U(/@=_R.XQ:3N.CN.G*KAW7]@5"J[YV[/<>I[1FQ;(WN<K2-RQH
MM7$*VJ5Y(QCGEHJ-DCW0""CI`'#94"@8>IS)(X^WMRYFSS.0VSNV2"6YL;5M
MTVYB88Q)`:AQ?'4ACV$=#30CHZ*G,W9LO;V2V_B]Y;%BN(+/(WCK1]I,\2.B
MN`&N:(I=+#)&]KJ@N:"'<"36C9#V;2/AEZ8Y"17`K9M/W=;]BHS56UCL[F+7
M=JMX*%I&XK4WC4''P5TTM7'$++Z\I]AF$6CQ1^Y%^)$EA`%!3`RF@M\US&R^
M"=OC&RV<6/+'S0V#X2YTD#*D:YP\.;+(UI<T-;HJ6]%>'476W.4>`W*SEKEH
M+Z?+:V03Y-D[6MBN7Z0[L[8QEKH8GNTN,CQ)1KJ5.G5!!KP/W?-<N]D\-ZT%
M8>7[5UBN;&T6JQ3\?3*+$4ZE.4S26RIR;G%TR155]Q'39^(`"[KNW)")IJ*"
M!1[AV^,-#M2WW;<=H+*YCC+&,:9)'22#A$UK1X3]56]0J#4@<5&;.66X;C?-
MWL:T[(WUG+*))'O;%$V*(G5.YSSX,>FC^MVDBC2>"O7XCG$S1G%2M</4M)7M
M+;"6TM+V6X7?;4:\?*UO8EEC[D:)-,5",=*'0BJNT#O6K$$`Z.FR2:QS*'.*
MAM-R]W5F]SW66.9A-J;:[:R.`@:XF&,.TO(Z7G@YU>@D@``471<V-C;;V988
M0;>N/'#=V;GRW`)T3/$KVET;3P:QM-+?9-:'$DDD]X-2\/3B[JK1:VZJ+=.8
MNZ]UZVCMK76/UCOZ.UQK_1<!9G;E&O4D'=5BK))SFTV+1DJI*LY(Z";182E$
MI"F+VO`W6_MRY2]&'FBQ.'L[AT,9FMC++<N8!JDH]S&MA)(#'-J7"IJ>K)99
M\J]G87''/P2YS/Y"U9<2B"[;##:,D+@R.L;)7.N&AI,L;RT-.D4ZS8_GIQHU
MYQXO.II_2\]9YS1_(_1],Y!:G1O1&A;W6:[<#OVSFH6Y1@BW8OI.!?QYBE=(
MD*FN@H3RG,0RA]WL;<=_G[*ZM\PR-F9Q]Y):S&.O9O='0B1E:D!P(X$U!!Z.
M`7,\S=H8O:^0LKO`232;?RN/BO+<3:>UC9+J'92::-+F.:?":-)!%*\2>FX)
M:5U_N;<=H=;BCY*2TKI?2.Y-];89Q,NXK[Y[7-<TQ\M"1#>;:"#J.6G;Y)1#
M,#)B"IP6$A/7&#/;>^8O\1B8F8ES6YB\O(+:$N:'`/ED`<XM/`Z8A([CPX5*
M\.6FWL9GL[-+G&.DP./Q]S=W#6N+7.9#$XL:'#H+YC$SNG50<:*P6CM2V7?V
MY-7:5J'HS6S[7O5;I$0LZ!11C%N+#)(,U9)[V1[X\?"-5%'*_0>V**!N@]<W
MF:RMO@L/<YB[J;>U@?(X#I.EI-!WW'@.^5S.W,#<[GW#:;?L*">[N61-)Z&Z
MW!NH]>EM=3NL`%9<H31_AC[*Y(2'A_T>H[RKVPE;1.Z@HG,Z7VDVEXFT[L@$
MGT8B:?TFC7T8)AK>RW&-48M#,W8OQ241,(I]X*J<4S9KF/CMOMWW>RV<EAV;
M9Y+!L):66[J..FXUEQE9&=3M3=-01QH`9U@VYRARVZ7\LL?!?Q93M76T63=.
M'-DNF5:-=KV8:())1I:6/,FES22.);'_`(]\4--4#3O(KE'S6BKS/4G0>XVO
M&ZN:2UU/(U2;VCOH?2G,Y"2]W6:.UZU5*O%M#+KJMTO25B]LQ!ZHE0<;[/[I
MR]_EL?MK9SH67E]:&[?<2M+VPVW`-<V,$:WO<:`$T'"O35O,;6V/M_$X3*;P
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M[@KIN<4%P(!2J!VNH=9<9RU\0O+K%D7US9AX=#"X/>96`GL2&UTR$\*$5%>A
M<%9;8OCE,?9YL.QME?F-S)[AKHXQ#(X#MP7!H=&!5VIIH0#0K*[KK1WAB\B.
M1JW`_3%'WLRMTL[N%,UCS//MME;8FZ7RFU^9EC6*<TZTKC>N(ZLL#F`<"W<1
M[HKL69DE1[D%!42B[(9KF1M_`#>^8FLC:-#))L?V!88XY'-;H;.7E_;-#A4/
M;IU`CC0`S?BMN\H-U;G/+?`6]^+YYDB@RGC#9&RRQ,>[6^W$09XN\L)!C?KT
M$$Z?"+8C<4N-.HG&O>2O)SE0%IF=*\8)*MT4NO=<SK:OV+<VY;I-.X>O4N.N
M#AF_3@:O'(L3OI-ZBD9R#11,R/7H8INJW1N3*B_Q^V]L]DS,9)KY.UE:7-MX
M(VASI#&"-3R2&L:33574N'V5LW!C&Y7=^\NVDP&)='&(87!K[FXE<6LC$A:X
M-8T-<^5P:7!M"RIX+O-Z:2XV;5XER7,WB53KSI]OK+:,+J;?>A[K>5-H-JT-
MSC%7U`V-2KTZB8B6=U^:>H&CW39\GWI'9OX,"D3$ROAA<UN+%;H;M'=4T-VZ
MXMG3VUS''V)?V9I+%)&'.:'-!#VEIIIZ>)X96XMM;2SVS/\`'FR8)[%EK=LM
M[NTDE[<,$@)BGBETL<6.+71N#QJUTT^"*NF%R+USX7W#R(XT5W9/$S=FU;CM
M_BUJ+>LY9JSR)G*E%DE+S&NDI1DG#N0=`B(2<4LN'="1(B:Q2%*'9SD\!?\`
M,K=DV1N,=E+2VM+3)SVS6/M6O-(W#2=51U.`[M025W6Y\;R?V+;8BUR^%O+N
M^O<-:W;Y&7;HVZIFN#AIT.^^83U"C@!T*,?)3C=Q4N7#B%YS\-VNTM?UF&W0
M31.XM)[:GF%O>UFS24&%A@+#3K<S;HKR<*Y9+MDUDW!E5#&=`(`B**A3])MW
M<6Y[/=K]E[N-M/<OL_&8+B!I8'L#]#F2,)(#@:D$4%!UU%./W?M'9>2V*SF)
ML(7=O:1WWBES:W#FO[-YC[5KXI`UI<PMH#JJ:GA32:R&\77P^./G%VCZPV1Q
MA86)C"QUO)J7>T7.V:5M)H78%FUI4-N:^=H.)5PX<,FLU4YAX!@+W:)U$R`4
M.T!NNAY4[\SVY+VYQVY'1NF=%V]LYK`S5$R:2"4$"@):]K>Z:$KI>>7+':^T
ML;:9;:#)&0QS>+7;7/+],TD$5S"17H#XGN/<\$`<:JFO"`X"Z0Y:#MNZ<DVD
MZ[H\8NVUGJB*A;!+5A>R;=/3;9M*>`DC$'27<(U37]+.LLB8PI?V^0QBB(%S
M)YL;YS.U_%;/;Q8+QP[:=SFA^B#M&0MX'@-<L@`/3X)6'R*Y:;=WFV]R.[&O
M=8`]A;-:\L[2X[*2X=Q''\%#"XD=%'M/<6$DP=#&#]PQ@#_8`P@&3*.A5V/2
MI%<3N-5TY=\@->:`HCIG%2UWD70R5CDR&4BJC585BXF;5:Y-,BB(K-H.$9+*
ME1`Z8N5^[1`Y3*`8.?W3N*SVI@I\Y>@NBA:*,'KGO<0UC!WW.(%:&@J:4"ZS
M8^T+_?.YK;;>/+62SO.I[O6QQM!=)([O,8USJ5&H@-!!(4Z+7M/PC]-V23UC
M4.'^VN5D%77BL#+<@+IR1LNK96WO6`^AREAH='I,*,`Q@7#U-12.%[V%%FXI
MBH4HCVAXBTQG-3+VS<E=9:UQD\@U-M8[1DS6`\0V221VHN`H':>`-:54F7^9
MY'8"\.'LL)=YFVB.AUY)?26[GD<"^**%A9H)J6:R7%M`X`U5H>3''CC56[[Q
M@O?&C8KVY:#Y/^XLB37MML$$XW)IR3;W.,K%RU_?VT&Y,[;ID4>&"*DE44A=
ME36[!URHE<K;7;NX-QSV&2LMQ6XASF-J.U8QP@G:8R^.6(N%#T>&P$Z:BNFN
MENCW;M39]OE<1DMIW1GVYEP'=@][#<VSFR:)89@P\`#_`+M]`'@&FH-UNDIX
MP_!?0O%"R:VM7%UM.MM7S,S?]17Z,G+!*V=Y6]SZZ=QTLZ:KR,NLX=MDK#4+
M*U7;(]L2&3:&5*`=L0SG^4N]<YN>WN+7<I8<DUD4\3FM#`^WE!:"`W@=#V.!
M/=<!U+J>?'+G;6SKFUO]G-D;B7236TS7.+^SN8'!S@2>(UQRL+1UAI/6N=X;
M7`G1&^^-/)?=_()O-NI6/KFS(_CE#1-CE*\+^RZ>U?);`V'9GR,:HB:6B(9>
M;@FH`J)FX+F43$HF-Y/QS#WQF\)N/'8;!%@B,L)NW.:'49/,(HF"OK7.TRGA
MQH`5Z\IN6NW-P[0RVX=S->ZX$%P+)K7%E9+:W=/-(:>N:W7`!U5<0:GHM3PO
MD_#;V=,<==#;9XE[HL^WMD6^EZWM.TH7D%)UVKN9^YVA"%1L36G,TDS,HY@A
M))"=LFH4Q^Z-T'J;KFQW=%S$QT-_G,9E;2/%6\,DS(76H<\-CC+BTO)XDD&A
MIUK6[%GY292ZQNV<MA+R7-7-S';OG;=EK=4LP8']GHZ&APJ-530T-2JGYJ&\
M,S2MWY'\==?<1=V1NUM:S]UUO5=H/^1$K*UEM;(-9:.C[4ZJ+U%=1]$D=D!4
MS-103'('9$P"/4,?9PYC9FSQ^?OLK:.QEPR.5\(M6AY8X`E@>"*.IPU`=/%9
M/,%_*+;][E-KX["7C,S:R301SF[)8)&.<P2&,L-6U%=.KHX$@K#ODN*OJ81,
M(F$3")A$PBRJ>"7^T[XQ?G^R?U0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_`*K.
MO1"R@J^I2U,OM0/GX8_C;U_)U5EI/-L_>_YM^75)O/"_</H7GW;9:FV6D5)4
MPB819XO#<V3`:B\-/Q.-@VC55!W9!P%QXL>FZSV<B\<4FQ^Z-S<Q3?W918*H
MNSC%.7Q'K?L&#^VFZ?7R=<@_F'CI\KS%VY86UU/9S/BO:30D"1E(@XZ2:CP@
M-)X>M)5FN4V6ML'RFW5D[NSM\A;QSXZL$X)B?JN'M&H-()+20]M"/":%%*X^
M(/H^T5&TUF.\-'A-3Y"Q5R;@F-MKT1;$Y^KO)>,=,&UB@U%I4R*<Q"+."N6P
MG`2@LD7J`AG3VFP\S;7<5S)N++RQQR-<6.='I>&N!+'4;ZUP%#WBN/R'-#`7
MMA/9Q;3PD,LL+V"1D<H?&7-+0]I,I&II.IM0>('!5-X4MBB[Q<]Z\'+E(I-:
M7SCTS/:XA%WZX)1\/O.ELWUSTK9%>T4Y`<-YMHY;)@``*KAPB7KY`S'YH6\M
ME:66\[1I-WAKMLKJ=+K:0B.X9]EI!/<#2O;DK>19*^R7+V^<&V.X+%\+*^M9
M=Q`RVDAKP\&0%H'6YX"[FX,Y+B%X6\;KB4;*P&ZN?.Y9:?O4:J((RT+Q_P"-
MDXO7(:"DF_9!RT+8MKE<.D^H@1RU*H'00#/&T<S=G,MU_&0_#X.T:V,]+77-
MVT/<YIZ#I@HT^Q<0LG(,=L7DZW&.!CSFX[YSY011[;.Q>6,8\=+2ZYUO:>AS
M6$4(4G-:[WIF@O!AT'9+KQVT[R0837,[:T&TJVYVDH[@H%X-8GY#X011(IRU
M6++@BR.VZF$2]RN<.G7H(<UD<)=YWF]?6]G?W>/>S$PN+X"T.<-8&EVH'P>-
M?1`7:XC<=CMGD+C;N^QEGE(WYJ9@CN&N<UI[*NMH:YIU<*<32AZ%COWAS9U%
MM[65BU]6.`O$O24Y.FB!9;,UE&69M=JY[FS4?*KA#+/I-5F7W6;,CLG`*$.`
MMG"G0`-V1#O\)LW*XG)1W]SG,G>0LU5AF<PQOJTM&JC0?!)#A0]("BG<W,+#
M9W"S8NTVWB;"XD+*3PLD$C-+VN.DF0CP@"TU!\%QZZ$32N^_-A\7^$W@H[WU
M9(^YUTU[+<RI1FFJ90(^;C5MS1[2>J\TFD8IW$%9H=99F[(`]KNE>T02J%(8
MO(6>"L-R[QWCA,DW5:3LQX/=:1;N+7M[CF.HYI[HX\*A=Y?;GR6SM@;`W)B7
M:;VVDRKAW'--XP/8[NL>VK7`4):30@T(F]2-#:Z&N<[><_&:/*WXN\M_#.Y+
MRQ*\@9N9326]V[RL.]DZ;F&[4")QQ$Y%)T]BR]A-(R)'":!?1T4#J<9>9O(>
M,839>XW5W)BMQV;=1K_U%L0\13M)Z>%&OZ2#0N\(D"0K/;F+\2W'S#VFRFT<
MUM'(.T`@^*W=8C-:N`Z*$.=%T-+*A@TM:78*_#2_:"<,O]8?6G]W4,FSF-_D
M3+_T";^057+E#])V$_O.W_&M5)\\_P#/?Y@?ZS.[OUBV#,O8_P#DS$_W=;_B
MF+6\ROI"SG][7?ZQ(IC^!1^T^X^_]$;B_4]=\Y'G9]&]_P"V@_6(EWWFW?2[
MC/:W/ZK.L45AZN+5/H-RF<N'%FF$&S9N45W#E=:7=)HMVZ"0'57774,!2$*`
MF.80``$1R3K<AEJQSB`T1BI/5P4-74,LU^]D;27.D-*#NE9\N8G'JP;HWAX1
M'`Q<%4=KPW%345.V\W3`ZLI0V%A=FGK"RF$N@JMGU)I->D'ADC``E)V!\QR]
M8,VGGH,/AMU;W;0XM^3G?`>J4M`:TM[HDD<UM>[7N*S6^-LW.>SVR.7#@6YJ
M/$6D=P!ZZ$.+GO:[AZZ"(%Y;['O%26O&\N"E>\22G\KHGQ%HNHPNA#5_3-?T
M='<8-QS=?B=24.ON]<V36[.\,W9H=]&S1'4HX)()-%&A%G1%B$4(F41YZRPN
M];CE[-MF7`.EFOM=P^Y-Y;M<Z>1XE;*8R-0+:,!:7!U&T)!)759#<7+NTYK0
M;O@W0R&WQW9VT=HW'W;V-MHH^P?`V9IT.:]ID+7AI:#)J`-`L)/B3<:VG%CF
M+MG7=>32'7%@D&^TM0/FIN\CG^KMCE4L-;)&.``".F<$LLYB@4+U*8S`1#R#
MDR\N]Q/W-M*UO[BOQA&TPS@](FB\%^H=1=P?3J#@J[<W-I1[.WU>8VTI\52N
M$]L132;>;PX]-.EK`3'7K+'*3W*K]C]X6_\`E&Y9_P#C][G-;8^EG<G]'L?Q
M(79[R^@G:/\`2<E^LA70\+K8,'JO@9XJNP+)K2D;BA*W!\97+_6NQT7;BE6H
MCJ\VF/2:SR+%5%VH@S7=D=)`0Q1[]`GX.N:WF7839/>^V;&WN)K2:1]X!+%0
M2,I$PU:2".(&D\.@E;GDODX,/RZWADKJU@OH(F8XF"8$QR5GE:-0:03I)#FT
M(\(#BHQV3Q#M&3U=GX)GX9'""N.YJ$E8EK88:'MJ<O`N9%@NS0FHHZDL*9)*
M+56!=`3!T!5,O7.CMM@YJ"XCG?N/,2,8]KBUSH]+@""6N\#H=T'O%<K><TMO
MW5I+;1[2PD4DD;FA[8Y=3"YI`<W\+ZYI-1WPNBUF`:=\,?D-?SF32LO+/>NN
M.-]95/T+(&USIQB.Y=HO6AO(;W/D[*]KT>X$/(<Q!)^`P9[Y'_YMS'L+#IM\
M792W3^YVLY\7A![X8)G#TUAXD_$/*'*92FFZS.1ALV=1$-L/&IW-Z]+I'6S'
M=VE.ZKL>!-^T^X__`/0VX_U/7?-9SM^C>^]O!^L1K:>;=]+N-]I<_JLZQ/6?
M_M%9/\()O^ZCK)1MO^VC]HW[@4+7O_?2>W*VG-B?_P#1'Q2_R<ZH_P#[?[OE
M9+#Z!,I_2)OUEBNCD_\`_IS"_P!%@_4RH0AJ>>Y_\0M6Z]J*9GVWN*?.>:X[
M/%4V_>N&.@^5E^=/ZE8Y-R415-$TR_M'3<G;]8V:)J#U`O7.S^-(=C;KNK^[
M-,5D\,+H<:`W-E&`]C?]J2(M/#BYU.M1Z<)+S)V398NQ%<SAL_XF>EVFUR$F
MJ*1_7ICN&O8*\&,)-0%?3;^UZ[M?C=XV(4,Y0U3J17@;QYTXT17,NQ::QT9L
MY]0(%6/,/0/19Q[%NY0!```QGPCT#KTS38K%W&+W!LXWW_E+KXSNIS2A,US"
M)7U[[0X,_P#2M[G\O:9?:>_QC#_\FLAAK*V%:M%O:7+H8RW_`&7Z3+Z+RN#O
M?DYKWC[P/\*UE=^)?'[DLM9^/EY=1TANMC-/'=23B[1!).&=?&*>-2IMI<SX
MAW';[0B9NGTZ>7/[@]MW^>WMN9]GE+['"*^C!%N6@/U,=0NU`\6TX4[I7KN;
M=^-VQR[VBR_PV/RIFQ\Q!N6O<8],H!#=+VT#JU-:]'4L2_)'EIK+?5,B*G3.
M%_&KCE)QMF;3Z]STVPL#.RRS%O&2K!2LOSRD@Y:GA'2TBFY4`"=YWS1+H(!V
M@&5-N[6R.#O'W5YE\AD(W1EHCG+"P$EIUC2T'4*$#C2CBH+WCO?%;EQL=E88
M'&XN5DP>9;=DC7N`:YN@ESW#22X./"M6CCTUC7=-M[*V5%4:!OM\LERAM6UM
M*EZ\BYZ45D6=)JJ/<]U7:^BH(EC8M/T9/LHE\@`F7]P,Z.RQ6-QTT\]C!'%-
M<R=I*6M`,CSTN=3I=QZ5QN2SF9RMM:VN3N)IK:TA$<#7N<1'&.AK`30-'<'!
M9&?#K`#<=/%=*(=0'A`X`0'\(#=V.1YS"_\`/[9_O@?BW*7^41(VONXCI^)#
M^.B4JM+G_P#4^TQIN0-_SISOX%V36(OA#HK8N1O$N+OD&(O%!,/?3%XU"HJ(
MJ'$1561,(CWJ\B'=<SF`>6^8NXQX.R<W'+3V%K>NC=P[C8YZ<.H$?>M9Q[+;
M<C.;N`L9R-?,3;CX00.,E[CVR-`/'BZ6V+N)J26&IUR/&F2,,B>Y^(SXW^B*
MTH0NV=Z<=]O5G4S(JG=OK+/P]?@9&2I\4(=#*R,Y'N0."8>44FJAA\A!Z<[(
M?$]@[-S=Q_XJRR$#YSU,:YS@)'=YIX5[K@.M=8P?&',S?VV[3_S>0Q5VRW'0
M9'@-<8F_[3V@FG<:3U+5M7359J+MWB*K)PS55;/&KM([9RS<ME#(N6KM!8I%
M6SELL02*)G`#$.42B`"'3+,M<U[0]A!814$<00>@@]:IA)#-',8)&N$P<000
M:U]!9EN?39_K+P]/"CT=<0=Q.WX:F[QW&_A'A3M9^GT7:%Y:2]!([04$KN.5
ME$`%1--0I#I*L3EZ`9,0"(=C.9DM^;GS-I1V*?-;0!PXM?)#$6RT/0=)ZQTA
MP/6I_P"98DPG+#9N`OZC-QPW=R6G@^.&YG#X:CUPUM!-#0@M(-"I-6O1L5XB
MN]?#8Y8R0M0J6]J.I`<RI558B;*%N7#=B+W;,K8W/=@G%EV!KV';E9]YUZH]
MV;R]<YRUS4VP,+N':\=?&K*;58-ZW1WYI`U@^^[*5QU4ZZKKKW;MMS0W%M3>
M<Y'B>1MRS).(H&R8QM;E\A^\[:W:PQUKU'K4;^./(=_RL\;[4N^G0K$C[UR3
M(I46*WD&(U_!P,M7J!#E3`"D1]SZC%LRG*4"E[[MFZ=3#G0;AP#-L<F;K"-I
MVD./\,C[Z5S@Z5W?J\N([U%RVT]T2;R\X6UW"^HBGR8[-IX:8F^!$RG46QM8
MTTIQ!-.*[;D-XA.CJWR`WK7'_AF<([2_K^YMI0CVT3L/;#SED>1-ZGF#F?FC
MHRI$3RTRLW,Y<B0`**RIA``#R9XX#869N<%97$>XLQ$R2TA<&-='I8'1M(:W
MP?6MK0=X++W3S0P%GN;(6DNT\)-)%>S-,CHY2YY;(X%[B)`"74J:`"IZ`OSX
M5NQH#;7BUT?8-8U=1-+P=@I6Z#,M9ZT1?(4FL^Y_'6V13@D*C).'3P@2KED=
MZN!SB'I+E3L@!>@!^N9N/GQ7*R:PN+F:\GCFMZS2D&1];N-PU$`#P0=(X=`"
MQ^3F5M\WSM@REK9P6%O+#<D00APC9IL)FG2'%Q\(M+CQ]<XTH."[ZFZ1D/$:
MXJ^'VUBCG<WK1/(=SPAW#*)]XXD8S15M<J;0U[<Y$``10@Z/46<PP24Z@7O2
M"7R#Y1\+S,,Y?[GSSI>%E>V'QA`WH!N&#L98QW72O,;B.X5F8_`/YH[,VP(B
MXY''Y/XKN'#US;60FX@E/<C@8)V`]!+:*N^0.[HSD-PK\5+9E;31;T53F/Q>
MI>KF+8@(LXW5&MHTM"URT9-RF,1LW4JU?;N!(4>G>N#F\HF$1P,%AI<#O#;6
M.N23>C$WDDQ/29I2)923U^&XBO<`6WW+G[;<VPMWY>R`;CSF+&.`#H%O`V2&
M``=7X)C*@??5/757(YI<M*-Q\TYX;-:M/#WC#R,>3GA_Z5G&UHWE7)B:L,"V
M"/!A[@0Z\;)L4D8856PN.P8IC=^J<>O3,#:&UKW/9C<-Q;9;(X]C,[<M++=[
M6M<:UU.JT^%QIZ`"V&^MZX[;&W=JVMY@\5E'R;:LGB2ZC>][1I<-`+7L`:*$
MCIXN<H[<Q[C5^:OAI4+EA7**CQR3XS[I7XYH:$H;I!#CU,M+M#(VM[=M:5PD
M9&J0ET,[>-R2O:.[47104%14PE((;[:=K<[.YAW&V+B;XP.1L_&O&9`3=-,;
MNS$<SZG5'0'1P:`2`!Q*YS>UY9\P.5UGO*TM_BEN)R(LQ9Q4;9N$C!,98(Z`
MLE)([3B[4T!Q)H%*#Q+.8.K=&[6T92;AP@XO\@Y<_$/0,V%^V]&V!U;2-'\/
M+((P!58Q^V;>Y,:=D=1$.SV@.N?J/FSF^7>T\GFL9>WEIF<C81?&MRWLH',#
M*AP.KPFDU->/H!=7S6WUB=N93&V%[M_%Y.8X2S=VUPR1TE"P@,JU[1I%.'"O
M'I6$KD'R/H7(.>UHI1^+>B.-`522=DDDM)LYIF6Y^[,A`"T/9"RSUV508#W,
M4!H*8%$/3%NT(^MZ3+@-O7V!@N1>Y*]R/:M%/&"T]GI#JZ-+1Z[4-5:^M%.M
M5ZW5NO';HNK-UAA[#$B`O#O%FO;VNLLIKU/=71I.FE/7.K7A3.]XG?+;B5JG
MQ`[A2-\^'MJO?9(Z%U"K<=J.[I:8G8\O"2FO:V\*5E$)$+6U'M=CG`-VJ1U$
MB.2(%*=5(3"<L(\N-J[JRFQ8KW"9VYL=3Y^SA$;'1-<)7CB[U]'$5)XT)-`:
M4-DN;>^MDX/F3/C=Q[;M<@6BW[2X,LC)7-=;Q&M`0S4QI#6@\"&BKA6HA7XO
MK^_1]:XXPFKT]6QOAT7.#>[/XH1VD:4XI545E)1L4EG0V4W>2<W(O]P0*4B9
M-T==R4@D=+&(@BX%ZDGV/*>.QDN<A-DO&7;_`(7B&]-Q()'Z6GP#"0&@0.I5
MM!U"I+=!,><]I<I'98N#$"T;RPG8ZXL!:Q&*/4[A()P7/<;IFK2\N=]\:!KC
M(T6D\(<Y7^R.8=+9E%6U;#\/#E14Z2T2+VWDC9%(6ORA(Z/3#^$5>.HZ-<=D
MI/7"4IA\P#FVYK?@[#$7C^%M;Y^RDD/4&!SFU/>!<%SO(T=KD\]8QBMY<[7R
M,40'2Z0L8X-:.DDM8[H[BX?@P_VCRZL%T=IC\%M=\6^2MTNSLP#Z)'U9MK-_
M%KN'Y^G=IMC2$LW)U/Y!,8/PY_>;WX3:L5HS_N;C)6D<8ZR\S-<`._1I7IR%
M!AWO<WTO_:6F+OI9CU"-MO(TD][4]H]$A4_X2.M*C8^24OO+9D:E):KX:ZBN
MW*>XQSGNBMY21US'IJ46%-WY%$3N%K>Z;NTTC%,"HL!(("`B&9'-/)7<&W68
M7'.+<GE[J.SC(Z6B8_A'>@(PYI/5J!6)R4P]C<[OGW)EV=IA\%:3Y"0&E'FW
M%8F\>LREC@..H-(/2H![8VA;]V;-OVW[_(*2=SV3:YJY6-XH<QB^Z$V\4>&:
M-@,(]S'QB)R-FJ0="(MD4TR@!2@&=UBL9:8;&P8JQ;IM+>)K&CO-%*GND])/
M622>E1?G\S?;BS5SF\B\R7UU,^1YX]+G$T`/0T5HUO0T4`X!6^*8IP`Q3%,4
M?,8H@(#_`+`AU#-@M006FC@05-;B)PUD.1WPNV3?KQ"Z)XN:C,S7W7R!MB?:
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MN9R.!DETU('@L'@MX5)M=S;I=J<>*[OJFHL'WPHL_,ER6`9`BKZ:Z&\[`C96
MI':I`'>*`^CIQHH@)?WQ#E$/)TS9[-O+5O*^QNR6^+18D:CU#LXB'U]`M<#Z
M!6CY@XZ]=SJR%@UKO')LT_0.L]M.714]L'MT]VHITK]^+K86$WXDW+YW`NA]
M!^'[&MOQ:+&(DY>UVF5*"GV;@$C%*L5*=AU2*D-U#O4O*'4N.5-N^+EYBF3C
MP^P+Q7N/D>YI'_I<*=XK\<\KMDO-C-RVK_`\9##0]<<;&/!]"1CJ]]5KXA/^
M:]X3O^IW.?K#6S!V!_F7<_\`>K?Q06YYK_Y-V?\`W0[\?(J.XP</M:L-9,N9
M/-VRNM<<5&LP[:42BQ)BDVYRNM$*H/IE+U?%&6;.&523=I>CRUA4,F@@7MD2
M43$#N6^9N7=N0DR)VCLV-MQN5S099'?[BR8[HDF=Q!?3BR(5)X$@BC7:W9FP
ML9%B6[]Y@ROMMHL>1#"W_N;][#QB@;4%L8/@R3&C65H"'5<R.W+SE-:.7FY'
MNT)R&B:=78F!A:!JS6M>$!K>KM5U))5K4*-"]E-`BB4<W6.JX6!-(J[M=4Y4
MTTQ(D3H=I[9MMJ8@8Z%[IKA[W2S3.]?-,_C)([IXDT`%31H`))J3R&_=XWF]
M\\<K<1MM[..-D-O`P49!;QBD<3.`X-%2305<7$!H.D2$U&`:@\-7E)M$X)H6
M/E%N'6/%2G+B;L/0I&OT3;NW`X:!T[1H^0=HUZ.<&`>R(G['EZCTT&5_^;<Q
M<;C!QM\;:37L@ZNTE_Z>`'O@&9X]"JZS`_\`R#E)E\ST766O8+"(]#A'#_U=
MP1W6N(MF.]&G=ITOA0345`>([Q`?S*B23-7;;.'3.L)03"3L<#.UZ#+U-Y`4
M4FI1N0GX>V8.GESVYHPRS\OLK'#4O%J7<.XQS7N_]EI6'R0N(+7FIA9+@@1F
M[:P5]E("Q@]VYM%VW%ZD6Q#Q9M0TA5D^1MD!SH9)3#845?362E0V^ZE;*X72
MZ=Z0L?'0[E=41_>IIF,(]/+GCN2]M3RMNKP%OBLF%=I/4>T@HP#T2X`=\K*V
MCC;[_6VRL-+O'(<_'K'&H[*Y:9"?:AKB>Y0J7LMR"U%.S'B0:BY%ZQW)8N%&
MS.;MXV17=[Z/B6;^2TAO#X56B.K3XJLV"%0EVEVJZ1$CL5W!7!VQ#BBFIWW;
M2Y./!96&+;^6V_<VD>\+;#1POMKAQ`N+?0PO%&UD:8W\0X`C41J(I0][)N7"
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M@DN)/$T)4!QR;KWO?6."#[B]O&1-@M8W.)TQM'@1LU&C6@=`%`%DL\+WD3_-
M7O6K<,K9QXI#&6W/>++Q\O&[:FRFJGRYH#V^2+BJ2*=<V8VDWJ<#'TN0()'+
M5JQ1/Z(BL8RPF*`C'/,G`#)X23=]ID)G16D+;J.W>6OL91$.T&N$M&HR#H)<
M>)'!2[R>W0[#;BBV!D,7`R:^G=9RW437QY&$SN$1++@//9B,GP@U@-`ZIJN]
MOFJD-4^'#XB&@Z[,!;5>-OB74EE8[`V(3O7M);1<SK:LV"2(WZIH$?3L=V%/
M^#([$Y0\V>%CDW93F#@,Y<,[(9#;TA8T]4A+)GM%>FC#7NTXK.R>%9AN56Y]
MN6LG;NQ>Z6"1XZ3$&S6\;G4Z-4C>CV1H%9WCFH2!\([Q+I68(*4=>-K<1*+4
MUEB]E%_;H&W2MLF&C(Y@[*KUA6UR+*E+ZXJ)P$?)FVW"#/S3V]%#QD@M;Z1]
M.ICXVQM)[Q?P'?7/[/!MN2NZ)Y^$5S>XR**O09(YY)7@=\1\2.FA60[Q`]N\
M(*"TX/1')7A_==_W=SP#XZR$5<*YO^QZK91M94C)9NUKRM?AX]VW>.6TDW=.
M!=F,!SE<E)TZ)AG![%Q6\[Y^9EV[EH;&S&=NPZ-]JR8E^II+M3B"`06C3WJ]
M:DSF9F^7>-BV]!N["3Y+(';-@YLK+R2W`C+7@,T,:X$AP<[4:$Z@.I8GN4O.
M:N;?TU3>+_'SC]6^+O&>G75SLE6BQ5NF]@VR];"<1IH=*V7V\SS=F]EG+&.5
M4(@B"0]GME[2AR(MR(RCMG95QB<O+N3/7\F2W%-"(NT=&V)D<0=JT1QM)#07
M4)->/<!+B85WGS)L\[@8-G[7QD6(VK!.9S$V5\TDLVC0))9G@.>0SP0*<`:5
M(#-.:[E-W>Z^6'B4\'WG9<26Y.)^@=YZ9:*)F66_GSXW:7IUQ8QD04!ZH/[E
M2P>M%C%`>VW:=D?)D.;9+L/MC;N\F<([3)W-O.>KQ:[N)(RYW>CDT.'?*L+O
M`,SV\=U[`DJ9K_$6=U;#K-U8V<,K6,'4Z6'M6./6UH!5-<(`+I;DGX:/#EN4
M6<W6.._(CE/NYF454EPV_P`D]&7"5K<+.-3]GNY>B:ACHIIT$O4A7I@Z^7R9
M&\B<QM[<6['<89+^UL[<](["TN8VO<T^QDG,CO\`TA8?+]K,!NG:>QXZBXAQ
MM[?W(Z/^HOK*9S&R-ZGPVK86_P#K<M6TW[X_XY_RARS(Z%3`]*R[^";*Q)>8
MUDH3F190]EW1QKWOJ/7,H^<)M$FU_L=>92<,DDZ4,0J+IXT@7*:700,=00(7
MJ8P`,4<Y(I?\)QWS6E]O9Y&VGE`%:Q,>0[AU@%P)[@%>@*=?-ZFA_P`<3XQS
MVQW=_BKNV@)-`)I(ZL->HT8YH[I<`.)4#].HZ@T[N.:KW,;3NQ[G7Z@VL54L
M^M:K:S:VND-?(YTW9HG?R;I(5$$(A5JY(LW$`[T5"&`1*7UW:Y9V6RV'CGVE
M=V\,\I8]DKV=K&Z,BO``CUU005'^#;@\%N2:#?EA=3VT?:,=`Q_8R-E!IQ.E
MWK34%M.GT%D>Y`:-XC1NB^`?*OB]JK9.IR;UY(SE4FH'8NP7=[>#&:]M\7&,
MW+=PH1-B4CY\T46341#J*1@*(CTR/,'F]U29G.;9W)=6]T;*P8]KHHA&*RL<
M2"*D\!04*ES<VW-E1;?VYO#:5G=68OLC*QS)I3*:1/8T4\%HXFIZ/N*:'+4B
MW(+8GC.\0P26D[=K^\5#F_HV+3[*CE6?U?0Z75MSQ<6@("NYD)W6\D@"2"7K
ME#I&-V3=!Z<CM4_$-AM'===-K/"_'7!ZM,TCWVY/<#9@:D\!5=WO=C=T9/?&
MQB`;RVGCRMJ*5.N!C(KJ@'%SG6[QI:.)T5H:+O--&2U5O!MPGCE"E2XF>$MR
M7/L9!(4135Y#[UJ]9VKM]90R`B"RL224BHHHG$5$P8F3'H!>R'CE@[)X?_&,
MG3E-TVG9'_X6V>Z&#T-6E[^X==>^O;!%F&S1V!%0?$VS+[MATTO+N(7%SQZP
MW5'%W1V5.J@P+\!O\]CAS_K):._6#7LG'?'^3,M_=US^)>JS\N?I(PO]\6OZ
MQ&JQ\2K]H+S,_P!8G9?]WW&8?+G_`")B/Z!#_("S.;WTFYS^\[C\:]0CSM%'
M"81,(F$3")A$PBRJ>"7^T[XQ?G^R?U0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_
M`*K.O1"R@J^I2U,OM0/GX8_C;U_)U5EI/-L_>_YM^75)O/"_</H7GW;9:FV6
MD5)4PB813JXD\_MG</Z1M?7-2UGHG:=)W/)5*4N]9WI0GFP()VXI7IYX(B<.
M6P1$6JB@Z?\`?B#E%P)5T4CD$AB>7B=T[$QN[+VUR%U<WUM>6C9!&^VE$3@)
M*!WA:'.X@4X$<"0:U4D[(YGYC8V.O,396F-O,=?.C,L=W"9V$Q%Q9X/:,;P+
MJ^$'<0TBA"D%_P"KG:_]!'PS_P#[3HW_`!IS1?Z56O\`;>X_Z\?YBZ?_`%PN
M_P#Z;VE_^F-^%6,*HWFQT._UG9E1>!!6VG7"(O5:?,2"DG$V"!FD)Z*6:I%,
M'8;M'[8G93Z].[#L]>F21=V-O?6$F-NAKM9HG1O!^^:YI:X$]\%0_892[QF4
MAS%B1'>P3-EC(%`U['!S2!WG`$>@K[\ON7VU^:^UD-N;<0JL9,Q]6BZ="UZC
M13R#J,!!Q;N2DQ0B(I_*3#E!62F)AV\=',X.*KA<P^0H%*&DVGM/%[.Q9Q6*
M,KH72ND<Z1P<]SB`*N<&M!HUK6CAP`"Z3?6_,WS"S(S6;$#)V0MC8R%I9&QC
M274:TN>15SG//A&KG$]'`7[X_>)KM/C]H>'XYHZ.XM;CUO`W.P7V):;ZU.YV
M2[862R`)'SUJ1W9F,2V520.=))1-J58J2AR"<P&'-'G>7&,SN;?N`WN3M,@^
M%L;C;3B$%C>@&C"X\>)!=2H!HNGVUSAS6V]MQ[5^+L-?XJ*=TK1>6QG(>X`$
MBL@:#04!#0:$BM%W.Q/%`LNQ:%<Z"XX9>'S4T+I6)NL+6BC<9X^O7.O)S<>X
MCCS-5GB6-P>'L$:5P*K1R!#B@N4IP`>G3/''\MK?'WT-\W,9Z4PR-?HDO"^-
M^D@Z7MT#4TTHX5XBH7KE><-UE<9<8QV`VQ`VXA?&9(<>UDK-;2W7&_M#H>VM
M6NH:&AHHD;%Y*7[9VBN/7'NPL:PA2.-)=EEH#V+CWS>QOPVI9D+78QM#]>3=
M,Y$6\DW*5IW#9KW2/4I^\'UV=5C]NV.-S=_GK=TAO<CV/:AQ!8.Q86,T``$5
M!\*I-3T4Z%Q.6W?D\QMS&;8NFPC'XKQCL2UI#SXS()9.T<7$.HX>#1K:#@:]
M*N)Q^YT[XXW:9Y!:!HCVOR6K>2%4E:O=ZY:X]_*)0RTU`OJQ)6BF&:2L:6$L
MSR#>@@LJ<KA!<&[<5$3B@F(:_.[)P>X<Q89V]$C<GCY6OC<PANK2X/#)*M.I
M@<*@"A%74(J5M=L\R=R;5V]D]KXYT3\/E8'1RLD:7:=;#&Y\5'-T2%AH20X&
MC:@Z6TL1I+;-ET)M[6NZJ8VB'ELU9<82[UQI8&SEY".)>!=$>,D99JR>1SMP
MQ.J0`4(DNB<0\QP'RYO,SBK;.8JXP]X7BUN8G1O+2`X-<*'22"`>Y4'T%S6W
M<]>;9SMKN#'B-U[:3LE8'@EA<QP<-0!:2*CB`X&G6%U^V-D3VX]H[&VY:D(Q
MK9MGWBT7^PMH5NNTAV\U;9EY.2:,4U<N7KAM')/'IP1(HLJ<J8``G,/E'TQ>
M.@Q&-M\5:EQMK:%D32X@N+6-#1J(`!-!Q(`X]2\<WEKG/9BZS=X&"[N[B29X
M8"&ATKR]P:"20VKC0$D@=95R.*O)G8'#_>50Y`ZO85>3NU*;V-K$L[E'OY2O
M*IVBN2E7D1>LHR4A7JIR1TNJ9(2.4^RJ!3#V@`2CKMS[<L-V867!9)TC;.8L
M+C&0'^`]KQ0EKATM%>!X+;;+WAE-B;B@W-AVPOR%N'AHE:YS/PD;XS4-<PGP
M7FE'#C0]Y3J#QB]QQ+LDY0>+'`+5]U:KF>1.P:-Q<@F5Q@I$QA.$I$2,C.22
M"$BFL/;*H=%3U_E$!SB3RDQ,K.QO<GG;FS(HZ*6\<8W#N.`:TD=ZH4DMY\YR
MWD\9QV&VU:7X-6S0X]C96'V37.>\`CIJ6E16U/SMW_JC>^R>39)>)O\`O;9M
M/N52DMC[%:/YF;KZMV9M(V1M-3",DX5I$62,B696<<(IJ,63,103;`ET('39
M39&"R>$M]N%CH,+;2QO$41#6N[,DACZAQ<PN.I_$.<[PBZO%<9A>9>Y\-N*[
MW:'LN=Q7<$L;IY@Y[V&4!IDCTN8&R-;X+#0M:TEH9IH!#7IU`0.)E!'KVS*"
M)S'$?WQCF'RF,<1ZB(^<<Z_O=2X$N)=KZZU4G=^<L-D\D:1Q_IFRXVI.7''+
M71=4TZZ1D=)-KI/T=J9E[BQ%VDG4P]8S'P=(R[+,Z+9J8G?K"?MF4,.<W@MK
M8[;U[?7F.=*!D+CMI(W$&-LAKJ=&`T%NNOA5)Z!2@"[#<^^,MNS'8S'Y9D!.
M+M?%XI6M<)7Q"FALKB]P?V8!#"&MIJ=6I-5PK]RAV'L;CGHCC%.Q]50U]QYF
M=@SE'D(V.D$+2]=[)EU9J>)8Y!>5<Q[Y!N[6,#8$&C8Q$^@'$XAUS]V.V<?C
M]P7NY('2F_OV1-D!(+`(6Z6Z`&@@D=-7&IZ*+SR6\\KE-J8[9]PV`8O&/G=$
MYK7"0F=_:/UN+RT@'UM&MH.!JKI<1.>NS>&]<V]3J9KK2.SJENXM/)?*QO"C
MO+[7GR5(6F7,(B2&3GX>.61!U-J*J$<IN"BJDD8O9,3J.LW7L;&[NN+2[O+B
M]MKJS[3LWV\@B<.T#0[PM+CT-`%".!(-:K<;&YF9?85I?6%A:X^[LLAV7;1W
M<)F8>Q+RSP=;&]+R3J#N(:10A2,#Q<[7U_S$?#/_`/M.C?\`&G-!_I5:_P!M
M[C_KQ_F+JO\`7"[_`/IO:7_Z:WX50>V]R/G]M:LT9J%6KUVHU+1@[5D(MK6_
M2DTK!:-PWA2ZVRR2+18PH,E4BI,XUF@CU(WCV*1`,/ESLL3MZ#%9.]RPEDEN
MKWL0XOIX+((^S8T'I/WSW$]+G$J/L_N^YSN$QV",,4-GCNW+0RHU/N)3)(XB
MM!P#(V@#P61M"^?%3DUL#A]O*H\@=7,*O)W:EMK(TB65RCW\I7E4K37)2KR(
MO649*PKU4Z<=+*F2$CE/LJ@4P]H`$H_K<^V[#=F%EP63=*VSF+"XQD-=X#VO
M%"6N'2T5X'@O+96\,IL3<4&YL.V%]_`'AHE:YS/PD;HS4-<PGP7FE'#C3T%8
M!\Z4D'CU\N!2K/W;IZL"8"5,%7:ZCA4$RB)A*0#J#T`1$0#\.;UC!&P,;ZUH
M`])<S+*Z65TSJ:G&O>4\IGQ&]ZSG,:@<WWD%K4FW=<PT!!040W@IU.BN&=<J
M$I2V1Y*(-9E)=9=2*EU3J"F_2`5P*8H%*'9'AX>7N$AVE/LUC[GXJN'N<YQ<
MWM`7/$AH[1IIJ`I5IX>FI,GYM;EN-\VW,!\=G\=6L;&,:&/[(AD?9#4WM-1.
MGIH\<>B@X*D>+_/#?/$2W;FNFGW5<:RN\JI-5>VHS<;(/X^/4E95Q-,;-7F[
M26CSLK/6'[Q<T:NL=PDB5<X'34Z^3*W)L?![JM;2TRHD,5E*U["T@$Z1I+'D
MM-6/`&L"A-!0A8.T>9FYMDWM_?81T+9<A`^.0.:2&ZC42,`<VDD9KV;B7`5-
M6FJMKKODI?\`6>A^07'B!9UMU2.2BFLU=@2$NP?.[.T4U395[57#5N11DVK1
MB9W).#`]%=LZ%9+R%[L?79LK_;MCD<W89Z=T@O,<)NR#2`P]NP,?K&DDT`\&
MA%#TU6HQF\,IBMN93;%NV$X_+&W,Q<TEX\6D,L?9N#@&U<:.JUU1P%.E3,U_
MXLFV:3I[4NDYOCAPSV_5]*5A2HT24W5I!;8=FCHA=T+QV4)&3M9&S=5ZL!!7
M]%0;D5%(@F*(E`<Y"^Y6XJ\RUUF(,AE[2YO)-<@M[D1,+@*#@UE30=%2:5/%
M=]CN=^;LL'9X&ZQ6`OK2PB,<3KJS,[VM)U'PG2T%3TZ0T&@J."MWOGQ$)_?>
MKK#JU]Q0X0:P;6%6'54NNFN/K*B;#BO<>88S)"0EG1GGRD>F_.Q!NZ`$S=\U
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MX_85H\HE+&<UI9G)L$6,OZ0D`=XNFZ2[`_[WUZ"'XS&W;'-W=C>W;I!+C[GM
MH])`!?I+:/JTU;0]`(/?7KM[>&4VU89''6#8709.U["4O:XD,U-=5A#F@.JT
M<2'"G4NGX^;\V7QAW%1]YZCF2PMZH<H+^-4<)JN(N49N4%64O7I]BBNU/)5Z
M?C%U&KQ`%$S'24$2'(H4AR^V>P6.W+B9L+E6:[*=M#3@X$&K7--#1S2`6FAX
MCB"*A8NUMT9?9V=M]PX.3L\A;OU"O%KAT.8\5&ICVDM<*@EI-"#Q%3[#Y4[@
MOW)NP<N6TVEK[=$[>4MAH3>O/385M7K(@V:M$U8%)\^E72306[4"*(N%G!%T
MSJ)J@=,YB#C6&U\38[;9M5S#/AV0]D6RT<7,XGPJ!HKQJ"`*&A%"*K.RF]\]
MD]WR;W9(+;//G[8.AU,#'CV(+G&G=!<:BH-02%-=?Q:KG+RY=A6_AQP0NV^2
MB#H^^K#H8371].%'MDMDO$,+(SJDE:TENBA7@LR=E0`$"!T``XUO*NTBB\0M
M<OFX<)T>+-N?P8;[!I+"\,ZM.KHZU(;N>-]/-\97N"V]/N*M?&WV=97/_P"(
MX-D;$Z6O$/[/@>I8\-U[NVIR+V79-O[HN4G>]@VMPFK+3LGW*0%0;)@BPBXN
M/9I-XZ&A(ML`)-6;5))N@F'0I0$1$>_PV%QFW\='B</"V&QB'@M'=/$DDU+G
M$\2XDDGI*BG<>Y,UNS+2YO/SON,C,:N<ZG0.`:T"C6M```:T!H'``!7ZTOSQ
MWUH;CENSB_0W5;+KK>?NF,\^E8MZ[M=5&Q0+:K6\U$ED)5HV@S7&M,DF4B*C
M=SWB)`['8,(F'1YC8^#SFX+/<E\)/'[*FD-<`Q^EQ>SM&EI+NS>2YE"*$\:A
M=-M_F9N7;6U;_9^.,/Q7D-6LN83(S6T1R]DX.`;VL8#'U:ZK0`*'BK':!W5;
M...YM<[SHC2#?7#6%B1LU>9V1H[?0+A^@U=-")RC-@^C'B[44G9NI4W")NT`
M"!O)FZSN&M=PXBXPM\7MM+F/0XL(#@*@^"2'`'AU@KG-K[CO]I9^VW%C6QNO
MK60/8)`7,)'L@'-)'H.'HK(Y)>,+?9J2D)F9X0^&[+3$N^=RDM*R?%EH_DI2
M3D'"CM_(R+YU;%7+U^^=K'5664,9150XF,(B(CD?Q\IK&&-L,.9W"R)C0&M;
M>D``"@``CH`!P`'`!2K-SVR-Q,ZXN-O;4DG>XN<YV.#G.<34N<3*223Q))J3
MQ*L2R\1?9D#RFI_+6BZ;XV:PO%*HDY08VEZSUBXI>K'K&PPUK@I.;EJI#6)!
MP[LJT=;EB>E`[(`@W;@8ABIB4VZ?R_QT^V9=K7MWD;FRFG;*9)IA),"US'!K
M7N80&5C'#2>EW'BN;CYK9>UWC!O7&V&)L\A;V[H6Q6]N8K<A[)6.>Z-D@)D+
M92-6H>M94$-H;<\8N;^].(]9WQ5-0OX-K%\AJ,>CW(TTP?/G,.3T.=CFEHJ*
MC23CR1-LC6%F?)-W*I7*9"K]12,)2B&PW)LO";JN;&ZRK7F6PG[2/20`[BTE
MCZM.IA+&D@4/#I6KVAS&W'LBRR5A@W1-AR=MV,I<TDM%'M#XR'-TR-$CPUQ#
M@-1X'A2WM6Y&7FH\;]I\78MA6E-=[=O-%V!9I!VQ?*VII-:]*<L(WAI!.31C
MVT<N!_[8(JT74/T]:<GEZYUSMVQNMP6VY)'2"_M89(F`$:"V6FHN%"2>'"C@
M.Z"M?9[QRMEM:\VC$V$XV]N(II'%KNT#HM6G2X.#0#J-06D]%"%.N$\7W;C+
M7VJM=VOC%PAVPPTYKFKZLID_MS0JM\M;>I5*-;QD:T7EY:W&`AEB-^^7*W30
M0.X.<X)E$PYQ<W*C%/O[K(6N2S-K)=W#YI&P7/9,+WDN)TMC[]!4DTH*J0K;
MGIFX\798J]Q&WKV*PM8[>)]S9=M((XFAK07.E[U30-!))H*J,O*7G?O;EI7J
MG0KNGKZA:FHCQY*4_3>EJ-&ZVUC"3+]%9NYG"U^.4=*OYCT9RJFFLY76!`BR
MO=%3[Y43]%MK8^$VM/+>V9GGRD[0V2XN)#+,YHZ&ZS2C:@$@`5H*UH*<KO#F
M=N3>=O;X^^%K;8>U=JCMK6)L%NUYZ7AC:DNH2*N<Z@)TTU.K+-_XRVW["RK"
M%YXH\#-ER53J->I$79MD\>5+G:#5ZL,2L(EDYFIFXN')DD2`<_=D[")5%3B0
MA>T(9R\?*+$V[Y'664SEM'+*Z1S(;KLV:WFKB&MC`^STT`J5V4O/O.744+,E
MA=MW<L$#(FR3V/:R:(VZ6@O?*3PZ:"@J30"JC'R1YT3O).JUNJON-W$739:U
M;F5O0L&@=)M=:V>2<,6+]DG"S,NVFI`[ZO*^G]\HV[)0,NBD?M!V`SI-O;)@
MV]<R7+,CE;OM(C'INK@S,`)!U-:6BC^%`>X2.M<ANOF/<;KLXK-^)P=AV4PD
M#[.T%O(XAKFZ7.#W59X52WV0::\%:;E9R<V#S!W;9-][185:,N=HC*Q%2+.F
MQ[^+KZ;:IU]A6XTS1E)RLT\25481Q#*B9P<#*"(E`I>A0VFV-MV&T\-'@\8Z
M5UG&Y[@9"'.J]Y>:D-:.DFG#H6DWKO'*;[W!+N/,-A9?3-8'")KFLI'&V-M`
MYSSZU@KX1XUZ.A5%&<PMH->)<[PPFHJF7'4#Z]([(J;BTQ<H\N.K+:51-1Z\
MUQ.-)IBWAFDP(N`=-EVSM%0'[OH4HN%!''DVEC';I9N^%TT.6$)B>&.:(YF=
M0E:6DN+>&D@@C2WI#0LR'?V89LF38-Q';SX1UP)HS(UQE@DZS`\/:&!PJ'-+
M7`ZWD`%Q)L_IG<6Q>/\`M&E[DU-8W%4V%0)A.:KDT@DDY(DOW*S1VR?L7)5&
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M=0\E[_I/6'(C5-.85A2#Y,TN`H-^E9:/?N;#&UV`EW4P1O57K649-8Y236=F
M3=BX0=D42``*4I@[6=#EMN6&9R5AE+MTO;8Z9TD36D!A<YH;5X+23II5M"VA
M[JY#`;RRNW,1D\-CVPFWRL+(I7.:XO:QC]=(R'-#=70ZH=44H!TJQ<,[.PF(
MA^F+$#L96->D&415<Q8':/4'!1DVR!%%W,<!D_X=,A3'.EVBE`1$`S=S,[2%
M[/"\)I'@\#Q'43T'N'NKF[23L;J.4Z:->#X0JW@>L"I([H4K^>FW]?[VY4;'
MV5J]A7&5-E&5"B&:M/J!Z#4YF7JFO:O6;59:S35R)OJ]7K+:XIZ]8MW8>G`T
M63,Y_AS*`'+['Q-_A-L6^.R3I#=M,KCVDG:O:U\KWL8^3H>YC'-:XM\'4#I\
M&B[7F9G,7N/>5UE<.V%M@]L+1V478QN='!''(^.(\6,?(QSV-=X8:X:_#U*^
MVC/%+VIHKCW5>,S/C_Q)VAK*IV&:MS1MN?4+Z_OI&USDA(O7%EEBO+:UAW,X
MU;R1F3=R1FFJDQ331`1`O4=)FN6>,S6>EW&Z_P`K;9&6-K";><1`,:``QM&%
MP:2-1&H@N)*Z3;O.;-;=VQ#M)N,PEYB8)72`75J9BZ1Y<=;JRAI<&NT-=I!#
M`&UX*T/)SF[-<GZA`4^2XY<2],)0%D)94Y_CYI=KK*T2:I(R0BPB)B8;3,B=
M[!"60%<6_9+_`&PDD?M=2``[7;FS(=MW<EW'D,K>&2/1INK@S,'A`ZFM+11W
M"E>X2.M:+=W,6XW=9164F*PEAV4W:!]E:"WD<=+FZ7.#W:F>%733UP!ZE?2&
M\67=#$*K<9W2G&.]\D*'5V-1I7+2ZZQ<3&\X6.B(X8F#EGCSW?0J=CN,!'#W
M3.6?QJSD@!U4!4W4PZ.;E9AWF6U@O,E#M^>0ODLHY@VV<7'4YH&C6R-QXN8U
MX!ZJ+J+?GEGXF17EQ88FXW1;Q-CBR$L!==-#&Z6.+NT$;Y6#@R1\3G``:M1%
M5C%FIJ7LDS,6.PR;Z:G[!*R$Y.S,FX4=R4O,RSM:0E).0=*B95R]?OG!U55#
M"(G.<1'SY)4,,5M"RWMVAD$;0UK0*!K6B@`'4`!0#N*&KJZN+VYDO+I[I+F5
M[GO<34N<XU<XD\22222>)/$J].XN1EZW?0]`:\MK&MLH3CAK=YJZB.(%B^9R
M3ZO/9@\TJYLB[N2?H/I8KH_9*HW2:I@0/*F(]1S2XC;MCA;V^O[5TAFR%P)I
M-1!`<&AM&`-!`H.@DFO6NES^\<IN+'8W&7S(!;XNW[&+0UP+FEY?^$)<X.-7
M'H#13JZU/Y/QD-N.*;K>BV7BGP1OT)J:E0^OZ&.P]`.[D^@:S"L&4>@Q8.9N
MZ.09%=$8)J.`0*D198.V)>O3IPQY1XIMY<7MME,W!-=3.EE[*Z$8<]Q))(;&
M*TJ0*U('!22.?6;?C[3&WF&VY=6UE;LAA[>R,I9&QH:`"^8TK0%U*`GC10<Y
M.\FI+E!::W:9+3F@=,*UJOJU].$X^:V0UG79=-617DAE9V+;R,D61FB&7[DK
M@3%$$"E)T\G7.TVWMN/;5M);1W=_>"1^K5=3&9[>`&EKB!1O"M.[Q4<[PWA+
MO"[BNY;#&6!BCT:;*W%NQWA%VI[0YVIW&E>X`.I=-L+D!-W[1O'[085V'KM1
MT`.SI%DZC'#Q:0NMKVK96D]8+790<#Z.G(-6,6RC6I$0[";-J7RB8QL]L?@8
M;'-7^<[1\EU?=B""!2-D+"UK&4XT)<YYKTN<O/+;JGRFV\9MD1,BL\;VY!:3
MJE?<2![WOJ:$AK8V-H!1K!W2K(14K)P4I&3D)(/(F:A9%C+P\K'.%&DA%RL8
MZ2>QTBP=(F*JV>L7B!%4E"B!B*$`0\H9N98HIXG03-#X7M+7-(J"TBA!'6".
M!"YJWN)[2X9=6SG,N(W!S7`T+7--001Q!!X@CB%E"D?%JW4Y//7>(TKQCJ7)
MFV55Y4+/R\J^L%XS>\DPDHSW%E9QF\]WE:C`WB7B?[7<S#*,1<&3Z@0$QZ"$
M:Q\J\.W19RWF1EV[%*'LL7S`VP(=J:TC3K=&UW$1N>17IJIGEYY[@>V2^@L,
M3#NJ:(QR9&.`MNW!S=#GAW:=DR9S>#I61-=2H&FM5&#C/S!O_&AEL6J,ZEKC
M;^I-OLHIIM+2VYZ\YM>OKBO`.5GE>G%4&DE%3$3:(%TX4.U?M'2:I3&`3@<2
M)B3I-Q[2L-QOM[ITMQ:92T+C#<6[@R5@<*.;4AS7,<``YKFD=RE37C=G\P,I
MM%EU9MAM;[#7P:)[:Y89(9"PES'T#F.:]A)+',<T@FO&@IR>2?,K8'(ZN4;7
M'P,UCI726LW$C(T31^DJRO4]?1$_,)]U+VR22?2,Q,V:W2*(B0[]\Z5.0AS@
MD5/O514_.W=H6&WKB;(=M<WF9N0!)<7#P^5S6^M8*!K6,'2&M:.JM:"G[W?S
M"RF[+6WQ786EA@+5SG16MK&8X0]WKI'`N>]\CN@O>]QZ=-*NK3U^Y6[&NLQQ
MZLL/#T355JXT4JGT[7UJU-6_@A//W-'<MGD'=[<\*\>EGKWZ4S(HN^$B95S=
M>TF/:-UR;':^/LXK^WE?/=6V1FDDE9._M&@2`AT<8H-,="0&\:=U8>0WQEKV
M;%W5O':V=YB;>**&2WC[)[C":LEE.HZY:T+G\*D5HIA.O%RV^2:FMGUGCWQ(
MHW)NRQCR.GN5=5U"JVV^Y<R3(S"5L\:B^L#ZE0=UF&QS%=R;>+`ZW;-U(`&$
M!Y%G*G$]DS'7-_E)MN1N!;9/GK!0&K6&C!(Z-I]:POX<./!=_)SUSO:ORMIC
M,-;[KE:X.OX[:ES5P+72-K(Z)LK@3KD;$"ZIX"I42..?+S:O&VVWRPPC>J;)
M@-O0SRN;IUKN"&5N^O\`;T*^?J2JR-WBUGK1^[DT91=1RWD$7*+U!=5004$J
MJA3]7N#:>,W#:P6\QEMY[1X?;S0.[.6!P&G\&ZA`!%`6D%I`'#@".%VIO[-[
M3OKF[@$-W;7S"RZ@N6F6&X:3JI*TD$D.\)KPX/::T=0N!J#DAS1O'(6CTO3\
M;KS4^A=$:_F).SUO2VC:V]K5.5N4RV%E)7>S.):5FYRUVQ5B8S=)T\<F!NW.
M8B1"]HPFQ]O;.LL!>3962>ZOLU.P,?<7#P^3LVFHC9I:UK&5XEK1Q/$D\*9F
M[>8V3W38P86*VLL=M^VE,K+:UC,<9E<`#+(7/>^22G@ASG&C?!:`":T9R2Y2
M;$Y2O]32.Q8^J1Z^FM+TK155+5(Z0CDW5.HGI_N.\F@D):6,[GUO=%3TA9(4
M$3]"]E(@!F;M[;./VRRZCQ[I7"[O)+E^L@TDEIJ#:-;1O`4!J>Z2M3NW>>5W
ME)9291L+76&/ALX^S:YM8H=6@OU.=5YU'410'A1H4;<Z%<DIO63G]O6Q\QZM
MSC%"F0VY:DXI2L>RA(F6;4QTVI-2:4="-D(E>==2B\=/5IL9O(D(^3%8JZG=
MBD`E`O&6^Q,);[2EV969^(E$E2YS3(#(\R$AP:&U:\U8=)I05JI'NN:.Y+K?
M4/,*EO'G83$0&,<(B(HVQ!I:7EQ:^-NEX#Q4.=0MKP_5<\0#>U=YE6/G,5O2
MY?<MF<7!5VPF8F6<4EHUN%-=T)2+CHA">;2B$9`UAR5O')F?'%($$^\%7H8#
M+C8F$GVC'LNLS,1&(Z%KFB0F.02U+BTBKGBKSI%:FE$M>:&Y+;?<O,.EN_.R
MF6H<QQB`EB=#I#0\.TLC=I8"\T#6U)IQA`(]1$?W1$?_`&CUSLU'!XKLH2;F
M:U,Q-CKDM)0-@@)-C-0<Y#O7$;+0\O&.4WD=*1D@T42=,G[%VB15)5,Q3D.4
M!`0$,\YH8;F%]O<-:^"1I:YK@"US2*$$'@01P(/2%[VMU<65RR[M'NCNHGAS
M'M)#FN::AS2.(((!!'$'B%E82\7C95F2BY/??%7A-R<V-"M&C1CM_<NBFC_8
MCPL>@DW8'LLA`RT-&6$S5-`G3MM4@$0ZCY1$1B\\J<?;%T>#R>9QN/>23!;W
M)$0J:G0'-<6UKU.*FL<],I>-9-N7#8#+96-H`N;JS#YCI``[1S'QM?2@I5JB
MQR%YW<CN3]WH-PVO:(IU&:JDX^1UCK.LP+2J:JH18UVP=I,ZY38@R2**:X1B
M"*RZRJSU1!,J8K@0I2EZ;`['V]MNRGM,9&X2732)IGN+YI*@BKI'5/"I(``:
M"2:5)7';HYF[KW=D;:^R\K#!9N!@@8P1V\5-/!D3*``Z14DEY``+B`*5'$>(
M/O>!YLRO/2(:4=EN.<F)24EX(D/+&UW(H35/+2)2$=02D\:66AW4.0IQ(,@*
MA7)"J@<!*`!X2["P<^SF[(E,QQ+&-#7:F]J-+^T#@[3IU!W^S2G"BR8>:FY;
M?F`[F/"VV;G'O<YS-#NP<'1F-S2SM-1:6D\-=:\:U"I6C<VMST7>F].1#<M5
MG]B\AJKN"H[`6L<9(NHHL=NM4JMJ7@V;*88+Q[N/`A4X[MK+)-DB%(8BA0S)
MO=F8>]PMC@7=K'86$L$D6@@.K;^L#B6D$'[_`(`D\:A86.YC;@QVX<EN9O8R
MY/*0W,4Q>UQ;INJ]H6`/!:17P*DAO10C@K`:DV-.Z9V=K?;%40C75EU==:M?
M*ZVFVZSN(<3-1F&<W&(RK5JY9.',>J[8D!8B:R1SIB(`<H^4-]E,=!E\;<8J
MZ+A;7,+XG%I`<&R-+3I)!`-#P)!X]17,87,76"S5MG;,,-Y:7,<[`X$L+XWA
M[0X`@EM0*@$$CK'2NRW9MJR[YV]LK=5R;1#.V;3N,W>+$T@&SEG"-Y>>=G>/
M48IH]>2+MNQ(J<03(HNL<"^<XCY<\\-BK;!XJWP]F7FUMHFQL+B"XM:*#40`
M">[0#T%Z;BSMYN;.76?R`C;>W<[Y7A@(8'/<7'2"7$"IX`N)IUE6OS9+2IA$
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M_:=\8OS_`&3^J&^Y&/.3Z-\E[6'\?$II\WKZ7L/[>?\`59UZ(64%7U*6IE]J
M!\_#'\;>OY.JLM)YMG[W_-ORZI-YX7[A]"\^[;+4VRTBI*F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+*IX)?[3
MOC%^?[)_5#?<C'G)]&^2]K#^/B4T^;U]+V']O/\`JLZ]$+*"KZE+4R^U`^?A
MC^-O7\G566D\VS][_FWY=4F\\+]P^A>?=MEJ;9:14E3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%E4\$O\`:=\8
MOS_9/ZH;[D8\Y/HWR7M8?Q\2FGS>OI>P_MY_U6=>B%E!5]2EJ9?:@?/PQ_&W
MK^3JK+2>;9^]_P`V_+JDWGA?N'T+S[MLM3;+2*DJ81,(F$3")A$PB81,(F$3
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ME-/F]?2]A_;S_JLZ]$+*"KZE+4R^U`^?AC^-O7\G566D\VS][_FWY=4F\\+]
MP^A>?=MEJ;9:14E3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A%E4\$O]IWQB_/\`9/ZH;[D8\Y/HWR7M8?Q\2FGS
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MWG_59UZ(64%7U*6IE]J!\_#'\;>OY.JLM)YMG[W_`#;\NJ3>>%^X?0O/NVRU
M-LM(J2IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBRJ>"7^T[XQ?G^R?U0WW(QYR?1ODO:P_CXE-/F]?2]A_;S_J
MLZ]$+*"KZE+4P^U!G(4W#`#'*41'>W0#&`!'H7577H`CY>G7+2>;9T9C\V_+
MJD_G@@GXA`XFEY]VU6IKWJ?MA/9E]7+2*DVA_</I)WJ?MA/9E]7":']P^DG>
MI^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7
MU<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#
MZ2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[8
M3V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PF
MA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)W
MJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E
M]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P
M^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V
M$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)
MH?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=
MZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9
M?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_<
M/I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?M
MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7"
M:']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG
M>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F
M7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W
M#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[
M83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5P
MFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)
MWJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9
ME]7":']P^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']
MP^DG>I^V$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^
MV$]F7U<)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<
M)H?W#Z2=ZG[83V9?5PFA_</I)WJ?MA/9E]7":']P^DG>I^V$]F7U<)H?W#Z2
MRJ>"6HF/B><80!0@B+_90``&*(C_`.4%^'R!UZCY`R,><?T;Y+VL7X^)31YO
M;7-YO8?4"/#G_59UZ(N4%7U)44M_?U'OA!"_UI/ZJOPI]R!^#O\`/]_-)[N^
MX7IB_;]Q/YQ?[?\`<KT_O.UZ/_!=[UZ^NSJ,%_C/L'_X9^-/%M?A>*]OIU4'
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MOYP:_P#S%?U'_P"=7MO_`(*_S2_S#?S@]Y[F/?=3X/\`P._^8^W[C>D>D>C>
M7T7O.W_!]K-?E?\`43Q"3X[^.OBSAK[?QGLND4U=IX'KJ4KUTIQHMMA/])OC
D.+_#?^'?CFI[/Q;Q/MJZ3JT=E^$]9JKI^]K7A53@SBU(B__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g438628g69f51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g438628g69f51.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+@#+`P$1``(1`0,1`?_$`)\``0`#``,``P``````
M```````&!P@#!0D"!`H!`0`"`@,!`0`````````````%!P8(`0($"0,0```&
M`00!`P,"!0('`0````$"`P0%!@<`$1(($R$4%2(6"1<8,5&!,B1!8:%"4B-#
M)289$0`"`00"`0,"!`0%!0$````!`@,`$00%$@8A,1,'02)183(4H4(C%?!Q
M4Q8(D<'A,R07_]H`#`,!``(1`Q$`/P#]^IE"%WY&`-M]_P"FV_I_77`()('J
M*X9@B%V\(/K5.7G*RD7"/W^-H4N69F'L3"O3E;JDU&FD8=9VL5-RM(B`NO:G
MCTS<SIF(!A`?7B`"(5IVOY$EUNIFR^C8![+M<7.AQY\;%F3W(><JI(S^MO;4
ML[#ULIM6::3J,>7GIB=IRCI,.;&DFBGGC<+)P7DJI<`-S\`$'ZBNP?SLA`SS
M^T6"ZQ,?0FD)&QSJN*QR9W\59GSU,I'[R7;*+K@DNFX(D1OXMN0\]^/KKOL=
MSE:7=3=CW.VQ<;I\6'%'+B%.<L&2Y9N;2HQ87#*O`Q6:P((\DQ^'B1;'!AU6
MMP9YMY).Q6?EQ62);^%C8`'R#=^7TM:H++V=6#@[94&^;&#*Z5,S&T3]HN,3
M'`C7JS/3(NV+=\@FWCXD[08TBC1!0%/+OQ$X\QUB>3LLW6:#8=8B[4L?:-?)
M'EY.7FPK_1Q,B59%C!7VXB%C/M(P#-<B_GS4UBZQL_9X6T?42OJ\T/CPX^.Q
M)EFC2Q<#DT@(8<FN`I\VN*E1<DS!;C\,I579<?I4P+0IEX\K')54[CT4^.$B
M@\DP4:CY05$_`I/7?;UUDL?>MM'W*/23ZV3_`&,NI3+;=&2-<4D@_803<%@.
M7J/!^E1YZ]@R=:DV\.6I[1'L'Q_[7P<Y%EL.5[#Z^+!;WN/RJT(6<A[#&,YB
M#EHZ9BWR7F:244\0?,'2>XE,=LY;**HJE*<H@/$P["&P^NK`UNTUVUPDV&MR
M(<G"D4,LD;!D8'T(()%C]/-8SDXF5@S-CYL4D.2ALR."&4_@00#_``%=MKW@
M@BX]*_"FN:4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5F
M;L[D3*^.Z8S?X9I#;(%S>3;1J,"H"KEXE#BBL=Y(LXMLY:O'Q4EB)IG,0W%(
M#\C>@:I?YM[?WCI_5DS/C_5C;]@ER53V#_I`?>UA8FQ/\35G?$O6.D=K[+)@
M?(&PFU77EQV;WUL%,PMP3DP*B]_X5#:#16%6^>;5_']DQ38,D5.,R#?;Y$.$
M9R+AK8*GN):JL4Y-:24"08'4<&%(J/#@<>/U;;8KUGJV'UB7,BZ]J\[09^YP
MTVFRS8626*+(CXEH")1(!*RL]E%OMN;5(]K[-L.RPXR;+8X>XUNJRVP<'&E4
M1R28[`@3CCP)`XIY8^MOI>I5=K(TB"3Z<.[A*U)VY7'ZL79(ZMN+A.O'LTJN
MT1?W"H)-6Z["'!DP%LD\=&*DCS$QQ)X]M2O:<Z+$;..H./B9NR7!5,V*"++G
MDED]Q1-E8W!N*`)Q$A556Y]*AM!J'SC!DY[39.)@G(9HI)OVL:1Q!3[4,X90
MSEI.0C6[-]`:R%D#-%@L1;Y#.6<<#"_HT]>'J&?J`>I4NMUA&QA7))A,W*.<
MJ%EIRPORD<QK917Z4C`<OU"`:J7L?=MCO)=AC_\`S286QDQ%7#V^(,>*+'29
M(VBYA8RTCN5DC#,?TBPJW^K]#P]7/@90DDCR\&'*#Y.JS/W&5),86FC`C);B
ML*J5F95'@,":@\ID.PF_66[TFBY2R/0W4LQP=:<,6M-S7J!3:W%1B+>5M%;<
MMG*JQ8GQL3(HJ>)M[,K@3N5#`8@AB$F\V8P.P=CTVMVFYZGFRIJLG5RL5P<:
M*$>W+-C/ZA+$W(-O'DUFV#UW%7-T/6>Q[33ZG>10R[7&V4"B7/R996Y1P9(]
M&DY6(!N6^@^M:*P=?[5!Y1B\5T'',!']6V<&J:I9(CYD95@_DG+5.1530LBD
MBNQF9-:=77;*M4P%4@D$_H!1U9WQ;V3=:/O$/0^I:+&A^#H\,?MLT2%R2%'`
M<F8W_#SY^M5E\B==Z_N.ER]S[)M\S_\`;I<TG)P6C"!5+L"3&$!7[0&!)XUZ
M$)B(@(CM_</_````]0V#8=PUMJGU^[EY_P"GY5KCZ>#Z@5R:[TII2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*;A_/_?\`I_/2E>/&>7V.I[OO
M6$D;1D9+(5(BH99I5HM@S"!L-CC()Q:(.K1DZI*%=PP6!J\23<G%H=`RA]A-
MZF'6A'RG/U'<_P#)7$QTS]F.WZS%B*XD4?&&<A#*L9E#`V82+R)6P)M?Q6[/
M0<;NFF_XT9T[8.M?I^URI5.1*Y]Z)2PA>;@4*GVVC;B`X:P]*TIA`RA:9$3[
M['62,8J76[W7)ML(>WC(0]??P:BBA&=I?R"A7R%9M"/JFV3;G`#)#R'8"B-G
M_'4>5C=?ARUT^WTF3M-GG9N48\GW,:`P>ZZC(D+#C#,HOP4$<K7JF/D.8-OY
MM;!MM;N$UNNQ,/%M!PED5H@&$5E(]^(^.3LMQ?C^%2\,5-\M7.37N+^6<4Z`
M3BC(PK:162^\):4;A83*S<VWC(I],U>NHS"C..037.S6;N%/*F"@!K)-=T?5
M=U[%FC/F9M-BB)'A+<Y)9"#.KR3?Z:B;^DH)\$W`J"Q.V9/4]1&^IB2+=Y`8
MF4@,L*+:,K$A)"RL4O*Q%[JMK^;6+,X8Q[#0CQQ`5R+AB1;8)$62")5(I\2-
M39+`A(1SHKEF<W"&;`5R4I7B(($!)9/81',MO\;]2UVHER=9@QPMC1/+X-N?
MMJ7XD^2`W$#EZKZBL=A[CV+9YZMFY4LTD[A/<_G)<\;"UB0>1'&_%@2&%92G
M<.Q$M)59PWJDW?F2\=(XCDEW63YMFX@\3Y%BBSRT]8#3(&):+?[F4<E#VBJY
M4D@3]1,0-J)DZ%K<K,U_[;`DVO[M)->Y.QD7CJ<X";)<!N(>>&6:9$`)/%$M
M]*M[6_(F?I-=G8<VPAUAQFBV26U\;WS,,^R$0K<I'_1%U(!8EK@7\^>N0JK7
M*MBFA1>4X^YX9:4'+-N@J?`4IVVN<I;HYRX9S=BGI)ZZGVS:/FHA=!))!P!P
M%5(XE30``]-:^SZO2:3I^K/=_P!_H$T^]>&&'"D,_O(9O<]V=PPO)"(PMSY;
MD;"ML^H;G=[[O&V3HAU_8\G<:..;(GS8QC>PWM&,0P(8S>*4R$\1<+Q')Z_0
M10[#$VNG5NR03IP^A9R%C).+=NTSI.G+!ZR07:+N2*`!RN%4#E$X"&X'$0U]
M2-+G8^QU6/FXC,V-+"C*6_459`RLWYLI#'\S^-?,O;8&1J]ED:_,"C+AGD1P
MMK!U=E91;Q92"H_("O.;\CMT[6X)Q]/9ZPMG2L5"G5Q&F0:^-I;$\-:7<C-V
M*VMH-Y.A;9&2*NW332EDCE:^V$G_`&!#D'/<)2H^HCG?/F?^F5>ZOR6;\^5>
M\Q60.R#&#RE<V>(V=;:L\1NJDX?NH9K`0JTZ_P#D&3]H98'K8!<'*<"`GZ:4
MKCK_`.1F"R/V?R9&X@N<=?L!8SZ:7/,\M'(U65@)1?)-0M295VY9*Q143+BT
M<5U=-/@5(S?F?F!A.7T4JF)?L_WSQ]U>I??RY7W#4_BVQ'J%QL_72.QRXCG$
M'C"ZS#9DR2@<E!-J2SNUQT=(HK&%=N*!U-PV';85*M-7\@-PH?Y';=@');V)
M9=<I.K4".J%F<Q35@%(R):Z&WO46E9;$`@=PTM+1N\03*N8J:*R9.`[`;2E5
M;A+\AW97.\[WLG<=TAA:*]CG%\=?^JM`6KGMIRRQ;R6G8:'L4BX1<)R<TG:6
M\*:01:#QY@!4TO[O52K.Z7=G,E92E!G;IW'QWD1[7*).63)_6A?K^IB#*U2F
M&4$J[<,HY64GDY4[*MS`&14<"S=MW:(%'FF)ATI53?ND[]+]2U?R(I7S"Z&+
M404OC?K0?';@RSG%+>U_;QD%<FC+J3*=O6:%%UN"((`8`#TW%/2E23,GY%,N
MXG[B4TKE@R=].5L8X-L^4N,&T&>QT;.:DJPKUS?SR(_)&C8V8;-R.$Q+X/&)
M@'8QB:4K=O5'-%WR[>NW4-9Y>-EH#%/8%Q2<=GC(]LT!.E*4RN3S%)9XU'>6
M,LM*G4(Y-]1R&#;<-A%2O,O)_=[.C','<Z*'N;@[`S'KQ>'T+C3%E^QA!3TI
MD>,85E">1;)R!YJ/GW2CR1,+#DV265YJE$``0#=2I%F;\@N9F(]*&=@R-7>H
MS#.V!Y_+.4K7*8GD<I.X:PLC1K:%KL;4U//*LXV675.H502G.DFJ4%#;!N*E
M7E']J,DMW'01K4L]0><JUV!SKD2DW[(+?$9<=#9*Y7X20<-8II69,@/JV]A)
M5H**KH@$.ZX\MN(ANI5E7K+/86V=W,E=6L:9*K^.(9OU7K&3*?/2-!BK@M!7
M=SD9.)DI)TU=O(]6:8NH%([<K4ZQ4D5%/*`B8`#2E4=U5RIW4OEC[(V+(?8>
MGV>F]5LJ9-QM.TUKA6`@G62TZ+7WSIK*$L3"5([JPO7WC$R:22XE(00Y;CI2
MJ[Z.=WKUGZPX<7R%W4JA+K?I:25FNMT9UID&A$T4G<R+>L-,HI%.R;*FBF*;
M@KT5A`/[!`3[Z4JC9#\A78Y"J=B,DG[?X'@+=B7+^1JG2^JMBQ7#.[3D6"JL
MR1I`13"1C)I"TF=6=`3MVRR+57_)1$QC;''92M(]B>XO8FL9BQ_6;)DB#Z4X
M;M6%Z+>8[*EKPA*Y6@9S)5FCT'EHHD].*/&T72$ZDNL*0B[\0J&*`J&`!WTI
M6N/O'+'P>W[WNN7R7[6OO/Y7].X'X[Y7]1-_W'^U^_\`;],OM3_TOL/+[+Y7
M_(]SO_CZ4J$=A*7D5;M=7I>"Q%3OL2SUIO6[=EQ9!BPGFL=)QKZ'G7);8YDF
MQJ].0\8<J;$Q$A64*!"@8Q1$I=-OE/5=L7YTP<C5:#"?K>7@I'D[-N*S)?W$
M=4=I8P'XJ@6P8V45ME\=[OJ!^#L_!V^_V"]CQ,UY<;5*7:!V7VWC9HUC?E&6
M+E_*@$F_XU0V$Y21JU?0;5[$&3`DL%WVQ-&9;7DU&OGD:+<BOR6B\3$,_CV+
M.32JK%D18H(HKL4RK<Q4$0,&JQ^/L>7`U$6+K-/MWS>O9V3&K2[((\N'FQ2O
MD9+I+'Q=HDN$`29`I_4#:K*^1<3&V^<N;LMWJDQ^RZ^%G_;:[W%AS<7@F/BJ
M\<A91D,;$LT;D^B_6M>TOLO4X,S51U)Q;YE)H"Z3L1;!%O4;?!-9AM4(*UJ7
M(T97JV2T2;E-1)U#K*@]#PI%1)Q`=7CUKY6UNF]O(5DE7-X$!7$@G4%H(Y?>
M]N*(Y!]HQ&*XN(QQMY)UXW/Q5N<DLB1R+DP?:\9B:-H)0ONR1F`232B!5=7$
MP4J.9Y$UVMVS[,W+C1JO7YBM,9=HN>RV23?0SNT-:^Q-$$LK&F5"LR$]-2\^
M1&6,T,OXC-X]T0?.42;#J=[#\C[+?H>OZG$E@Q\F!??RY'2-E1W1)5QX8CDD
MR!'8%F-D()(->31]#Q>LQ_[@WN3%EY<'W8^+$LC*\MF,;Y$\JXZK%R4.JJ"T
MBV"D$U;SJ`;N6U?2DZ]5IUK1)!Y-%06LJXOJY;8:.1;45K#(';,V3=S)12I3
M+E5\)$E5]R)F`V^IF35S9D&O;986!*NKE:5BV44>#*A1!@A'X1(WOPK$\H8<
M1([_`&FL-CRN61/_`&^?)AESA[9*P!D>*5N66Q!9FX1N7"FY)5?45YMY.Q-?
MX:H42!QKUJ@IES=KY*W[)U#OTO&W^9K<][Q)A$`BH1\P6AZ_)Q!E5#."%WV$
MJ:AC#L`ZO=EZ5V2+K^LQ.M=4B;*V>X7-V6#L\A<F2`DM;V_;=2%C#D`@D$>O
M*MM>E=UT63O]ELNT=KRL2+7:=L36Y>'"<=)TX@F-KJRLS,HNI/@BZE?->S$`
MR2C8EBQ09-HU!HU:MT8]FF1)FR(BV12!HU(GL0K9N)!(F````0H!MKZ#8&/%
MB8$&+#&D21PJ."_I6P_2+^;#T'Y"M%9IWR<F7(E::29Y69GE-V<DD\B?S%C_
M`)WJ@^VW7DO:3!UCPR:UGI06"4JTD-A)#EG3-?MFR1EA\/QIY"+*M[WXWP\O
M,7Q\^6QMN(^NNE=9GGK6&<+)UMGW%K+7R]>\P0F5O8C!DF4[=\1%.HOX)0ZD
MBP+#^X!SS]P!'/`0V\8_QTI7367J3"VGLC8LZRD^F:`M76>;ZUS..VL(DS(X
MB;!933LC81LB#X%"+G:C[0K<&GTE$#@IZ<=*5D1/\9N49&A5?KE=NW%AMG42
MFSD*_CL3EQI7(V[S-;KLG\M"4&PY,3E%'3JN,%B)IB8C0%54DBA]&P;*5;N3
M_P`<&.,UVWLU+9,LTJ_JW8J*PRR;P%?8-82>QT_PRP.SBYBOVI=>6!P]D0,)
M!W9I>)NJHGN?D)M*5-*9TR/BK)&7<B8DR"C1CWO!.,L*T*%+2(^7:XR-BR+?
M1\#:!!S+D:6P3BX34.R50:E$Q!`53<OI4JNZ+T;RD_[$53L7V0SY!Y>L5"IE
MSH]6B:=A^#Q0S?QMYCE(>76N3^+FI5_/$;QJQP;-Q$$DE#B8#`'TBI54F_&-
ME`F,U>L#;MW94^G#B<,[5Q.;&U=-?T:DM/?<:^.VV4`DTW!*Z:2$0Y^R%0J0
MB`%'?2E:CDND%'GLE9LM-D?H36/\R]>Z+UX<XR4A4TV\%7Z.K+&9RS:>._7,
MZ=&))$,@06B8M%FY#E4,/\%*^GT0Z7.>E-(OM-7RG)Y:4NEU):R3TS"&A))B
MT:P<?7X^(=&/-SIY,[./BTB`OS2Y%*``0I0``4JO9_\`&EC6[)=R$;]+1]E6
M[679"[PL\6H,&=IPY)L(AHSB3UJ?5D'KY\JPEV*3P3)F8%5`#)&+L81%2OKW
M_HYFRQ6#K?E2L=E8F*SQ@3%M@Q/)7RQ8B86>!R!#6#V*;F9=U%[9SHPTZ9)E
MNJ<'#DJJBAC!P]`!2I9D;IUE7+N.<0A>>P2#3L3@S(SW)>/,T5#%L+"U]I)+
MMW+(L)*XT-+KQTI#*QJH(.!%TDJL8@'#CN)14J5=?>J-SQYFB^]C\UY?_6?-
M%ZID'C=.0BJ4PQ[4*G18*0-+(PT'7FDC++JNGDH)5EW*RXG,("``&XZ4KO,&
M]3D,.I=HD'MQ<6IIV:RS?,FOVZ4.2&6JJ%[9'8NX%NX&2D@E3,DE!$KDQ4>1
MO_'I2J4ZO].^S'6A''=!C^S],LF"\=.7:+:DKX$A&EOF*\YD9.3"*<7T;,J\
M:OA=2(B+H$U!`"[`38=*5$S_`(L**OA;*6.WEU;ER)<,]S_8#'V;(FAQT?<L
M66F0G6<]`L60C,N'LY&0;EL<BJ9GK5)TFN<?&F8`$%*NW.'7_MCE*'3K-;[0
MT:K5.9H+"HWVN6'KM6KJUGIHS19E8K;&N)*S%5C_`)T%?(2/5\Z30Y`X*#OO
MI2LX?_D+C7[-^ROU7NWQG[./VE>?X>&]YXOUX_<!]_>3S\/<?=O^/\7MX/8?
M1YN7U:4K?78W`->[%TIO2;)-S<"R:3+>:1>0GMQ4,X;-EVXINT'A%&KAN9)R
M80Y!]!R@8!W#55?+?Q1K/EWKT6AVF7EX<$&4N0'QV592R`@*"ZL.)OY\>M6-
M\8?)V?\`%/8GWVNQ<;,GGQG@*3JS1A7()8\&4\OM\7-JPZ^QBI>G]ZO&/L=V
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M^"(Y_30MG78XZJ"$%<%YZQ.5GEGN==L`D.^0+=':&P,`$I04VW*'H`6;H='K
M]5^YP#EP2O%UZ/(,>OQ0F3R/!I)X92&=SD^0([G]=K55N[[%G;D'(>/+6#^Y
MF%3EY)DB2%+B&*2.X6\0]'`%@/J:F^1$4']5LKJR59I:ZM'56,N#*BMT7K3(
M,I9H`WR:!7?MG)4C*E,U;I)%!,3`X(8IMR[%U)]NP\?9=3S/[W@Q;+IT>GBR
MTUI$L6UEEC#-_7LX;U`"\54AKCZ5&=;:6+=8<.NRY<3=29<D!RVL<"+'?[2!
MR!(O=F8EO0W%JJ/"N%ZW=,GL>X+A#(-0N%OB'K9W0+$L4C>,$[4D$8ZHBV0>
M&8+,X\BS=N<"IE.?R``#Z:Q;XV^-]'VSM\?_`"!9]S@[G.PTO@9,I,,091X$
M9`8<;6MY'Y5EW=>_;30=/;X13^UYVDPLPE<Z"/\`J2E68\ED!*\23Z^3:WFM
MSIE`O/83#N?^!AWV'B4-B_[:VA``\@6OY_Q^%48L90FY)!\^?IXM;^%<FN:[
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5Q;!R/N/I_S`
M(#L`<0_IKD\O'I^7XU^2A`7N;_C^7BJ*[`M\1+T5$F:'SEE3ON"#,FJT3L!U
MAFRN]XDG_P`XU=R/B.X]#;D\6W]P@'KJE_G2#XLFZ8J?,4S1=4_>P$,HGO[_
M`#'M#_YDDDL6M_+Q_$@5G_Q?)W&/LX;X\19.Q_M9_#>W;V>#>[_[V1/"W/K?
M\`34O3BY$)]24/:&!J$>L(,VU66@R%*A)D6!0\RK.JJBJJ"K(2IBW.GN7;EO
MK*,?69XVZ[`[._2CKHUBQ),<>T%XCVY7G>P/C^1K'\:QA<G5-K#B8^,5[`,J
M4O/#(2QO;DBQ("00?/)?7_*NM?0U^>5$[`ET@(>VJ2I%F-@B:PL\8-X4LN19
MHR^'=O53+.%(\`045%0"<Q$X%`/349DZON.5UTXD&TPL7L392M%/BXQ<)B"1
M3[:Q`EF#H.#N?L4$L/`KU0Y/7(-H)FQ<B;4B`JT<TO&\Y6PD9[!05D^X*?N-
MK&HL5MAT.P/F&0<#FX*(5-1J"5D]J:I`X*(N"B#3[;*N9?;8`6]P'^A?]=0G
M[;XV7YKCFGR)&^7ET85D1<D(V)R;^H_",XXNW*P:0/Z67TK)C+W<_&SPPQJ.
MAG/)YWBYB?Q=0.7NV]/(3C^=7]M](`8X".WJ(`(#OZ;B(?QWU<A]H`>[8M_+
MROZ?2]_-_P#.J^^[W+K^C\#_`-JY2?Z^N_J'\_\`I+_/7H'^/_'Y5T\<C;UO
LYKYZYKFFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
